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Summary
Ankylosing spondylitis is a common inflammatory arthritis that is characterised by 
inflammation of the spine and sacroiliac joints. The genetic association between AS and 
the MHC Class I gene B27 is one of the strongest disease associations known, however 
the evidence points to AS being an oligogenic disease. The aim of this study was to 
investigate several candidate genes that may contribute to the susceptibility to AS.
The MHC Class II region is a highly polymorphic area where associations with particular 
alleles and other autoimmune diseases have been previously demonstrated. This study 
investigated the distribution of the MHC Class II DRpl alleles and the DRpl *04 
subtypes in a large well defined group of AS patients in comparison to both nonnal 
healthy controls and HLA B27 positive healthy controls all from the West o f Scotland. A 
significant increase in the distribution of the DRpi*01 alleles was seen in the AS patients 
in comparison to both control populations. No significant differences were seen in the 
distribution of the DRpl*04 subtypes between the AS patients and the B27 positive 
controls.
The TNF genes lie within the MHC Class III region on chromosome six in close 
proximity to the B27 gene. There are several polymorphic sites within the TNF genes, 
some of which have been linked to differences in production of the TNF proteins. TNF is 
an important pro-inflammatory cytokine and it has been suggested that increased levels of 
TNF could contribute to disease pathogenesis. Six different polymorphic sites were
investigated in total. A significant increase in the 1* allele at the -308 site within the 
TNF promoter was seen in the AS patients compared to the B27 positive controls. Other 
associations were seen at other sites between the patients and the normal population but 
they would appear to be linked to the presence of B27 and not to the disease. None o f the 
associations demonstrated would appear to be with any o f the alleles linked to increased 
production of TNF.
Recent whole genome screens have highlighted areas other than the MHC that may have 
a role to play in susceptibility to disease. One in particular is on chromosome two where 
the IL-1 genes lie. The IL-1 genes are also important pro-inflammatory cytokines where 
particular alleles have been associated with other autoimmune diseases. Three sites were 
investigated, one within the IL-1 alpha gene, one within the IL-1 beta gene and the third 
within the natural antagonist IL-1 receptor antagonist. No associations were seen in the 
IL-1 alpha or IL-1 beta, however a significant increase in the carriage of the 2* allele o f 
the IL-1 receptor antagonist 86 base pair variable number tandem repeat was 
demonstrated in the AS patients compared to B27 positive controls. This allele has 
previously been shown to predispose to increased levels o f the anti-inflammatory IL-1 
receptor antagonist.
Overall this study has demonstrated three different associations at three different loci, one 
within the MHC class II region, one within the MHC class III and one within the IL-1 
region. This study has also demonstrated the possible existence of extended haplotypes
that could cross the TNF locus into the MHC Class II region that would incorporate the 
HLA B27 gene. Large family studies would be required to confirm this finding.
In conclusion none o f the associations demonstrated in this study are with any of the 
alleles that have previously been linked to increased pro-inflammatory cytokines. In fact 
it could be hypothesised that the associations demonstrated in this study could in theory 
lead to a reduced pro-inflammatory response.
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1.1 Ankylosing spondylitis
Ankylosing Spondylitis [AS] is an inflammatory condition primarily affecting the axial 
spine although other systems may be involved. The name is derived from the greek 
words ankylos meaning bent or crooked and spondylos meaning vertebra. In severe 
conditions the spine can become rigid due to the vertebra joints fusing together but the 
condition tends to start with inflammation in the sacroiliac joints. Patients will 
therefore have varying degrees of restricted movement in their spine.
AS has been described as far back as 2900 B.C. where illustrations in mummies and 
graves of ancient Egypt provide convincing evidence o f its existence (Bourke, 1967). 
The existence of AS was firmly established at the end of the nineteenth century by 
individual descriptions by Bechterew, Strumpell and the description now generally 
agreed as the most detailed by Marie on two autopsies in 1898. With the advent of X- 
rays by 1896 the first spines showing AS were X-rayed by Beneke in 1897 and in 1906 
Schlayer was the first to show the spine in an X-ray of a living patient. This aided 
diagnosis but it was not until 1930 that sacroiliac disease was fully recognised.
During the first and second world wars a large number of young men underwent 
general screening including X-rays giving rise to an abundance of information. The 
insidious nature of this disease that often went unrecognised even by the patient and 
the realisation that this was a familial disease came to light. A National Insurance 
Service formed in 1912 and a National Health Service formed in 1948 meant patients 
could be referred to hospitals with X-ray facilities. This meant patients who were less 
severely affected and a wider spectrum of clinical disease was recognised.
The term Ankylosing Spondylitis describes a condition that belongs to a group o f inter­
related disorders termed the Spondyloarthropathies [SpA], Other members of this
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group such as Reiter's syndrome, reactive arthropathies, psoriatic arthropathy, 
enteropathic spondylitis and other rare disorders share a number of clinical, 
epidemiologic and genetic features. The spondyloarthropathies share several 
characteristics in common such as the involvement of the sacroiliac joints, peripheral 
inflammatory arthropathy, the absence of rheumatoid factor in serum and a strong 
association with the major histocompatibility complex [MHC] class I gene product the 
human leukocyte antigen [HLA] B27. The various members of the 
spondyloarthropathies can be distinguished from one another on the basis of the 
particular peripheral joints involved, the time course o f the disease (i.e., remission or 
relapse) and the associated clinical features (i.e., urethritis, conjunctivitis, skin 
involvement). However there is clinical evidence of overlap between different 
members in that a patient with inflammatory bowel disease may go on to develop AS 
or an individual with reactive arthropathy may develop uveitis or sacroiliitis.
The majority of AS patients present with lower lumbar pain approximately three 
months after onset of symptoms. They find it difficult to locate accurately the site of 
pain. They complain of early morning stiffness that eases with exercise. The onset is 
insidious and normally occurs in patients below the age of 40. Patients will have 
various constitutional features such as fatigue, weight loss, low-grade fever, 
hypochromic anaemia and increased erythrocyte sedimentation rate. Some patients 
complain o f ‘pleuritic’ chest pain that may affect sleep patterns. The pain is worse on 
inspiration and is due to insertional tendinitis of the many costostemal and 
costovertebral muscle insertions.
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The disease progresses with a series of excacerbations and remissions with spinal 
limitation and deformity increasing with time, although few patients seem to progress 
relentlessly to the classic stage of bamboo spine (fig 1). The course o f the disease can 
be very different from patient to patient and no two cases are exactly the same. In the 
classic case the spine becomes very stiff and movement is severely restricted but in 
many cases the patient can play a significant role in influencing how serious the 
condition becomes by paying particular attention to posture and maintaining a regular 
exercise regime under the supervision of a physiotherapist.
It is now recognised that AS is not the ‘immunologically silent’ disease that it was 
once thought to be and it is evident that other body systems may be involved. 
Approximately 20-40% of patients will also present with extraspinal joint disease at 
some point in the course of their disease. This peripheral joint disease [PJD] frequently 
affects the lower limbs and although is similar to rheumatoid in appearance it is 
normally less severe. Hip and shoulder involvement may cause major disability 
although any joint may be involved. The initial changes seen in peripheral joints are 
similar to those seen in rheumatoid arthritis [RA] with tissue swelling and periarticular 
demineralisation followed by narrowing o f the joint space and bony erosion. Bony 
ankylosis is the final change and occurs more often in AS than in RA. Bony erosions 
can be seen in the region of the Achilles bursa and plantar spurs.
In 1850 Sir Benjamin Brodie (Brodie, 1850) gave a detailed clinical description o f a 
31-year-old man, with onset three years before, becoming completely rigid but without 
pain. This was described as a Tong continued chronic rheumatism of the spine with a 
hoop like deformity’ and ‘occasionally suffering severe inflammation of the eyes’. 
This was one o f the first descriptions o f an association between AS and Uveitis,
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(inflammation of the eye). Uveitis has been shown to occur in approximately 25% of 
AS patients. The iris itself or the iris and the ciliary body can become inflamed. 
Frequently both eyes can be involved although it is uncommon for both eyes to be 
affected at the same time.
The inflammation can occur as often as every two to three weeks and it has been 
suggested that attacks may be seasonal (Ebringer, 1985). The presence of uveitis has 
been suggested as indicating a more severe form of the disease. (Nussenblatt, 1996).
AS patients may also have pulmonary involvement where chronic infiltration and 
fibrotic changes in the upper lobe o f the lungs may occur. This slow progressive 
fibrosis tends to appear on average 18 years after onset and radiographs depict 
bilateral, upper lobe pulmonary fibrosis with occasionally cyst formation and 
parenchymal destruction (Court-Brown, 1965).
Approximately 3.5% of AS patients with a disease duration of less than 15 years and 
10% of those with a disease duration of up to 30 years have cardiovascular 
involvement. In those patients with more severe disease, heart disease is more common 
especially in those patients with peripheral joint disease or extra articular features. The 
most common findings are aortic incompetence, cardiomegaly and persistent defects in 
cardiac conduction.
Ileocolonoscopic studies have demonstrated the presence o f gut inflammation in as 
many as 60% of AS patients as well as being present in other spondyloarthropathies 
suggesting a common pathogenic mechanism in both diseases. The successful 
treatment of inflammatory bowel disease by sulphasalazine has also been shown to be 
effective in the treatment of SpA. A prospective study carried out by Mielants 
demonstrated a link between the presence of gut inflammation and active joint
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inflammation and correspondingly the absence of gut inflammation with disease 
remission in patients with a variety of SpA’s including AS (Mielants, 1995).
6
Legend for Figure 1
Post mortem X-ray o f spine from AS patient showing classical Kyphosis 
(Picture courtesy o f Dr. Max Field, Centre for Rheumatic Diseases, 
Glasgow Royal Infirmary, Glasgow).
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The first internationally defined and agreed criteria for the diagnosis of AS was in 
Rome in 1961, which was revised in New York in 1966 (Bennett, 1968). The 
definition of the New York criteria for AS is described in Table 1. Diagnosis is based 
on clinical features and radiographic evidence of grade III or IV bilateral sacroiliitis, 
together with a history of pain. There are five grades of sacroiliitis according to the 
New York criteria ranging from 0 where the joint is normal to grade IV where there is 
definite ankylosis. The condition is considered to be primary if no other 
rheumatological symptoms are present and secondary if conditions such as psoriatic 
arthropathy, inflammatory bowel disease or Reiter's syndrome accompany the 
sacroiliitis.
A limitation of the Rome criteria was that spinal movement was not defined. The New 
York criteria does define a limitation of chest expansion as 2.5cm or less and although 
chest expansion is normally reduced in AS its measurement does have drawbacks in 
that some patients may be reluctant to take a deep breath. Also reduced chest 
expansion is normally seen late on in the course of the disease when the diagnosis has 
been well established. Other measurements such as spinal movement especially lumbar 
and cervical spines, wall-tragus distance and in early cases tenderness of the sacro-iliac 
joints all aid diagnosis. There are several features that help distinguish AS from 
mechanical back pain such as morning stiffness, which is nearly always a symptom of 
spondyliitis. The AS patient’s pain improves with activity and will worsen with 
inactivity and pain relief can be achieved with non-steroidal anti-inflammatory drugs.
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AS has in the past often gone undiagnosed since low grade back pain may be mistaken 
for mechanical back pain. An individual may have pain free sacroiliitis which unless 
they were being X-rayed for another reason would go undiagnosed.
In the past women have gone undiagnosed due possibly to a reluctance to carry out 
pelvic X-rays and a tendency to blame female pelvic organs for chronic low back pain 
(Calin, 1975). However the treatment o f AS and mechanical back pain differ greatly 
and therefore an early diagnosis is o f great importance in order to establish the correct 
therapy.
There are obviously other criteria used in the diagnosis o f AS such as the European 
Spondylarthropathy study group (ESSG) criteria however the patients in this study 
were diagnosed on the basis of the New York criteria. The purpose of this study was 
not to evaluate the different diagnostic criteria and therefore they were not discussed 
here.
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Table 1: New York Criteria for AS
Clinical criteria
1. Limited movement o f the lumbar spine in all three planes (anterior 
flexion, lateral flexion and extension).
2. History or pain in lumbar spine or at dorsolumbar junction.
3. Chest expansion limited to less than 2.5cm
Radiological Grading 
Definite AS
1. Grade 3-4 bilateral sacroilitis with at least one clinical criterion
2. Unilateral grade 3-4 sacroilitis, or grade 2 bilateral sacroilitis with 
clinical criterion 1 or both clinical criterion 2 and 3.
Probable AS
1. Grade 3-4 bilateral sacroilitis with no clinical criterion.
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1.4 Epidemiology
With increased awareness of the condition, better diagnostic criteria and the link with 
B27 well established it has been possible to carry out population studies to give a 
clearer picture of the epidemiology of AS. AS was originally thought to be a male 
orientated disease with often a ratio of 10:1 being quoted (West, 1949). However this 
picture has changed and several large studies have put the ratio at nearer 3:1 in favour 
of males. There have been several reports suggesting that the progression and disease 
severity tends to develop more rapidly in males than in females. This leads to a delay 
in diagnosis in females to an average of 10 years after onset compared with 3 years in 
males (Hill, 1976). One major difference between males and females is that females 
are reported to have more peripheral joint involvement, which has sometimes led to a 
misdiagnosis of seronegative rheumatoid arthritis.
In comparison to rheumatoid arthritis AS has an early onset with sacroiliac and spinal 
disease developing in males with primary AS around the age of 20. An early onset was 
considered to indicate a more severe form of the disease as is the presence of extra 
spinal joint disease (Wilkinson, 1958). The pattern of onset also appears to differ in 
different parts of the world with an early onset seen in developing countries compared 
to the later onset seen in developed countries. A study from 1992 in patients from the 
United Kingdom has also suggested that the age of onset is increasing in this country 
(Will, 1992).
The prevalence of AS throughout the world has been a subject of much debate. The 
under diagnosis in females as described earlier and the lack of facilities in developing 
countries to confirm diagnosis by X-ray have all lead to conflicting rates of incidence. 
The prevalence of AS has been easier to establish since the discovery of the link with
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B27. The true prevalence of AS in developed countries ranges from 0.25-1%, with a 
peak of around 2.5% being found in Norway. The apparent low prevalence o f AS in 
black Africans appears to follow the distribution of the B27 gene, which has a lower 
incidence in this population than the West were B27 is seen in approximately 8% of 
the general population. A recent study has put the incidence of B27 in a population of 
black West Africans at 6% (Brown, 1997). This is confirmed in a population of Haida 
Indians were the incidence of B27 is found to be approximately 18-50% and 
correspondingly the prevalence of AS is increased. AS is seen less frequently in 
Japanese populations where the incidence of B27 is less than 1%.
The non infective inflammatory nature of AS has been well established with the 
primary pathologic site being the enthesis (insertion of ligaments into bone) in 
comparison to rheumatoid arthritis where the main pathologic site is the synovium 
(Bywaters, 1968). The initial lesion appears to be non-specific inflammation that tends 
to be brief but recurrent. Rheumatoid arthritis is characterised by joint destruction and 
instability whereas AS is characterised by fibrosis and ossification. In the spine this 
process leads to squaring of the vertebral bodies as can be seen in Figure 2. Periods of 
inflammation followed by new bone growth leads to syndesmophyte formation, which 
are vertical outgrowths of bone from a vertebra. Fusion of these syndesmophytes 
across joints between vertebrae contributes to the rigidity o f the spine. The process 
normally begins in the sacroiliac joints and Figure 3 demonstrates sclerosis (hardening 
of the tissue due to fibrosis following inflammation) in the sacroiliac joint of an AS 
patient. The disease tends to progress from this joint in an ascending pattern although
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progression may be sporadic and slow. Not all patients progress to end stage disease 
where the spine takes on the classical bamboo shape seen in Figure 1. The fused spine 
has the classic kyphosis shape that gives rise to the posture seen in Figure 4 of a patient 
with severe end stage disease.
The pathology o f the inflammatory enthesopathy has been difficult to determine as 
biopsy material is not readily available and most work has been established using post 
mortem tissue. The histopathology at this stage may differ from the initial stages o f the 
disease. It has been shown that there is an inflammatory cell infiltrate that tends to 
spread along small vessels that lie within or close to the ligament causing lesions, 
which are directly repaired by the deposition of reactive bone. It is this new bone that 
leads to the formation of the bony spurs. It is this cycle of inflammation followed by 
ossification and the localisation o f the disease to the spine and sacroiliac joints, which 
has made the pathogenesis o f AS difficult to understand. A recent study examined the 
histology o f computed tomography assisted biopsies from the sacroiliac joint o f AS 
patients (Braun, 1995). They confirmed the presence o f T cells and macrophages in the 
cellular infiltrates o f the joints o f five AS patients with active disease. Messenger RNA 
for the cytokine Tumour Necrosis Factor [TNF] was detected in abundance along with 
message for Transforming Growth Factor p2 [TGFf32] at the site o f new bone 
formation. The presence o f TNF may have important implications for a possible 
therapeutic intervention in AS as has been seen in rheumatoid arthritis (Elliot, 1995). 
A further study has used this technique to make a quantitative analyses of sacroiliac 
biopsies confirming the predominate role of T cells and macrophages in early and 
active sacroiliitis (Bollow, 2000).
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Approximately 30% of AS patients also develop a peripheral arthritis at some point in 
their disease whereby joints out with the axial skeleton become inflammed. Biopsy 
material from diarthrodial joints o f AS patients appears to be very similar in the type 
and density o f inflammatory cell infiltrate to that of rheumatoid patients (Julkunen, 
1966). The synovial fluid of AS patients was reported to contain less 
polymorphonuclear cells and a higher percentage of lymphocytes than fluid from 
rheumatoid patients (Kendall, 1973).
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Legend for Figure 2
X-ray o f spine from AS patient showing fused lumbar vertebrae with 
syndesmophytes linking vertebrae. (Picture courtesy o f  Dr. M ax Field, 
Centre for Rheumatic Diseases, Glasgow Royal Infirmary, Glasgow)
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Legend for Figure 3
Pelvic radiograph o f AS patient showing sclerosis and loss o f jo int space in 
sacroiliac joints. (Picture courtesy o f Dr.M ax Field, Centre for Rheumatic 
Diseases, Glasgow Royal Infirmary, Glasgow).
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X  e t -
Legend for Figure 4
Figure 4 shows a male AS patient attending the Centre for Rheumatic 
Diseases showing severe end stage o f disease. (Picture Courtesy o f 
Professor Sturrock, Centre for Rheumatic Disease, Glasgow Royal 
Infirmary, Glasgow).
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1.6 Genetics of AS
Since the 1950's it has been recognised that, AS has a strong hereditary component 
with twin and family studies suggesting a strong genetic link long before the 
association of AS with HLA B27 was established. For example the disease was said to 
be 30 times more prevalent in relatives of AS patients compared to controls (Strecher, 
1957). The discovery in 1973 by two independent groups of the strong link between 
AS and the MHC class I gene HLA B27 has helped in the explanation of this family 
association (Brewerton, 1973). HLA B27 has been shown by several groups to be 
present in approximately 95% of AS patients whereas the prevalence of B27 in the 
normal West of Scotland population is approximately 9%. The prevalence of AS in the 
West of Scotland is between 0.5 and 1% of the population. The fact therefore that there 
are individuals who carry the B27 gene who do not have the disease and vice versa 
suggests that there may be other genetic or environmental factors involved. A recent 
study has been undertaken by a group in Germany where they have investigated a large 
group of blood donors for the prevalence of spondylarthropathy in conjunction with the 
presence of B27 and found that 6.4% of the B27 positive subjects investigated had 
definite SI changes indicative of AS (Braun, 1998). This may have consequences for 
any study where normal B27 positive blood donors are used as the control population 
as they may have asymptomatic sacroilitis thereby under-estimating the risk of AS in 
B27 positive individuals. However the contamination of the blood donors with 6.4% 
having AS is not likely to have a major effect, as the genetic risks we are looking at are 
relatively weak.
Since the discovery of the link between AS and B27 estimates of the risk apportioned 
to B27 have varied from between 35-50% (Rubin, 1994, Brown, 1995). However a
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recent study on a large cohort of monozygotic and dizygotic twins has claimed the 
overall disease risk attributable to B27 to be approximately 16% (Brown, 1997). Due 
to the different statistical techniques used in these studies however it is unlikely that 
the risk apportioned to B27 is probably not significant. Although there may be 
controversy as to the true risk defined by the gene for B27 and also to the role of B27 
in the pathogenesis of AS, it is well recognised that there is increased prevalence 
among relatives of AS patients. Several family studies have shown that for first degree 
relatives of B27 positive AS patients the risk of developing the disease is 
approximately 20% (van der Linden, 1984). Pooled data from all published studies 
(ascertainment bias minimised) on family recurrence however puts the risk in first 
degree relatives at considerably less than 20% (Brown, 2000). If only a single gene was 
involved the concordance rate amongst monozygotic twins would be 100%. This is not 
the case in AS. Also most B27 positive relatives of B27 positive AS probands show no 
evidence of disease and these two facts point to the involvement of additional genetic 
and environmental factors. This raises the question as to what other genes might be 
involved?
1.7 MHC Class I Associations
Since the discovery of the association of AS with the MHC class I molecule HLA B27 
its role in the disease pathogenesis has been investigated. However even though it is 
one of the strongest known associations between an autoimmune disorder and an MHC 
gene its actual role has yet to be established and several theories have yet to be 
confirmed or denied. One suggestion is that a bacterial agent is involved in the disease 
pathogenesis of AS and that the B27 molecule through its antigen presentation role is
19
crucial to this process. This has been demonstrated by the use of transgenic animals 
expressing human B27 genes whereby the animals develop a spondyloarthropathy 
similar to the disease seen in humans when the animals are maintained in conventional 
facilities (Hammer, 1990). However the disease does not develop if  the animals are 
maintained in a germ free environment highlighting the need for both genetic and 
environmental susceptibility factors in this disease.
Molecules of the MHC class II and class I regions are vital to the initiation o f the 
immune response in that they are necessary for the presentation of antigen to T cells. 
Only antigens bound to membrane associated MHC molecules can be recognised by T 
lymphocytes. The class II and class I loci differ in the type of antigen they present and 
in the population of T cells they present to. The class I MHC molecules tend to present 
endogenously synthesised proteins to CD8 + T cells whereas the MHC class II 
molecules present antigens from extracellular proteins to CD4 + T cells.
All class I molecules B27 included consist of two separate polypeptide chains, the 
polymorphic a  chain which noncovalently pairs with a non-polymorphic molecule p2 
microglobulin. The 44 kilodalton [kD] a  chain is encoded by the MHC and the 12kD 
p2 microglobulin is encoded on chromosome 15. Three quarters o f the a  chain 
protudes into the extracellular matrix with a short hydrophobic segment crossing the 
membrane and a carboxy terminal with 30 amino acids located in the cytoplasmic 
region. The p chain interacts non-covalently with the extracellular portion of the a  
chain known as a3 and has no connection to the cell. Peptides bind to the class I 
molecules through approximately 180 amino acid residues of the amino terminus of 
the class I a  chain. This region consists of two homologous segments of about 90
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amino acids each termed a l  and a2 which are linked by a single N-linked 
oligosaccharide at the junction between a l  and a2. The a l  and a2 segments interact 
to form a platform of an eight-stranded (3 sheet supporting two parallel strands o f a- 
helix (see figure 5).
The two a-helices form the sides of a cleft whose floor is formed by the strands o f the 
p-pleated sheet. This cleft, which is capable o f binding 10-20 amino acid protein 
fragments is the presumed site of peptide binding. The small size of the cleft means 
proteins have to be processed to smaller fragments that can be bound and presented to 
T cells. It is differences in the amino acids in the a-helical sides o f the cleft or the (3 
strands that form the floor of the cleft that give rise to the ability to bind different 
peptides. As was mentioned before MHC class I molecules present peptides to CD8+ T 
cells and it has been shown that it is the nonpolymorphic a3 segment that contain the 
binding sites for the T cells.
The gene for the B27 molecule lies within the MHC class I region on the short arm of 
chromosome six. The MHC itself can be divided into three regions; the class II, which 
includes the DR, DP and DQ loci, the class III which contains genes some of which are 
involved in the inflammatory process such as complement genes and the gene for 
tumour necrosis factor and the class I which contains the HLA A, B and C loci. A 
diagrammatic representation of the MHC is shown on figure 6.
The MHC genes are highly polymorphic and many different alleles exist within the 
population and these alleles differ in their ability to bind and present many different 
antigens thereby allowing the MHC to control the immune response to protein 
antigens. The region consists o f several tightly linked genes that are co-dominantly
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expressed. The total set of alleles for all the MHC genes gives rise to the MHC 
haplotype. In humans certain HLA alleles at different loci are inherited together in 
linkage disequilibrium. There is evidence that such haplotypes may be associated with 
certain autoimmune diseases (Dawkins, 1993).
There are a large number of alleles at the HLA-A, B and C loci each having 59, 118 
and 36 alleles respectively. At present there are 22 different B27 subtypes with B*2705 
being the most common in European Caucasians followed by B*2702. Several groups 
have investigated the distribution o f these subtypes among different populations along 
with possible associations of a particular subtype with the presence o f AS. This has 
been disappointing as most studies have shown an equal distribution of the subtypes in 
normal and disease populations (Breur-Vriensendorp, 1987), with B*2702, B*2704 
and B*2705 all equally linked to disease. The subtypes B*2703, B*2706 and 6*2709 
have not been shown to be associated with disease in population studies with B*2706 
and B*2709 being suggested as having a possible protective role for AS (Ren, 1997). 
Larger patient and control populations are required to confirm the distribution of 
susceptible and protective subtypes along with a better understanding of how the 
disease pathogenesis can be altered by the presence of just a few different amino acids 
which is all that distinguishes these different subtypes. Studies involving animals that 
are transgenic for these different subtypes are under way and will hopefully shed light 
on the role o f B27 in AS.
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Legend for Figure 5
Diagrammatic representation o f an HLA B*2705 molecule highlighting the 
sites (shown in red) at which it differs from other subtypes o f HLA B27 
(taken from Immunology Today, 1996;!7:6).
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Main Genetic Regions o f the MHC
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Legend for Figure 6
Figure 6 is a diagrammatic representation o f the main regions o f the M1TC. 
Highlighted below are some o f the polymorphic sites that are known within 
the TNF locus.
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Along with the clear association of AS with HLA B27 there have been several reports 
o f associations with MHC Class II genes. A recent study of dizygotic twins found those 
carrying the B27-DR1 haplotype were more concordant for disease than B27 positive 
DR1 negative twins (Brown, 1997). Another association between a small group of 
Sardinian AS patients and a B27-DR2 haplotype was observed (La, 1993) which is 
consistent with the finding of similarities in peptide presentation by DR2 and B27 
(Lopez, 1993), although this observation has not been confirmed in other populations. 
Other observations have linked the presence of particular alleles with the presence of 
extra spinal features such as the carriage of DR(31*0803 being a risk factor for the 
development of Acute Anterior Uveitis [AAU] in a group of Japanese AS patients 
(Monowarul Islam, 1995). This finding has been subsequently attributed to DR8 being 
associated with a younger age of onset, not AAU primarily (Ploski, 1996). The 
presence of DR4 has also been reported as a risk factor for the presence of peripheral 
joint disease (Miehle, 1985).
The MHC class II molecules consist of two polypeptide chains of similar size and 
structure. The a  chain is 32-34KDa and is non-covalently associated with the p chain 
which is approximately 29-32KDa. Each chain consist of an external region linked by 
a connecting peptide to a transmembrane region followed by a cytoplasmic tail with 
two thirds of the chains lying in the extracellular space (see figure 7). The two chains 
are synthesized separately but associate shortly afterwards in the cytoplasm along with 
a third chain y. The three chains only remain associated as long as they remain inside 
the cell once they reach the plasma membrane the y chain dissociates itself leaving just
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the a  and p chain expressed on the cell surface. The class II molecules domain 
structure is similar to the class I domains (figure 5) with the a l-p i domains forming 
the groove which is believed to serve as the binding site for the processed antigen. 
This antigen binding groove is formed by a floor of p-pleated sheet conformation with 
the sides formed by the a  helices. The ends of the floor are open allowing access for a 
larger peptide, which is clipped to a smaller peptide of about 25 residues before the 
complex is transported to the cell surface. As with the class I molecules it is genetic 
polymorphisms that determine the amino acids that lie within the a  1, p i residues that 
give rise to the ability to recognise different antigens.
The MHC Class II genes lie closest to the centromere on the short arm of chromosome 
six (as shown in figure 6). This region consist of several genes the majority o f which 
are associated with immunity such as the DR, DQ and DP loci which are the major 
products and are involved in antigen presentation to CD4+ T cells. It has been shown 
that there is variation in the number of functional a  and p chains with for example the 
DR loci having a single a  gene and up to nine p genes. This along with the large 
number of potentially different alleles at each loci due to genetic polymorphism made 
the standardisation for the nomenclature o f this region very important. The class II 
genes are designated by three capital letters followed by a series o f numbers o f which 
the first letter identifies the gene. The second letter specifies the family and the third 
letter indicates the gene type i.e. A for the a  chain and B for the P chain. The first 
number specifies the locus and the remaining numbers the allele, which are usually 
separated by an asterisk. The first two digits indicate major alleles and the following 
digits the minor variants e.g. DRB 1*0401.
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There are a large number of possible alleles at each locus for example HLA-DRB1 has 
168. These nucleotide variations lead to discrete changes in the gene product, which in 
turn may have functional consequences in that they influence the way the HLA 
molecule binds and presents the antigenic peptide. This large number of possible 
alleles means a large number o f possible peptides may be recognised.
The evolutionary mechanisms that appear to have brought about this extensive genetic 
polymorphism seems to utilise a form of segmented exchange in which genes are 
interspersed and interchanged with other HLA genes. This means specific sequence 
patterns at particular gene loci are often repeated in other alleles. These regions are 
often called “ hypervariable regions”. This mechanism sheds light on the “shared 
epitope” theory that has been implicated in RA. Originally RA was associated with 
DR4 but with the advent of molecular typing techniques and the clearer understanding 
of the genetic organisation of this region it became apparent that RA was associated 
with not all o f the DR4 alleles and was also associated with other DRB1 genes. It 
would appear that the acquisition and or severity of RA depend on the presence of a 
particular sequence in the third hypervariable region of the DRB1 chain. This region 
termed the “shared epitope” has particular amino acids at residues 67-74 which are 
thought to be important in the way the HLA-DR antigen complex is presented to T 
cells.
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Schematic diagram o f a class II molecule (Abbas AK. Lichtman AH. Pober 
JS. Cellular and Molecular Immunology, 19 9 1, pg 108).
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Legend for Figure 8
A diagrammatic representation o f the TNF gene cluster highlighting some o f 
the polymorphic sites investigated in this study, along with some other sites 
that were not studied.
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If the class II loci have an important role to play in RA may it also be involved in any 
other autoimmune disorders such as AS? The class II is involved in presenting antigen 
to CD4+ T cells and the class I presents to CD8+ T cells as mentioned before, therefore 
in AS which is linked to class I the number of circulating CD8+ T cells would be 
expected to be more than the number of CD4+ but this is not the case there appears to 
be more CD4+ T cells. The previous literature suggests also that the class II loci may 
be additional susceptibility loci for AS with links with particular alleles and disease 
itself or with markers of disease severity.
1.9 rumour Necrosis Factor
Tumour necrosis factor [TNF] is an important proinfiammatory cytokine that plays a 
key role in the pathogenesis of many infections and inflammatory diseases. It is a 
principal mediator of the host response to gram-negative bacteria contributes to the 
regulation of normal homeostasis and has both beneficial and adverse effects in 
infectious disease. TNF was originally identified through its ability to lyse tumour cells 
(Carswell, 1975), although its ability to do so was actually noted nearly 100 years ago 
when a tumour necrosing effect coincident with infection was seen by Coley in a 
patient with a sarcoma of the neck. Subsequently Coley’s toxins (sterilised gram- 
negative bacteria) were used to treat tumours in the early 1900’s (Coley, 1906). By the 
mid 1980’s the protein had been purified and sequenced following the cloning of the 
gene.
TNF belongs to a family of proteins that, includes TNFa, lymphotoxin a  (previously 
known as TNFP) and lymphotoxin [3. Activated monocytes (macrophages) are the
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major source of TNFa, which is synthesised as a 20kDa pro-protein that is cleaved by 
TNFa converting enzyme [TACE] to a 17kDa monomeric form. Under physiological 
conditions TNFa circulates as a stable cone-shaped homotrimer (Jones, 1989). This 
soluble trimer mediates its effects by binding to two receptor molecules TNF RI (p55) 
and TNF RII (p75). TNF induces a number of effects including cytokine production, 
expression o f adhesion molecules, activation o f neutrophils, costimulator for T cell 
activation and stimulates antibody production by B cells. TNFa contributes to the 
regulation of normal homeostasis as well as playing an important role in inflammation. 
In autoimmune conditions such as rheumatoid arthritis TNFa contributes to the 
pathogenesis of synovitis and joint destruction through its ability to stimulate fibroblast 
growth, induction of prostaglandin E2 and collagenase release from synovial cells. It is 
able to induce the resorption of bone and cartilage and inhibit the synthesis of 
proteoglycan in cartilage, increases adherence o f granulocytes and macrophages and 
regulates the production of Interleukin 1 [ELI]. TNFa has been detected in synovial 
fluid from RA patients and mRNA has been detected in synovial cells confirming the 
local production of TNFa in inflammed tissues (Chu, 1991).
Lymphotoxin p is a transmembrane protein that belongs to the TNF related ligand 
family along with lymphotoxin a  previously known as TNFp which was originally 
identified as a soluble cytotoxic factor involved in type I delayed hypersensitivity 
reactions. The activities of both cytokines overlap due to their binding and signaling 
through the same two receptors. The primary pathophysiological role o f the soluble 
forms o f these cytokines is to promote defence against infection. Lymphotoxin a  can 
be secreted or retained at the surface of the cell by binding to LTp in a 1:2 ratio. This
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surface heterotrimer called lymphotoxin recognises a different receptor than TNFa and 
LTa alone and is made specifically by lymphocytes. The role o f lymphotoxin in 
autoimmune conditions is not fully understood.
The genes for TNFa, LTa and LTp have all been cloned, sequenced and mapped to the 
MHC Class III loci on the short arm of chromosome six. This places the TNF genes in 
close proximity to the HLA B27 locus. The TNF genes are tandemly arranged within a 
7Kb region 250Kb centromeric to the HLA B locus and 340Kb telomeric to the C2/BF 
locus. The location of the TNF genes, its well established proinflammatory activity and 
its importance in joint destruction in rheumatoid arthritis as confirmed by the 
therapeutic use of monoclonal antibodies to TNF in clinical trials have suggested that 
the TNF loci may be important in HLA associated diseases. A recent study has Shown 
increased messenger RNA levels for TNF in biopsies taken from the sacroiliac joint of 
AS patients suggesting that this cytokine has a role to play in AS (Braun, 1995). The 
search for a possible involvement of TNF in autoimmune and infectious diseases led to 
the discovery of polymorphisms within the TNF genes. There have been several 
polymorphic sites described some of which are highlighted on figure 8.
Previously it has been reported that there are significant inter-individual variations in 
the level of TNFa induction in normal individuals suggesting production may be 
genetically controlled (Jacob, 1990). In autoimmune animal models it has been 
demonstrated by several groups that there is abnormal TNFa production especially in 
models of genetically determined DDDM in BB rats and NOD mice (Jacob, 1988) 
suggesting even minor stable differences in TNF production may have a role to play in 
the resulting immune response. Previous work has shown associations with particular
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alleles at individual polymorphic sites to be associated with differences in TNF 
production in vitro (Pociot, 1995). Several groups have also demonstrated associations 
of individual alleles with susceptibility to different autoimmune diseases such as 
IDDM (Pociot, 1993), SLE (Wilson, 1994) and RA (Brinkman, 1997).
This raises the question are there particular alleles that predispose individuals to higher 
levels of TNF making them more susceptible to HLA associated disease? The 
individual polymorphic sites examined in this study will be discussed separately in the 
methods section.
A recent genome screen of AS patients and their families for non-HLA susceptibility 
markers highlighted several other regions has having a significant contribution to AS 
(Brown, 1998). They suggested the contribution by non- MHC genes was 
approximately 60% and that AS is a model of a polygenic disease. One of the areas 
highlighted was on chromosome 2 close to the loci coding for the Interleukin 1 genes. 
There are two proteins that are designated as Interleukin l(IL-l), IL -la  and IL-1 [3 
which are products of distinct genes but both proteins recognise the same cell surface 
receptors. IL-1 is another cytokine that has an important role to play in the 
inflammatory response and its production is closely linked with that of TNF in the 
rheumatoid synovium. Like TNF stable variations in production rates have been 
observed, which may be genetically controlled (Molvig J, 1988). Several 
polymorphisms have been described that lie within the promoter regions of both IL-1 a  
and IL-1 (3 genes that have been suggested may alter transcription rates of these
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cytokines. These facts suggested that differences in frequencies o f these alleles may 
have a role to play in the pathogenesis of AS.
IL-1 was initially described in the late 1960’s as a protein produced by macrophages in 
response to infection or inflammation that induced fever hence its previous name of  
endogenous pyrogen. It is known to induce acute phase reactions, aid in lymphocyte 
proliferation, induce release of collagenase and prostagladins from synovial cells. It is 
also involved in proliferation of fibroblasts, helps promote bone resorption and 
cartilage destruction and has been implicated in the destruction of the rheumatoid 
joint. Normal production of IL-1 is crucial for the host response to injury or infection 
but inappropriate or prolonged exposure has been implicated in a number of different 
pathological conditions such as sepsis, RA, inflammatory bowel disease, IDDM and 
atherosclerosis. IL-1 is produced by a number of cell types including monocytes, 
macrophages, fibroblasts, keratinocytes and osteoblasts.
IL-1 a  and IL-1 (3 are both synthesized as 31kDa precursors, which are subsequently 
cleaved to proteins of 17 kDA, which show approximately 25% homology at the amino 
acid level and have similar biological properties. The mature 17kDa protein is the 
physiologically significant form, which is secreted from the cells. There is also a 
membrane bound from of IL-1 a  but its biological and physiological role is unclear. IL- 
1 mediates its response through two specific receptors termed IL-1R type I and EL-1R 
type II. Type I is a 80kDA protein found mainly on T cells, fibroblasts and 
keratinocytes and as a receptor binds IL-1 a  better than IL-1 p. Type II is a 68kDa 
protein found mainly on B cells and PMN’s and binds IL-lp more strongly than IL- 
la . The two receptors show approximately 28% homology in their extracellular
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domains but differ in their cytoplasmic domains. Only ligand binding to the Type I 
receptor induces signal transduction and all biological effects are attributed to IL-1 
binding to this receptor. Both receptors are members o f the Ig superfamily. The Type II 
receptor is membrane bound and acts as a precursor for a soluble IL-1 binding factor 
that can be shed under appropriate conditions which antagonises and modulates the 
activity of IL-1 (Sims, 1993). Glucocorticoids such as Dexamethasome are able to 
upregulate this receptor explaining some of the anti-inflammatory properties of these 
compounds.
Another naturally occurring IL-1 inhibitor is a protein termed IL-1 receptor antagonist 
(IL-IRa), which is produced by monocytes, neutrophils, macrophages and fibroblasts. 
This secreted molecule of 25 kDa shows 26% homology to IL-1 p and 19% homology 
to IL-1 a. By binding to the IL-1 Type I receptor, IL-IRa competitively inhibits the 
action of EL-1 since its binding does not result in signal transduction. IL-6, INFy, IL-4, 
GM-CSF and TGFp are able to upregulate the production of secretory IL-IRa. Pre­
treatment with IL-IRa has been shown in vitro to prevent death due to septic shock 
produced by LPS injection in rabbits (Ohlsson, 1990). Both IL-1 and EL-IRa are 
present in the joints of Rheumatoid patients but it has been suggested that the 
concentration of IL-IRa is too low to effectively inhibit the action of IL-1 (Firestein, 
1994). Although EL-IRa binds to the receptor with high affinity a 10-100 fold excess is 
required to inhibit the biological response of IL-1 by 50%. Pre-clinical and clinical 
trials are underway to study the use o f IL-IRa in RA.
As was mentioned before stable inter individual differences in cytokine production by 
monocytes stimulated by LPS suggest that production may be genetically controlled to
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produce higher or lower amounts of IL-1 (Danis, 1995). The three genes coding for IL- 
la , IL-ip and IL-IRa all lie in close proximity on chromosome 2. Recently a 
restriction map of this region has been constructed showing the three genes mapped to 
a common restriction fragment of approximately 430Kb (Nicklin, 1994). The three 
genes were mapped relative to one another at the following intervals: IL-1 a  was 
between +0 and +35Kb, IL-ip between +70 and +110Kb, and IL-IRa between +330 
and +430Kb. Polymorphisms have been recently described which lie within the 
promoter region of the IL-1 a  and IL-1 p gene and within intron 2 o f the IL-IRa gene. It 
is proposed that variations within these polymorphic sites may be involved in the 
susceptibility or severity of AS. The individual sites examined will be described more 
fully in the methods section.
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Although the association between B27 and AS is very strong it is not thought to be the 
only gene involved and other candidate genes have been proposed as contributing to 
the susceptibility of AS.
I. The MHC class II alleles have been proposed as further candidate genes due to 
their location on chromosome six, the strong association with other autoimmune 
disorders such as RA, their role in antigen presentation and work by previous 
studies suggesting associations with extra spinal features such as peripheral joint 
disease and uveitis. The occurrence of ancestral haplotypes spanning the Class I, 
II and III loci which appear to have relationships with TNF levels also suggest 
that this loci may have a role to play in the pathogenesis of AS. The aim was to 
type the AS patients and controls at the DRj31 loci and to subtype the DRpl*04 
positive individuals to examine for the presence of associations with disease as a 
whole or with the presence of extra spinal features.
II. The TNF genes have been implicated because of their location within the Class 
III loci in close proximity to HLA B27, the demonstration of increased mRNA 
levels in biopsies from the sacroiliac joints of AS patients and its well established 
proinflammatory properties. The existence of polymorphisms some of which have 
been shown to be associated with variations in TNF production may be a possible 
contributing factor to the pathogenesis. The aim was to investigate several of 
these polymorphic sites spanning the TNF locus in a large group of clinically well 
defined AS patients and controls to determine if there were any significant 
differences in the frequency of the alleles at each site. The distributions of the
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alleles were also investigated for associations with any extra spinal features that 
may indicate a more severe pattern of disease.
ID. Polymorphisms within the Interleukin 1 genes were examined because o f the
results o f a whole genome screen, which highlighted a significant relationship 
with an area on chromosome 2 where the IL-1 genes lie. The pattern o f AS in 
patients and family members suggest other genes are involved. The pro- 
inflammatory nature of this cytokine and the association of particular alleles with 
other autoimmune diseases and the functional differences seen with particular 
alleles have suggested that this area may be important in susceptibility to AS. The 
aim was to examine three polymorphic sites in AS patients and controls in order 
to determine any association with particular alleles and the presence of AS or the 
presence of extra spinal features.
It is strongly suggested that AS is a polygenic disease and it is hoped that this study may 
highlight the possible role of other genes involved in the pathogenesis of AS.
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MATERIALS
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The patients enrolled in this study were all attending the outpatients department of the 
Centre for Rheumatic Diseases, University Department of Medicine, Glasgow Royal 
Infirmary, Glasgow. All patients had previously been examined by a clinician (RDS) and 
fulfilled the New York criteria for the diagnosis of AS (Bennett,P.H, 1968). At the time 
of sample collection a detailed history was recorded (see appendix A for copy of form). 
This included screening the patients for the presence of extra-spinal features such as 
peripheral joint disease and uveitis. The diagnosis of peripheral joint disease was based 
on the presence of inflammed joints outwith the axial skeleton. lOmls of blood in EDTA 
tubes was collected from each patient. All patients in the study had previously been tissue 
typed and were known to be HLA B27 positive.
Purified DNA was supplied from a panel of 93 healthy unrelated normal volunteers who 
were HLA B27 negative by the Department of Tissue Typing, Glasgow Royal Infirmary, 
Glasgow. A second control group consisted of purified peripheral blood mononuclear 
cells of 88 individuals who had been previously tissue typed as HLA B27 positive by Law 
Blood Transfusion Services, Carluke, Scotland. At the time of sample collection a 
general health questionaire was completed (see appendix B for copy of questionnaire) 
and although no specific questions relating to ankylosing spondylitis were asked this 
group of individuals they were taken as healthy controls.
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2.2 DNA Extraction
Traditionally the extraction of mammalian DNA has been based on the digestion of cells 
by proteinase K in the presence of EDTA and a detergent such as SDS, followed by 
extraction with phenol/chloroform and finally precipitation with ethanol. However the 
use of phenol is particularly hazardous and over the past few years there have been a 
number of DNA extraction kits that have come onto the market that avoid the use of 
phenol are less time consuming and increase reproducibility. In this study three methods 
were compared as to their safety, efficiency, reproducibility, yield and quality of DNA. 
The first was based on modifications of the method of (Blin,N., 1976) which uses the 
traditional method of lysing the red cells, purifying the white cells which are then lysed 
followed by extraction with phenol chloroform and finally precipitation with ethanol. 
The second method investigated was the Genomix kit (Talent srl, Trieste, Italy) which 
following initial lysis of the whole blood via a cationic detergent uses a simplified 
purification step involving another cationic detergent that forms a micellar complex with 
DNA . The detergent is removed via ionic exchange during resuspension of the pellet 
followed by precipitation of the DNA with ethanol. The third method was the Nucleon II 
genomic DNA extraction kit (Scotlab Limited, Lanarkshire, Scotland), which uses the 
proprietory Nucleon resin to remove all unwanted cell impurities without binding the 
DNA. To investigate the advantages and disadvantages of each method 30mls of whole 
blood was collected from five normal volunteers in EDTA tubes and divided into 10ml 
aliquots from which DNA could be extracted by each method. From the results (data not 
shown) the Nucleon method was best suited for the purposes of the study and therefore 
was the method used.
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For the Nucleon DNA extraction kit lOmls o f whole blood was collected in EDTA tubes, 
4x the volume of reagent A (lOmM Tris-HCl; 320mM sucrose; 5mM MgCl2; 1% Triton 
X-100; adjusted to pH 8.0 using 40% NaOH and autoclaved) was added in a 50ml 
polypropylene tube which was rotary mixed for 4 minutes at room temperature. This was 
centrifuged at 1300g for 4 minutes (Heareus megafuge 1.0R, Essex, UK) and the 
supernatant discarded without disturbing the pellet into bleach. The process was repeated 
with the pellet being resuspended in 500ul o f reagent A before being made up to 40mls. 
This second wash was not recommended in the protocol book but it appeared to help in 
removal o f more of the red cell debris than just one wash. Contaminating red cell debris 
may inhibit the PCR process due to the presence o f heme from the red cells, which has 
the ability to bind to the polymerase enzyme. The resultant pellet was resuspended in 2ml 
of Reagent B (400mM Tris-HCL; 60mM EDTA; 150mM NaCL; 1% SDS [added after 
autoclaving]; adjusted to pH8.0 with 40% NaOH) and vortexed briefly to ensure the 
pellet was fully resuspended. The cell suspension was then transferred to a 14ml 
polypropylene tube, 500ul of sodium perchlorate added and mixed by inverting at least 7 
times. After the addition of 2ml o f chloroform and mixing by inversion at least 7 times 
300ul of the Nucleon resin was added. No further mixing was required before 
centrifuging at 1300g for 5 minutes. Without disturbing the interface the upper layer was 
removed to a fresh tube. Two volumes of ice-cold absolute ethanol were added and the 
tube inverted several times until the DNA was seen to precipitate out of solution. The 
DNA was pelleted by centrifuging at 4000g for 5 minutes and the supernatant discarded 
before washing the pellet with 70% ethanol. The pellet was air dried for 15 minutes and
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then resuspended in 500ul of sterile distilled water. The pellet was left overnight at 37°C 
to ensure it had fully resuspended before reading the absorbance.
In order to estimate the quantity of DNA in each sample an absorbance reading was taken 
at both 260nm and 280nm on a Cecil Bioquest CE2501 spectrophotometer. An aliquot of 
each sample was diluted in sterile distilled water (normally a 1:500 dilution) and placed 
in a quartz cuvette. The spectrophotometer was first blanked with water alone before the 
samples were measured. The reading at 260nm gives an indication of the amount of 
nucleic acid in this case DNA in each sample and the reading at 280nm an estimate of the 
amount of protein. The ratio of the 260/280 readings give an indication of the purity of 
the sample, for DNA a ratio of approximately 1.8 is optimum. The 260nm reading was 
used to calculate the yield, as lOD unit at 260nm is equivalent to 50ug/ml of double 
stranded DNA.
The DNA was standardised in order to obtain a final concentration of between 100 to 
500ng in each PCR reaction.
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2.4 p Actin Polymerase Chain Reaction
The polymerase chain reaction (PCR) was first described in 1985 by Saiki R.K., and is a 
method of amplifying a segment of DNA that lies between two regions of known 
sequence.
P Actin is known as a housekeeping gene in that it is found in multiple copies in most 
cells and acts as a control gene for the PCR since if this gene cannot be amplified it is 
unlikely that the gene of interest can be amplified. The DNA samples were amplified by 
PCR for the pActin gene first and only those samples that gave a positive result were 
included in the study. The two primers specific for the p Actm gene (primer 1 5’ GTG 
GGG CGC CCC AGG CAC CA 3’ and primer 2 5’ CTC CTT AAT GTC ACG CAC 
GAT TTC 3’ ) give rise to a PCR product of 584 base pairs. All PCR’s were carried out 
on a Techne Genius PCR machine (Scotlab,Lanarkshire). Briefly lOOng of template DNA 
was amplified using 0.5 units of Taq (Advanced Biotechnologies) in a final volume of IX 
Buffer IV [200mM (NH4)2S 0 4, 750mM Tris-HCL, pH8.8, 0.1%(v/v) Tween 20] 
(Advanced Biotechnologies, Surrey, UK);1.5mM MgCL; 200mM dNTP’s (dATP, dGTP, 
dTTP,dCTP); 0.12uM of each primer made up to a final volume of 25ul. This was 
subjected to 5 minutes at 95°C followed by 30 cycles of 95°C for 1 minute, 60°C for 
1 minute and 72°C for 2minutes with a final extension of 72°C for lOminutes. An aliquot 
of the PCR product was mixed with loading buffer (50% glycerol, 50% 10X TBE with 
orange G) and run out on a 2% agarose (Gibco Life Technologies, Paisley, Scotland) gel 
in a horizontal gel tank (Anachem, Bedfordshire, UK) in IX TBE (Tris base, boric acid,
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EDTA) with a constant current of approximately 50mAmps. The gel was stained with 
ethidium bromide before photographing the gel on a UV transilluminator (see figure 9).
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Legend for Figure 9
In Figure 9 lanes 1-6 represent the amplified products from six 
individuals amplified with primers specific for the (3 actin gene. The 
product o f  548bp can be sized in reference to the molecular weight 
ladder seen in lane 8 (123bp Ladder). Lane 7 is the negative control 
(i.e. no template added).
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2.5 MHC Class II Associations
2.5.1 DRPI* Typing by SSP
HLA-DR typing in clinical practice has until recently been carried out by serological 
methods but the new advances in molecular techniques has greatly improved the 
reproducibility, resolution and accuracy of the typing. By using PCR to identify the 
allelic polymorphism of the DR(31 series the typing can be carried out in a fraction of the 
time needed for serology testing. The typing method relies on the specificity of sequence 
specific primers amplifying the template DNA in a PCR reaction where completely 
matched primer will be amplified more efficiently than a primer with one or several 
mismatches. The presence or absence of an amplified product can be detected by agarose 
gel electrophoresis. This sequence specific PCR was first used to distinguish between the 
wild type and mutant alleles for the diagnosis of sickle-cell anemia (Wu DY, 1989). The 
method is now becoming more widespread for the typing of MHC class I and class II 
alleles and a number of companies now supply kits containing all the relevant primers. 
The Micro SSP Generic HLA DRB kit used in this study was from One Lambda, Inc. 
(Canoga Park, CA) and includes sequence specific primers for amplification of D R pi, 3, 
4, 5 alleles of HLA Class II gene locus and the Human (3-globin gene. The amplification 
of the Human P-globin gene, which is present in all DNA samples acts as an internal 
control to verify the integrity of the PCR reaction.
The primers used in this kit have been pre-optimised and dried onto a 96 well 0.2ml thin- 
walled tube tray ready for the addition of the template, specially formulated dNTP-buffer 
mix and enzyme (Taq polymerase, Advanced Biotechnologies, Surrey, UK). The tray is
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then placed in the PCR Express thermocycler (Hybaid, Middlesex, UK) for the required 
number o f cycles.
The actual cycling conditions and full procedure can be found in the manufacturers 
instruction booklet. An example of a worksheet, which was filled out for each sample 
tested can be seen in Appendix C. The results were then recorded against the reaction 
pattern sheet supplied (appendix D) and the alleles assigned. A copy of the primer 
sequences is also in appendix E.
The PCR products were loaded directly from the typing tray onto a 2.5% agarose gel 
using the Micro SSP gel system (supplied by VH BIO, Newcastle, UK). This was run for 
five minutes before being photographed. An example o f a gel o f a patient typed at the 
DRp locus is given in Figure 10.
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Legend for Figure 10
Figure 10 is a representative gel picture o f an individual typed at the generic 
HLA DRB locus. The 24 wells each represent unique primer sets that 
distinguish which alleles are present. The upper band in each well is o f the 
control primers for p-globin gene. The lower band indicates which alleles are 
present. Well H /l is the negative control (no template added).
By recording which bands are present, for example in the gel pictured above 
wells G /l, F/2, C3 and A3 all have the lower band, and by referring to the 
table supplied by the manufacturers the individual alleles present can be 
determined. In this example the individual is heterozygous for alleles HLA 
DRp* 01 and 13.
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2.5.2 DR01 *04 Subtyping by SSP
A single HLA-DR type represents a serologically defined specificity, which can be 
present on many different molecules encoded by distinct genes for example HLA-DR4 
has at present 22 different alleles. These alleles known as DRp 1*0401-0422 are closely 
related to each other and differ by only a few amino acids. Interest in the D R pi*04 
alleles has arisen through the association with Rheumatoid arthritis.
The kit used in this study to identify the D R p i*04 subtypes was from Dynal (Oslo, 
Norway) and incorporated primer sets for identifying D R p i*0401 to D R p i*0422 
recognised by the HLA Nomenclature Committee in February 1996 (Tissue Antigens 
1995: 46: 1-18) as well as D R pi*1122 and D R p i*1410 (see appendix G for the 
D R p i*04 specificities). All primers were supplied in a diluted form in sufficient 
quantities for 50 reactions. Each primer solution consists of specific primer pair as well 
as control primers. A reaction mix suitable for 30 samples was prepared containing 500ul 
of lOx reaction buffer IV (Advanced Biotechnologies), lOul of each dNTP (stock 
concentration lOOmM), 300ul of 1.5mM MgCl2, 250ul of glycerol, 25ul of lOmg/ml of 
cresol red and 385ul of sterile distilled water. This was vortexed to make sure the 
glycerol was well mixed and was stored frozen until required. For each individual sample 
5ul of each primer mix was added to 12 0.2ml thin walled PCR tubes (Advanced 
Biotechnologies, Surrey, UK). To 42ul of the reaction mix was added l.lu l of Taq 
(Advanced Biotechnologies, Surrey, UK) and 1.4ug of template DNA in 27ul of sterile 
water and 5ul of this was added to each of the 12 tubes. These were then subjected to 10 
cycles of 94°C for lOsec, 65°C for lmin followed by 20 cycles of 94°C for lOsec, 61°C
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for 50sec and 72°C for 30 sec on a Techne Genius PCR machine (Techne, Anachem, 
UK). The samples were then loaded directly onto a 2%  agarose gel run in lx  TBE at 
50mAmps. The gel was stained with ethidium bromide and viewed on a UV 
transilluminator and photograhed. A representative gel picture of AS patients typed for 
DRp 1*04 is shown in Figure 11. By comparing the pattern of bands with the
i
I manufacturers table of specificities (appendix G) the individual can be assigned their 
particular alleles.
50
Secon
Legend for Figure 11
The results o f two individuals subtyped at the HLA DRp 1*04 locus are 
shown in Figure 11. The 12 lanes on the 2% agarose gel represent 12 
different primer sets that distinguish between the different alleles. Lane 13 is 
the 123bp molecular weight marker. The top band in each lane is o f the PCR 
product for the Human growth hormone gene, which is the internal control. 
The lower band identifies the specific alleles present. By comparing the allele 
specific amplifications with the interpretation table supplied by the 
manufacturer the individual alleles present can be identified. For example the 
individual in the first sample is heterozygous for alleles HLA DRp 1*0401 
and 0404. The individual in the second sample is homozygous for allele HLA 
DRp 1*0401.
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In order to correctly identify the individual alleles at each polymorphic site and to 
act as positive controls for each PCR reaction DNA was prepared by the Nucleon 
method described previously from HLA defined cell lines from the European 
Collection of Animal Cell Cultures ( Porton Down, Salisbury). The cells were 
maintained in RPMI 1640 (Sigma, Poole, UK) supplemented with 10% foetal calf 
serum (Sigma, Poole, UK), penicillin, streptomycin and L-glutamine (Sigma, 
Poole, UK) in a 5% C 0 2 humidified incubator at 37°C. The cells were pelleted at 
600g for 5minutes at 4°C before DNA was extracted. The cell lines used along 
with their typing results at each site are given in Table 2.
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Name Ecacc
Number
DR TNFa TNFc TNFe
HOM-2 88052005 1 6 1 3
SAVC 88052034 4 11 1 3
DKB 88052074 9 2 2 1
WT47 88052063 13 4 1 3
MOU 88052050 7 8 1 3
Legend for fable 2
The names o f the individual cell lines used as internal controls along 
with their typing results are given in Table 2.
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The first site investigated was the bi-allelic restriction fragment length polymorphism in 
the first intron of the lymphotoxin alpha gene (Messer G., 1991). This RFLP designated 
Nco. 1 is due to a single base substitution of a cytosine for an adenosine which 
corresponds to an amino acid change of a threonine for asparagine at position 26.
This gives rise to two alleles, which can be distinguished by the restriction enzyme 
Nco.l. The Nco. 1*1 allele (TNF B*1 as described in Messer’s paper) contains the 
restriction enzyme recognition site and the Nco. 1*2 allele (TNF B*2) does not have the 
recognition site (see figure 12). Primers have been designed that flank this recognition 
site and therefore by amplifying this segment of DNA with these primers followed by 
digestion of the PCR product with the Nco.l enzyme the two different alleles can be 
identified.
In order to investigate the distribution of the Nco. 1 alleles in the AS patients and controls 
the following method was carried out. The PCR was carried out using 0.5units of Taq 
(Advanced Biotechnologies) in lx  Buffer IV; 1.5mM MgCl2 (Advanced 
Biotechnologies); 200mM of each deoxyribonucleotide; luM of sense primer (5’ CCG 
TGC TTC GTG CTT TGG ACT A 3’) and luM of antisense primer (5’ AGA GCT GGT 
GGG GAC ATG TCT G 3’) and 500ng of template DNA in a total volume of 25ul. 
Cycles were 95°C for 6 minutes followed by 35 cycles of 95°C for 1 minute; 64°C for 
1 minute; 72°C for 1 minute and a final elongation step of 72°C for 5minutes on a Techne 
Genius PCR machine. A lOul aliquot of the PCR reaction was then digested with Nco. 1 
restriction enzyme (New England Biolabs, Herts, UK) for two hours at 37°C. The alleles 
were determined by running an aliquot of the undigested PCR product adjacent to the
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digested product on a 2% agarose gel run in lxTBE, stained with ethidium bromide and 
visualised on a UV transilluminator. The Nco.l RFLP gives rise to two alleles and 
therefore three genotypes, which can be distinguished by the band pattern on the gel as 
can be seen in figure 12.
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Legend for Figure 12
There are two possible alleles at the Nco. 1 RFLP corresponding to three 
possible genotypes. Examples o f these are depicted in Figure 12. Lane 1 
represents the 123bp molecular weight marker. Lanes 3, 6 and 9 represent 
undigested PCR products o f 740bp. Lane 4 is an example o f an individual 
homozygous for allele 1 where the restriction enzyme has cut the PCR 
product into two bands o f 555 and 185bp. Lane 10 is an individual 
homozygous for allele 2 where the enzyme has not cut the PCR product and 
Lane 7 is an individual heterozygous for alleles land  2.
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The -308 RFLP first described by Wilson lies in the promoter region of the TNF alpha 
gene (Wilson A.G, 1992). This RFLP is due to a substitution of guanine by adenosine and 
gives rise to two alleles distinguished by a Nco. 1 restriction site (see figure 13).
Analysis of the -308 RFLP was determined using the following primers; sense primer 5’ 
AGG CAA TAG GTT TTG AGG GCC AT 3’ and anti sense primer 5’ TCC TCC CTG 
CTC CGA TTC CG 3’. The reaction was carried out in a volume of 25ul containing lx 
Buffer IV, 1.5mM MgCL2 (Advanced Biotechnologies, Surrey, UK), 200mM dNTP’s, 
luM of each primer, 0.5 units of Taq (Advanced Biotechnologies, Surrey, UK) and 500ng 
of template DNA. The reaction mix was subjected to one cycle of 94°C for three minutes, 
60°C for one minute, 72°C for one minute, then 35 cycles of 94°C for one minute, 60°C 
for one minute, 72°C for one minute with a final elongation step of 72°C for five minutes. 
A lOul aliquot of the PCR product was then digested with Nco.l enzyme at 37°C for two 
hours. An aliquot of the undigested and digested PCR products were run out on an 8% 
polyacrylamide gel on a Sturdier vertical gel (Floeffer, UK) in lx  TBE at 150volts, 
approximately 20mAmps. The gel was removed from the gel apparatus, stained with 
ethidium bromide and visualised on an UV transilluminator. Allele 1 (-308.1) which has 
guanine at position -308 contains the Nco. 1 recognition site and therefore is cut by the 
enzyme giving rise to two bands (as can be seen in Figure 14) and allele 2 (-308.2) with 
adenosine at this position is uncut. A polyacrylamide gel was used to give better 
separation of the PCR fragments.
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-308 RFLP
Nco. 1 cut site
A
g aggcaatag gttttgaggg ccat g [ J g a c  ggggttcagc ctccagggtc ctacacacaa 
Primer 1 G
Single base mutation
atcagtcagt ggcccagaag acccccct eg gaateggage agggagga tg gggagtgtga
Primer 2
PCR product using primers 1 and 2 107 base pairs
Digest with Nco. 1; cut site present (G) 87 and 20 base pairs
cut site absent (A) 107 base pairs
Legend for Figure 13
A diagrammatic representation o f  the -308  RFLP is shown in Figure 13. The 
single point mutation is highlighted along with the PCR product sizes after 
digestion with the restriction enzyme.
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1 2 3 4 5 6 7 8 9 10 11 12
t o t o  t o r t 107b
-----------------  87bp
Legend for Figure 14
At the -308  locus there are two possible alleles and figure 12 represents the 
pattern o f bands seen when undigested and digested PCR products are run 
out on an 8% polyacrylamide gel (as described in the methods).
Lane 1 is o f the 123bp molecular weight marker. Lanes 3, 7 and 11 are 
undigested PCR products o f 107bp. Lane 4 is an individual homozygous for 
allele 2 (i.e no cut site present). Lane 8 is an individual heterozygous for 
alleles 1 and 2 and lane 12 is an individual homozygous for allele 1 (cut site 
present).
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The Leucocyte-specific transcript (LST-1) the human homologue of the mouse B144 
gene lies between the Lymphotoxin P gene and the BAT1 loci within the MHC class III 
region. Although no known function has been found so far its close proximity to the TNF 
locus and pattern of expression point to a possible role in the immune response 
(Holzinger I., 1995). The gene is known to be transcribed in B cells, T cells, macrophages 
and haemtopoietic tissues. Analysis of the nucleotide sequence of LST-1 implies a 
possible signal function (Abraham L.J., 1992). Clones for full-length cDNA of LST-1 
have been isolated and show that LST-1 codes for INF-y inducible transcripts found in 
lymphoid tissues, T cells and macrophages. The LST-1 RFLP lies at position 2794 and 
can be identified by Pvu II restriction enzyme digestion. A previous study has 
investigated this polymorphic site in patients with type I diabetes and patients with 
Graves disease but no association was demonstrated ( Rau H., Usadel K.H., Ommert S. 
and Badenhoop K. European Journal of Immunogenetics, 22 277-282, 1995). However 
the position of the LST-1 site close to the TNF genes and its pattern of expression suggest 
it may have a possible role in autoimmune diseases.
Using primers LST-1 A (5’ AGC AGG AAC TCC ACT ATG C 3’) and LST-1 B (5’ 
GGC ATC TAC GTG TGC AG 3’) spanning the polymorphic site a 1323bp product was 
amplified under the following conditions: lx  Buffer IV, 200uM dNTP’s, 1.5mM MgCL2, 
luM of each primer, 0.4ul of Taq and 500ng of template DNA. The reaction mix was 
subjected to one cycle of 95°C for 5minutes followed by 30 cycles of 95°C for 30 
seconds; 56°C for 1 minute; 70°C for 1.5 minutes and a final elongation step of 70°C for 
5minutes. An aliquot of the PCR product was then digested with Pvu II (N.E.B, Herts,
UK) at 37°C for two hours before being run out on a 2% agarose gel, stained with 
ethidium bromide and visualised on an UV transilluminator. An example o f the LST-1 
RFLP is shown in Figure 15.
This PCR gave multiple bands on the PCR gel picture but since it was apparent early on 
that there was no significant differences between the groups it was decided not to spend 
precious time optimising the PCR.
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1 2 3 4 5 6 7 8
1323bp
Legend for Figure 15
The LST. 1 RFLP gives rise to possible alleles which are depicted on 
Figure 15. Lanes 1,3,5 and 7 are examples o f undigested PCR products 
o f 1323bp in length from four different AS patients. Lanes 2,4 and 6 
are examples o f the digested PCR product where the cut site is present 
giving rise to two bands o f 713 and 610bp in length. These patients are 
therefore homozygous for allele 2. The patient in lane 8 has both the 
uncut and the cut site and is therefore heterozygous for alleles 1 and 2.
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2.6.5 TNFa Microsatellite
Microsatellites are tracts of DNA in which a single base or a small number of bases are 
repeated. Expansions of such tracts have previously been associated with several human 
disorders such as the fragile X syndrome (Caskey C.T, 1992). Within the TNF locus are 
several microsatellites as described by Udalova (Udalova I.A., 1993) which have been 
associated with an apparent genetic predisposition to higher or lower levels of production 
of TNF in vitro (Pociot F., 1993).
The TNFa microsatellite is highly polymorphic in that there are a possible 13 different 
alleles that have been found in a number of different ethnic populations. The TNFa 
microsatellite is an AC/GT repeat that is found in the upstream region of the TNF-f3 
(lymphotoxin) gene. Previous work has shown an association with alleles 6 and 2 with 
differences in production levels of TNFa protein. These alleles differ in size due to the 
different number of repeats they contain that can be detected by amplifying the region 
containing the microsatellite by PCR and then separating the products out by 
electrophoresis. A diagrammatic representation of the TNFa microsatellite is shown in 
Figure 16.
The method for identifying these 13 different alleles is based on the method of Udalova 
with the following primers being used; primer 1 5’GCC TCT AGA TTT CAT CCA GCC 
ACA 3’, primer 2 5’ CCT CTC TCC CCT GCA ACA CAC A 3 ’. An initial first round 
reaction contained lx Buffer IV (Advanced Biotechnologies), 200uM dNTP,s, 1.25mM 
MgCL2, luM of each primer, 0.02 units of Taq and 500ng of template DNA in a final 
volume of lOul. This was subjected to 96°C for 3 minutes, followed by 30 cycles of 94°C 
for 30s, 65°C for 30s and 72°C for lmin with a final extension of 74°C for lOmin. A
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second round PCR was carried out on 0.5ul o f the first round product incorporating a 32P 
labelled dCTP. The reaction mix contained lx  buffer IV, 1.25mM MgCl2, luM of each 
primer, 0.02units o f Taq, 200uM dATP,dGTP,dTTP and 20uM dCTP along with 0.05ul 
of a 32PdCTP (3000Ci/mol) in a final volume of lOul. This was subjected to 5 cycles of 
the same parameters as before.
The PCR reaction was stopped by the addition of 5ul of formamide buffer. The samples 
were heated at 80°C for three minutes after which they were kept on ice before being 
loaded onto a 6% denaturing polyacrylamide gel (7.6m urea). The gel was run in lx  TBE 
at 75W for approximately 90minutes. The gel was transferred onto 3mm filter paper 
(Whatman, Kent, UK) before being dried at 80°C for 90minutes. The dried gel was then 
transferred to a film cassette with intensity screens and exposed to BioMax film (Kodak, 
Herts, UK) overnight.
This method of two rounds of PCR was established after several protocols were 
examined to try and clean up the PCR products. This was important when the gels were 
examined as there is an inherent problem in this type of microsatellite analysis. This type 
of analysis suffers from the problem of shadow bands that occur when there is 
incomplete copying of the PCR product. This makes it very difficult to read the autorads 
due to the large number o f erroneous bands. The difficulty in assigning these alleles is 
overcome by the addition o f HLA defined cell lines that have previously been 
characterised at the TNFa locus. A representative gel o f the TNFa alleles in AS patients is 
shown in Figure 17.
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1 2 3 4 5 6 7 8 9 10 11 12 13 14
Legend for Figure 17
A typical autorad o f the TNFa microsatellite is depicted in Figure 17.
The left hand panel is o f the cell lines, which have previously been 
characterised (as described in Table 2). These were used as markers to assign 
the alleles to the patients samples 10 o f which are represented on the right 
hand panel. For example the individual in lane 5 is heterozygous for alleles 2 
and 6. Lane 7 is an example o f an individual heterozygous for alleles 6 and 8.
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The TNF c microsatellite lies within the intron 1 of the LTa alpha gene and consists o f a 
TC/GA biallelic repeat that gives rise to two alleles depending on the number of repeats 
i.e. allele 1 contains 9 repeats and allele 2 contains 10 repeats (Nedospasov SA, 1991). It 
is thought that variation in the length of these microsatellites does not itself affect the 
regulation or structure of the gene but that they act as markers for another gene that may 
have direct effects.
The two alleles can be distinguished from each other on the basis of size by first amplify 
the region by PCR followed by separation of the PCR products by electrophoresis. 
Primers designed to flank this microsatellite; primer 1 TNFc (1 )5 ’ GGG AAG TCT GTC 
TTC CGC CG 3’ and primer 2 TNF c (2) 5’ CGT TCA GGT GGT GTC ATG GG 3’ were 
used in a PCR reaction containing lx  Buffer IV, 200mM dATP, dGTP, dTTP, 20mM 
dCTP, 1.5 mM MgCL2, luM of each primer, 0.02 units o f Taq, a 32P dCTP (3000Ci/mol) 
and 500ng of template DNA in a total volume of lOul. This was subjected to one cycle of 
94°C for five minutes followed by 35 cycles of 94°C for 25 seconds, 60°C for 1 minute, 
74°C for 1 minute with a final extension of 74°C for 10 minutes. The reaction was 
stopped by the addition of formamide/EDTA gel loading buffer. The samples were heat 
denatured for 3 minutes at 80°C before loading onto a 6% denaturing (7.6M urea) 
polyacrylamide gel run at 75 watts in IX TBE. The gel was vacuum dried and exposed 
overnight to BioMax film (Kodak). Characterised cell lines as described were run on 
each gel in order to size the PCR products as can be seen in figure 18.
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TNFc*2 
TNFc* 1
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Legend for Figure 18
A representative autorad o f a TNFc polyacrylamide gel is shown in Figure
18. Lanes 15,16 and 17 samples o f the characterised cell lines were used as 
markers for the two possible alleles. Lane 2 is a representative o f an 
individual homozygous for allele 1 (9 repeats) and Lane 5 is an individual 
homozygous for allele 2 ( 1 0  repeats). Lane 1 is an example o f  an individual 
heterozygous for alleles 1 and 2.
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2.6.7 TNFe Microsatellite
The TNFe microsatellite, which lies at the 3’ region of the Lst-1 gene, 8-10 Kb 
downstream of the TNF alpha gene, has been shown to have at least three alleles 
depending on the number of TC/GA repeats. The repeats were amplified using the 
following primers based on the method of Udalova (ref). Primer 1 5’ GTG CCT GGT 
TCT GGA GCC TCT C 3’ and primer 2 5’ TGA GAC AGA GGA TAG GAG AGA CAG 
3’ were used at a final concentration of luM in a total reaction mix of lOul containing IX 
Buffer IV, 1.5mM MgCL2, 200uM dATP, dGTP, dTTP, dCTP, 0.02 units of Taq and 
lOOng of template DNA. The reaction was subjected to 94°C for 3 minutes followed by 
30 cycles of 94°C for 30 seconds, 65°C for 30 seconds, 72°C for 1 minute and a final 
extension of 72°C for 5 minute. A 0.5ul aliquot of the PCR product was removed and 
added to a fresh tube containing the following reaction mix; IX Buffer IV, 1.5mM 
MgCI2, 200mM dATP, dGTP, dTTP, 20mM dCTP, 0.04ul a 32PdCTP (3000Ci/mol) and 
0.02 units of Taq in a final volume of lOul. This was subjected to the five of the cycles 
described above. The reaction was stopped by the addition of formamide/EDTA gel 
loading buffer. The samples were heat denatured at 80°C for 3 minutes before loading 
onto a 6% denaturing (7.6M Urea) polyacrylamide gel run in IX TBE at 75 watts in a 
Stratagene squencing gel rig (company address). The film was vacuum dried before being 
exposed overnight to BioMax film (Kodak). An example of a TNFe autorad is shown in 
Figure 19.
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Legend for Figure 19
A representative autorad o f the TNFe microsatellite is shown in Figure
19. Lanes 1,2 and 3 are results from the characterised cell lines where 
the alleles have been assigned as alleles 1, 3 and 4. These are used as 
markers in order to assign alleles to the patient samples. For example 
the patient in lane 7 is heterozygous for alleles 1 and 2. Lane 11 is an 
example o f an individual homozygous for allele 3 and lane 14 is a 
patient heterozygous for alleles 1 and 3.
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Within the intron 2 of the IL-IRa gene is a variable number tandem repeat (VNTR) of 
86bp length that has previously been shown to be polymorphic (Tarlow JK, 1993). This 
VNTR gives rise to 4 different alleles depending on the number of times the 86bp 
fragment is repeated. A previous report has shown allele 2 at this site to be over 
represented in a population of patients with Ulcerative Colitis (UC) (Mansfield JC, 
1994). This increase of allele 2 was not seen in patients with Crohns disease. The 
development of immune-mediated colitis has been shown to be prevented by treatment 
with IL-IRa in animal models and has led to clinical trials using human recombinant IL- 
lRa in UC patients (Dinarello CA 1993). Previous work has shown allele 2 to be 
associated with increased production o f IL-IRa and decreased production of I L - l a m 
vitro (Danis VA, 1995).
Primers flanking this region were used to amplify this polymorphic site, which could 
then be analysed by gel electrophoresis to distinguish the different alleles by size. Allele 
1 has been shown to contain 4 repeats and therefore gives a band size of 410bp, allele 2 
has 2 repeats and has a PCR product of 240bp and allele 3 has 5 repeats and gives rise to 
a product of 500 base pairs. Only three alleles were found in this study although a fourth 
allele has been seen in other populations (ref). Figure 20 shows a representative gel of AS 
patients amplified for this site.
Primer 1 5’ CTC AGC AAC ACT CCT AT 3’ and primer 2 5’ TCC TGG TCT GCA 
GGT AA 3’ were used at a final concentration of luM in a total reaction volume of 25ul
500bp
410bp
Legend for Figure 20
The PCR products o f nine individuals amplified for the IL -IR a 
polymorphism analysed on a 2% agarose gel are shown in Figure 20. Lane 10 
is o f the 123bp molecular weight marker. Lanes 1,4,5,6,7, and 8 represent 
individuals homozygous for allele 1 (410bp). Lane 2 is an individual 
homozygous for allele 2 (240bp) and lanes 3 and 9 represent individuals 
heterozygous for alleles 1 and 3 (410 and 500bp).
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containing lOOng of template DNA, 200uM dNTP’s, 1.5uM MgCL2, IX Buffer IV and
O.luil of Taq. The reaction mix was subjected to an initial denaturation at 96°C for 1 
minute followed by 30 cycles at 94°C for 1 minute, 60°C for 1 minute and 70°C for 1 
minute with a final extension of 74°C for 10 minutes. An aliquot of the PCR product was 
mixed with orange G loading buffer (50% glycerol, 50% IX TBE, orange G) and run out 
on a 2% agarose gel in 1XTBE at 50mAmps and stained with ethidium bromide. The gel 
was viewed on a UV transilluminator and photographed (Genetic Research 
Instrumentation, UK).
The 5’ flanking region of the IL -la  gene contains a single base pair polymorphism at 
position -889 (cytosine for thymine substitution). This polymorphism lies within the 
promoter region upstream of a sequence involved in transcriptional silencing of the II-la  
gene. It is known that single base changes can have an effect on transcriptional rates 
either by affecting the binding of trans-activating factors or by alterations in secondary 
structure. To date no known functional differences have been associated with any 
particular alleles. There are other polymorphic sites within the IL -la  gene such as the 
46bp VNTR in intron 6, which do however have functional significance (Bailly S, 1995). 
Only the polymorphism at position -889 was investigated in this study as it has been 
shown previously to be associated with other inflammatory conditions. An increased 
carriage of the IL -la  2 allele was found in patients with early onset pauciarticular
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juvenile rheumatoid arthritis (EOPA-JRA) and in particular was strongly linked to those 
patients who developed chronic iridocyclitis.
| Primers were designed to create a recognition site for the restriction enzyme Nco. 1 in one
i
allele but no restriction site in the other. The PCR was carried out on lOOng o f template 
DNA with the following primers; primer 1 5’ AAG CTT GTT CTA CCA CCT GAA CTA 
AGG C 3 ’, primer 2 5’ TTA CAT ATG AGC CTT CCA TG 3’, in a total volume of 25 
ul. The reaction mix also contained IX Buffer IV, 1.5mM MgCL2, 200mM dNTP’s and
j  0.1 ul o f Taq and underwent the following cycles of an initial denaturation at 96°C for 5
J  minutes, 35 cycles o f 94°C for 1 minute, 46°C for 1 minute and 74°C for 2 minutes with a
| final extension o f 74°C for 10 minutes. A lOul aliquot o f the PCR product was removed
i
| and added to a fresh tube containing IX restriction digest buffer (N.E.B. buffer 4), 0.5ul
I
| o f Nco. 1 restriction enzyme (N.E.B) in a total volume of 5ul. This was incubated at 37°C
iI
: for 2 hours. The digested PCR products were loaded onto an 8% polyacryamide gel in
formamide/EDTA gel loading buffer, run in IX TBE at 150 volts for approximately 2 
hours. The gel was stained with ethidium bromide and photographed on a UV 
transilluminator. As can be seen on Figure 21 allele 1 gives rise to two bands one o f 83bp 
and one of 16bp and allele 2 gives one band o f 99bp.
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Legend for Figure 21
A representative polyacrylamide gel o f AS patients amplified for the IL -la  
single base pair polymorphism is shown in Figure 21. Lane 15 is the 123bp 
molecular weight marker. Lanes 1,3,5,7,9,11 and 13 are undigested PCR 
products. Lanes 6,8 10 and 12 represent individuals homozygous for allele 1 
where the restriction cut site is present giving bands o f 83 and 16bp’s (the 
smaller fragment is not visible on the gel). Lane 2 represents an individual 
homozygous for allele 2 (no cut site present) and lanes 4 and 14 represent 
individuals heterozygous for alleles 1 and 2.
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Within the promoter region at position -511 of the IL-1 beta gene is a cytosine to thymine 
single base pair substitution that gives rise to a restriction enzyme site recognised by the 
enzyme Ava I. No previous functional difference of any of the alleles has been 
demonstrated and no disease associations have been found so far. However the three 
genes do all lie in close proximity on chromosome 2 and it has been suggested that there 
may be some linkage between the genes as the common alleles of IL-IRa have been 
shown to be associated with the common alleles of IL-1 |3.
Using primers that flank this region the DNA can be amplified, followed by digestion 
with the products being detected by electrophoresis in order to distinguish the individual 
alleles. The primers, 1 5’ TGG CAT TGA TCT GGT TCA TC 3’ and 2 5’ GTT TAG 
GAA TCT TTC CCA CTT 3’ were used at a concentration of 0.1 uM in a reaction mix 
containing 2.5ul of 10X reaction buffer IV, 2.5ul of dNTP’s (2mM), 1.5ul MgCL2 
(1.5mM), 0.1 ul of Taq (Advanced Biotechnologies) in a total volume of 15ul. Template 
DNA was added at lOOng in a volume of lOul which was then added to the reaction mix. 
The PCR conditions were an initial denaturation at 95°C for 2min followed by 35 cycles 
of 95°C for 1 minute, 53°C for 1 minute, 74°C for 1 minute with a final extension at 
74°C for 10 minutes. A lOul aliquot of the PCR product was digested with 0.5ul of Ava I 
restr ction enzyme (New Eng Biolabs) in a digestion mix containing 3ul of water and 
1.5u of buffer. This was incubated at 37°C for 2 hours. The digested and undigested PCR 
products were run out on an 8% acrylamide gel in lx  TBE at 150 volts for 2-2.5 hours 
befo*e being stained with ethidium bromide and photographed on a UV transilluminator. 
An example of an IL-1J3 gel can be seen in Figure 22.
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Legend for Figure 22
Figure 22 is a representative picture o f an 8% polyacrylamide gel o f the 
undigested and digested PCR products o f the IL-1 (3 polymorphism. Lane 10 
is o f the 123bp molecular weight marker. Lanes 1, 3,5 and 7 are the 
undigested PCR products o f four AS patients. Lane 2 is an individual 
homozygous for allele 2 (uncut PCR product, 304bp). Lanes 4 and 6 are 
individuals homozygous for allele 1 (cut PCR product, 190 and 114bp). Lane 
8 is an individual heterozygous for alleles 1 and 2.
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Population genetics is the study of the distribution of genotypes in a population and over 
the past few years has become very much the field of mathematicians. There has been 
much debate as to the most appropriate statistical test to use when comparing frequencies 
of different genotypes and alleles. In case-control analysis the aim is to detect whether 
certain marker alleles have different frequencies among cases and controls, suggesting 
that the marker may lie close to a disease gene or may itself affect susceptibility. 
Normally this would be assessed by applying a chi-squared test to a table of the allele 
counts observed in cases and controls. However microsatellite markers may have many 
alleles, some of which are relatively rare. If expected counts are less than 5-10 in a 
contingency table then the standard chi-squared statistic may be inaccurate. Standard 
approaches to avoid this problem include pooling rare alleles together, or testing each 
allele against the rest and then applying a Bonferroni correction for the number of alleles 
tested. For this study it was decided beforehand that for multiple allelic sites such as the 
HLA DR(31 *, TNFa microsatellite and the IL-IRa VNTR the best approach was to use 
the clump software programme which assesses significance using a Monte Carlo 
approach. The clump programme is designed to assess the significance of the departure 
of observed values in a contingency table from the expected values conditional on the 
marginal totals. This works on the basis of a 2x N contingency table especially when N is 
large and the table is sparse. The significance is assessed using a Monte Carlo approach, 
by performing repeated simulations to generate tables having the same marginal totals as 
the one under consideration and counting the number of times that a chi-squared value
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associated with the real table is achieved by the randomly simulated data. This means 
that the empirical significance levels assigned should be accurate (with precision 
dependent on the number o f simulations performed) and that no special account needs to 
be taken o f continuity corrections or small expected values.
All statistics were carried out using Minitab version 10 for personal computers. For 
comparison o f genotype and allelic frequencies o f bi-allelic sites p-values were 
calculated by the chi square statistics. Odds Ratio and 95% confidence intervals were 
calculated using the cross-products ratio. In order to take into account the number of 
analyses undertaken in the primary calculation, p<0.017 was taken as significant. 
Polymorphic sites with more than two alleles were assessed by the Monte-Carlo 
simulation index following the method o f Sham and Curtis (Sham, 1995). With the result 
of the T4 calculation being quoted.
In the IL-IRa polymorphic site the carriage rates (number o f individuals with at least one 
copy of the test allele) were also calculated.
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3.1 Clinical Data Results
A total of 203 patients diagnosed with AS were enrolled in the study. A clinician saw all 
patients and a detailed clinical history was recorded. The overall clinical picture can be 
seen in Table 3. The ratio of males to females in this patient population was 3.2 :1. AS 
differs from RA in that the average age of onset is much younger (in this case median age 
of onset 21). Disease onset may also occur much later though, the oldest patient 
presenting in this study was 54 years old. A number of previous studies have suggested 
that a significant proportion of AS patients develop the disease before the age of 16 
(Burges-Vargas R., 1989). In this study information on the age of onset was available in 
192 out of 203 patients. The age of onset was defined by the clinician based on 
radiographic evidence. The overall number of individuals with an age of onset below or 
equal to 16 was 42 (22%). The distribution of the age of onset in the AS patients are 
depicted in Figure 23. This early onset means that patients will be seen that have had the 
disease for a long time. The median disease duration in this population was 24 years with 
a range of 1 to 59 years. The distribution of disease duration is shown in Figure 24. 
Increased family prevalence is well documented in AS with 21% of this patient group 
reporting a family history'. Information regarding a family history was available in 186 
out of 203 patients but this information did not distinguish which family members were 
involved. It may be of interest to determine which other family member had the disease
i.e mother, father, brother, sister as there has been recent evidence regarding increased 
incidence of AS in families where the mother is the proband.
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It is also known that other systems may be involved in particular the eyes with 39% of  
these patients having a history' of uveitis. Peripheral joint disease was recorded as not 
including hip and shoulder involvement and was seen in 33% of this group. Other clinical 
features recorded are described in Table 3. There were 19 patients who had undergone 
joint replacement surgery: only one female had joint surgery. It is worth remembering 
that the patients enrolled in this study were all attending the outpatients department at the 
Centre for Rheumatic diseases, which is a tertiary referral centre and therefore all the 
patients are more likely to have a more severe disease than individuals in the community. 
It has been suggested that the under diagnosis in females was due to females having a 
less severe disease. A comparison of the female and male AS patients in this group was 
carried out to determine if  their clinical picture differed in particular the presence of 
extra spinal features which are taken as indicating a more severe form of the disease. The 
results are shown in tables 4, 5 and 6. It can be seen from table 4 that the median age, age 
of onset and disease duration o f both the female and male AS patients were very similar. 
Ths presence of extra spinal features such as peripheral joint disease, uveitis and a family 
history' in both males and females is examined in table 5. The percentage o f both males 
and females who had peripheral joint disease did not differ with 36% of females 
compared to 32% of males having peripheral joint disease. Neither was there a difference 
in :he presence of a family history (22% of both males and females). In females there was 
a slight increase in the number of individuals having a history' o f uveitis (47% compared 
to 37%) but this was not statistically significant.
Individuals who develop the disease early are thought to have a more severe disease. This 
was examined in the male and female AS patients with the results shown in table 6. The
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two groups of patients were subdivided into those with an age of onset below 21 years 
and those with an onset equal to or above 21 years. The additional presence o f either 
peripheral joint disease or uveitis separately or together was included. As can be seen 
from table 6 the number of females who had both an early onset and peripheral joint 
disease was increased when compared to those with a later onset (43% compared to 
31%) although this failed to reach significance. In the male AS patients the number of 
individuals with a younger onset of disease having peripheral joint disease was 
significantly increased (p=0.029) when compared to those with an onset greater than 21 
years. The number of females with an early onset along with a history of uveitis was 
decreased (38% compared to 52%) although this was not statistically different. There 
was no difference in the males.
Of 191 AS patients on whom information was available 19 required joint replacement, 18 
males and 1 female therefore males were significantly more likely to require joint 
replacement surgery than females (p=0.044). The percentage of patients having joint 
replacement in comparison to their length o f disease duration is shown on Figure 25. It 
would be predicted that the number o f patients requiring joint surgery would increase 
with increasing disease duration however as can be seen from Figure 25 the majority of  
patients who required surgery actually had it carried out between 20 and 30 years after 
onset. The distribution of the age at which the patients required joint surgery is given in 
Figure 26. The most common age of the patients receiving joint surgery is between 41 
and 50 years.
Overall the AS patients in this study are comparable to other groups o f patients found in 
the UK.
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Total number of AS patients 203
Male/Female Ratio 3.2:1
Mean Age (years) 47 Range [18-77]
Median Age of Onset (years) 21 Range [3-54]
Median Disease Duration (years) 24 Range |l-59]
Family History 21%
Uveitis 39%
Peripheral Joint Disease 33%
Inflammatory Bowel Disease 4%
Psoriasis 7%
Cardiac Defects 2%
Amyloid 0.5%
Lung Disease 1%
Joint replacement surgery 10%
Legend for Table 3
Table 3 describes the demographic and clinical details of the 203 AS patients enrolled in 
the study.
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Years Females Males
Number Median Range Number Median Range
Age of 
Onset
46 21 11-52 146 20 3-54
Disease
Duration
45 23 5-58 146 25 1-59
Age 46 43 26-74 145 48 18-77
Legend for Table 4
No differences were seen in the male and female AS patients with regards to their age, 
age of onset and disease duration as described in Table 4.
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Extra spinal 
features
Total AS patients
/o/ \(%)
Female AS patients 
(%>
Male AS patients 
(%>
Peripheral Joint 
Disease Present
63(33) 17(36) 46(32)
Uveitis Present 74(39) 21(47) 53(37)
Family History 
Present
36(21) 9(22) 27(22)
Joint surgery 19(10)
Legend for Table 5
Table 5 describes the distribution of different extra spinal features in the AS patients. A 
slight increase in the number of female AS patients with uveitis was seen in comparison 
to the male AS patients (47% cf 37%). The number of males requiring joint replacement 
surgery was significantly increased compared to the females (12% cf 2%, *p=0.044).
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Extra spinal 
features
Females Onset 
<21 (%)
Females Onset 
>21 (%)
Males Onset 
<21 (%)
Males Onset 
>21 (%)
Peripheral 
joint disease 
present
9(43) 8(31)
Uveitis present 8(38) 13 (52) 28 (39) 24 (33)
P.J.D + Uveitis 
Present
3(14) 3(12) 14(20) 7(10)
Legend for Table 6
A comparison between male and female AS patients with P.J.D., uveitis or both is shown 
in Table 6. The number of male AS patients who had an early onset of disease and 
peripheral joint disease was significantly increased compared to those with a later onset 
(39% cf 22%, *p=0.029).
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Distribution of Age Onset in AS patients
11 20 21-30 31-40
Age of Onset (yrs)
41-50 51-60
Legend for Figure 23
The distribution o f the age o f onset in the AS patients is shown in Figure 
23. No differences between the m ale and female AS patients w ere seen.
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Disease Duration Distribution in AS patients
D Males (n=153) 
*  Females (n=46)
21-30 31-40
Disease Duration (vrs)
Legend for Figure 24
The distribution o f the disease duration in the AS patients are shown in 
Figure 24. No differences between the m ale and fem ale AS patients were 
seen.
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Percentage of AS patients having joint replacement surgery compared to disease
duration
11 20 21-30 31-40 41-50 51-60
Disease Duration (yrs)
Legend for Figure 25
Figure 25 describes the distribution o f  the percentage o f AS patients having 
joint replacem ent surgery in com parison to the length o f their disease 
duration.
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Distribution of age of AS patients who have had Joint replacement surgery
31-40 41-50 51-60 61-70 71-80
Y ears
Legend for Figure 26
The distribution of AS patients requiring joint replacement surgery in comparison to their 
ages is described in Figure 26.
35% of patients required surgery between the ages o f 41-50.
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3.2 Clinical Data Discussion
In the United Kingdom at present approximately 0.5-1% of the population are diagnosed 
with AS (Gran, 1998). The use of a uniform diagnostic criterion such as the New York 
criteria allows comparisons to be drawn between groups studied in different centres. 
Overall the 203 patients in this study who were all diagnosed using the New York criteria 
are very comparable in their features with other groups of patients. All patients in this 
study had been typed positive for the HLA B27 gene using the polymerase chain reaction 
by the Tissue Typing Department (Glasgow Royal Infirmary, Glasgow). Previous studies 
using the standard serology testing may underestimate the number of B27 positive 
individuals due to false negative results, however there are patients who have been 
diagnosed with AS who are negative for B27 but it was decided to only look at B27 
positive patients in this study.
Original estimations put the ratio of males to females at nearly ten to one in favour of 
males however nowadays the ratio is normally put at three to one in favour of males. This 
study has confirmed that finding with a ratio of 3.2:1 in favour of males. In this study the 
male and female patients had very similar clinical patterns in that the average age of 
onset, disease duration and age of the two groups where very similar. The group of 
patients as a whole had similar median age of onset, disease duration and occurrence of 
extra-articular features as that described in the literature for other groups. However the 
incidence of inflammatory bowel disease is rather low at 4% since some groups have 
reported the incidence as being higher (Meilants,1996). This depends on how diagnosis is 
made and several papers report the incidence of inflammatory bowel lesions, which are 
much more common than full blown inflammatory bowel disease. For instance
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inflammatory’ bowel lesions may be recorded in as many as 60% of AS patients (Mielants 
H, 1996). In this study the low incidence may be due to patients not undergoing specific 
endoscopic examination for the confirmation of gut lesions. Many patients may be 
asymptomatic for bowel disease but will have definite lesions visible upon investigation. 
The incidence o f gut inflammation has been shown to be high (58%) in a group of 
Korean patients and not just in Western populations (Lee YH, 1997), confirming the 
strong link between the bowel and AS.
The strong family association has long been established with 21% of the patients in this 
study confirming a family history'. However no information on which members o f the 
family were affected was available. This information may have been interesting as it has 
been suggested that there is increased risk of developing the disease for first-degree 
relatives o f female AS probands (Kennedy LG, 1993). It also has been suggested that 
where patients have a family history’ they may have a milder course of disease compared 
to those with no family history' (Falkenbach A, 1998). This did not appear to be the case 
in this patient population in that those individuals with a family history had similar 
patterns o f disease to those with no family history'.
It is often postulated that disease outcome is milder in females compared to males with 
mere peripheral joint involvement, less dramatic spinal changes and overall less rapid 
progression. The process o f anky losis has been said to proceed much faster and be more 
complete in males compared to females (Feldtkeller E, 1998). The presence of extra 
spinal features in males and females were compared and it was noted that slightly more 
females had a history’ o f uveitis compared to the males (47% cf 37%) although this failed 
to reach statistical significance. The percentage of patients with peripheral joint disease
wais the same in both sexes. There were no differences in the sexes with regard to the 
presence o f a family history. However it was noted that out o f the nineteen patients 
requiring joint surgery all but one of them were males. This lends weight to the argument 
thait males have a more severe outcome in their disease in terms of their peripheral joint 
disease.
It has also been suggested that patients whose disease develops early are also more likely 
to have a more severe outcome. The incidence o f peripheral joint disease and or uveitis 
was investigated in those patients whose disease onset was below the age o f 21 years 
compared to those with a disease onset greater than or equal to 21 years. In the male 
patients the incidence of peripheral joint disease was significantly increased in the 
patients with a younger onset compared to those with a later onset p=0.029. Overall the 
male patients did appear to have a more severe outcome if  their disease developed early 
on but this was not so convincing in the female patients again highlighting the milder 
outcome predicted for female patients. Of course the increased incidence of peripheral 
joint disease in those with earlier joint disease may simply be due to longer disease 
duration.
Two control populations were investigated in this study. The first group consisted of 
normal, healthy, unrelated blood donors who were all HLA B27 negative (kindly supplied 
by the Tissue Typing Department, Glasgow Royal Infirmary). The second group were 
normal, healthy, unrelated blood donors who were all HLA B27 positive (kindly supplied 
by Dr R. Green, Blood Transfusion, Law Hospital). All patients and controls were from 
the West of Scotland as it is important to use locally recruited controls that match the 
patient population. The B27 positive control group completed a general health
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questionnaire that does not directly ask about back pain. None of these individuals have 
undergone a radiological examination to rule out any sacroiliac damage. A recent study 
has shown a high percentage o f B27 healthy blood donors have signs of asymptomatic 
sacroiliac damage upon radiological examination. (Braun, 1998). It could be possible 
therefore that some of the B27 positive control population may have undiagnosed AS.
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3.3 MHC Class I: HLA B27 Results
All the AS patients in this study were HLA B27 positive as confirmed by the Department 
o f Tissue Typing in the Glasgow Royal Infirmary and information regarding the presence 
of other B genes in these patients was available in 120 cases. Previous work has reported 
the risk of AS to be increased three fold in patients with HLA B60 in addition to HLA 
B27, (Rubin, 1994). Although the association with HLA B60 has also been demonstrated 
in HLA B27 negative AS patients, suggesting HLA B60 may act independently as a 
disease susceptibility gene (Brown, 1996). In B27 negative patients it has been suggested 
that HLA B39 may be increased (Yamaguchi, 1995). Peptide binding studies predict that 
particular peptides may be capable of binding to both B27 and B39.
Epidemiology studies have concentrated more on the actual subtypes of B27 itself to 
determine if particular subtypes are disease associated. HLA B27 represents a family of 
22 subtypes that differ only in a few amino acids. The most common subtype found in 
European Caucasians is B2705. Some subtypes appear to be disease associated whereas 
others such as B2706 and B2709 appear to have a protective effect (Lopez-Larrea, 1995). 
100 AS patients in this study were subtyped all were B2705 (Alan Walkinshaw, 
Department of Tissue Typing, Glasgow Royal Infirmary). The subtypes of the B27 
positive healthy controls were unknown.
The distribution of the other B antigen in the AS patients in comparison to the normal 
distribution of B antigens in the West of Scotland population are described in Table 7.
A significant difference (T4=0.01) was seen using the Clump statistical test (Sham, 1995) 
in the AS patients compared to the West of Scotland controls. In the AS patients the
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inc idence o f B27 was increased compared to the control population (10% compared to 
3%, T4=0.01).
B60 and B61 are splits of B40 with the majority being B60 in the West o f Scotland. In 
the Table the results are given for B40. The distributions were very similar between the 
two groups however the incidence o f B40 (B60 and B61) is relatively small in these West 
of Scotland populations. In this study all patients were B27 positive and therefore no 
comment on the distribution o f B antigens in B27 negative patients can be made.
The distributions o f the B antigens were investigated in the AS patients in comparison to 
their additional disease features. Table 9 describes the results for the AS patients with 
and without peripheral joint disease and those patients with an early onset of disease. No 
significant differences were noted. Table 8 describes the results for the AS patients with 
and without a family history and those with and without uveitis. In those patients with 
and without a family history' there were no significant differences. However when the 50 
AS patients who had a history of Uveitis were compared to the 64 patients who had no 
history of Uveitis there was a significant difference in the distribution of the other B 
antigen by the Clump test (T4=0.01). The frequency of the B7 gene was significantly 
increased in the AS patients with Uveitis (T4=0.036) whereas the B12 gene was 
significantly decreased in these patients (T4=0.0069), when analysed by Monte Carlo 
simulations.
Unfortunately the number o f the AS patients on whom the information about the other B 
gene was available was relatively small (n=120) and therefore it is difficult to draw any 
conclusions. However it is o f interest to note that the distribution of the B40 gene was not 
increased in this population although in those patients with a family history there was a
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slight increase in its frequency. The different distribution of the other B gene in those 
patients with a history' o f Uveitis is also o f note although again numbers are small.
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HLA B Antigens AS Patients (n=120)
[%i
West of Scotland 
B27 HealthyControls 
(n=890) |%1
B5 6 (5 ) 24 (3)
B7 23 (19) 163 (18)
B8 19(16) 155 (17)
B12 19(16) 155 (18)
B13 5 (4 ) 12(1)
B14 6 (5 ) 49 (6)
B15 11 (9) 46 (5)
B17 2 (2 ) 3 8 (4 )
B18 2 (2 ) 31 (3)
B22 1(1) 20 (2)
B35 6 (5 ) 50 (6)
B40 5 (4 ) 46 (5)
OTHERS 2 (2 ) 76 (9)
Legend to Table 7
Table 7 describes the distribution o f the HLA B antigens encoded by the non- 
B27 chromosome in 120 AS patients compared to 890 West o f Scotland B27 
healthy controls (kindly supplied by the Tissue Typing Department, Glasgow 
Royal Infirmary). The AS patients differed significantly from the West o f 
Scotland controls by Clump (T4=0.01). The frequency o f AS patients 
homozygous for the B27 gene was significantly increased (*T4=0.01) when 
compared to the West o f Scotland controls.
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Family
History
Uveitis
HLA
Antigens
Present
n=27
(%)
Absent n=76 
(% )
Present
n=50
(% )
Absent n=64
(% )
B5 2 (7 .4 ) 4 (5 .3 ) 3 (6 ) 361, 7 )
9 (33.3) 12(15.8)
B8 0 (0 ) 15 (19.7) 9 (1 8 ) 9 (1 4 )
3(11 .1 ) 14(18.4)
B13 1 (3.7) 4 (5 .3 ) 0 (0 ) 5 (7.8)
B14 1 (3.7) 3 (3.9) 5 (1 0 ) 1 (1-6)
B15 2 (7.4) 6 (7 .8 ) 4 (8 ) 6 (9 .3 )
B17 0 (0 ) 1(1.3) 0 (0 ) 2 (3 .1 )
B18 1 (3.7) 0 (0 ) 1(2) 0 (0 )
B22 0 (0 ) 1 (1.3) 1 (2) 0 (0 )
B27 4(14 .9 ) 6 (7.8) 6 (1 2 ) 6 (9 .3 )
B35 2 (7.4) 4 (5 .3 ) 3 (6 ) 3 (4.7)
B37 0 (0 ) 1 (1.3) 1 (2) 0 (0 )
B39 0 (0 ) 1 (1.3) 0 (0 ) 1(1 .6)
B40 2 (7.4) 3 (3.9) 1 (2) 4 (6.3)
B50 0 (0 ) 1(1.3) 0 (0 ) 1 (1.6)
Legend for Table 8
The distribution o f the HLA B antigens encoded by the non-B27 
chromosome in AS patients are shown in Table 8. The distribution is 
compared in 27 AS patients with and 76 patients without a family history and 
in 50 patients with and 64 without uveitis. No significant differences were 
seen in the AS patients with a family history compared to those without. In 
the AS patients with uveitis the incidence o f B7 was significantly increased 
(*T4=0.036) compared to the patients with no history o f uveitis. The 
frequency o f  B12 was significantly decreased in this group o f patients 
(**T4=0.0069) when analysed by Monte Carlo Simulations.
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PJD Age of onset
HLAB
antigens
Present 
jn=34) (%)
Absent
|n=82]
<21 [n=61] >21 [n=59)
B5 2 (5.9) 4 (4.8) 3 (4.9) 3 (5 .1 )
B7 8 (23.5) 14(17) 13 (21.3) 10(16.9)
B8 7 (20.6) 11 (13.4) 10(16.4) 9 (15 .3 )
B12 7 (20.6) 12(14.6) 10(16.4) 9 (15 .3 )
B13 2 (5.9) 3 (3.6) 1 (1.6) 4 (6.8)
B14 2 (5.9) 4 (4.8) 4 (6.5) 2 (3.4)
B15 1 (2.9) 10(12.2) 5 (8.2) 6 (10 .2 )
B17 0 (0 ) 2 (2.4) 2 (3 .3 ) 0 (0 )
B18 1 (2.9) 0 (0 ) 0 (0 ) 2 (3.4)
B22 0 (0 ) 1(1.2) 1 (1.6) 0 (0 )
B27 1 (2.9) 10(12.2) 7 (11 .5 ) 5 (8.5)
B35 2 (5 .9 ) 4 (4.8) 3 (4.9) 3 (5 .1 )
B37 1 (2.9) 0 (0 ) 1 (1.6) 0 (0 )
B39 0 (0 ) 1(1.2) 0 (0 ) 1(1.7)
B40 0 (0 ) 5 (6 .1 ) 1 (1-6) 4 (6.8)
B50 0 (0 ) 1(1.2) 0 (0 ) 1 (1.7)
Legend for Table 9
The distribution o f the HLA B antigens encoded by the non-B27 
chromosome in AS patients are shown in Table 9. The distribution o f  the B 
antigens are compared in the 34 AS patients with peripheral joint disease to 
the 82 patients without and in the 61 patients with an age o f onset below 21 
years to the 59 with an onset greater than or equal to 21.
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3.4 MHC Class I: HLA B27 Discussion
It is now firmly established that AS is a genetic disorder that shows familial aggregation 
but with a variable pattern of segregation. From family and twin studies where 
concordance rates for monozygotic twins is approximately 67% (Brown, 1997) it can be 
deduced that there more than one gene is involved. The strong association with FLLA B27 
and its direct effect on disease pathogenesis as demonstrated in B27 transgenic animals 
(Khare, 1995) is not in doubt. However approximately 9% of the population carry the 
B27 gene but only a small fraction (0.5-1%) go on to develop AS.
It is of interest that of the 22 B27 subtypes known there appears to be no difference 
between the subtypes found in the patients compared to the subtypes found in healthy 
controls. O f the subtypes that have been shown to be present in AS patients, such as 
B2702, 2704, 2705 these are also found at the same frequency in the healthy community. 
Several reports have postulated that there are some subtypes that may be protective such 
as B2706 in a Thais population (Lopez-Larrea, 1995) and B2709 in a Sardinian 
population (D'Amato, 1995). These subtypes differ by as little as one amino acid residue 
that can alter the peptide binding specificity. However the very low frequency of these 
subtypes in the population make it difficult to confirm their protective role and further 
studies are required.
120 of the AS patients in this study were typed to determine the B27 subtypes present. 
All the patients in this study were B2705 (Alan Walkinshaw, personal communication). 
The subtypes o f the B27 positive healthy controls were unknown.
It has been suggested that individuals heterozygous for both HLA B27 and B60 have a 
three fold increased risk of developing the disease (Robinson, 1989). Some studies have
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suggested that B60 may also act independently as a disease susceptibility gene (Brown, 
19*6). Information regarding which other HLA B genes were present was available in 
12( of the AS patients. When the distribution o f these B genes was compared between 
the AS patients and the normal West of Scotland population by the Clump test a 
sigiificant difference was seen in the two populations (T4=0.Oi). The overall distribution 
of he HLA B27 gene in the 890 West o f Scotland normal individuals was 3%. This is 
slightly less than the normally accepted distribution which ranges from 5% to 14% in 
Caicasians and which has been previously reported at 9.5% for UK populations 
(Dtpartment of Tissue Typing, Glasgow Royal Infirmary, personal communication).
In his population 10% of the AS patients were homozygous for B27 with B7 being the 
mat common gene to be carried with B27. HLA B60 and B61 are splits o f B40 with B60 
mat commonly found in the West of Scotland. The information regarding the 
disribution of the B60 and B61 genes in the West o f Scotland normal population was 
conbined and presented as B40 (supplied by the Tissue Typing department, Glasgow 
Ro-al Infirmary). No increase in the patients heterozygous for B27 and B40 (B60+B61) 
wa seen in this group although numbers are small. With advances in molecular typing 
tecmiques an HLA B27-B40 hybrid allele has been observed in some German patients 
whch could be mistyped by some assays as a B27/B40 heterozygote this could artifically 
infate the risk associated with this genotype (Weissensteiner, 1998). In this group o f AS 
patents therefore it cannot be confirmed that the additional presence o f B60 increases 
therisk of developing the disease.
Tfo HLA B39 gene has previously been reported to have an association with B27 
negative AS patients (Yamaguchi, 1995). In this study all the patients were B27 positive
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and none of the patients were heterozygous for B27 and B39. This gene would have to be 
investigated in a population o f B27 negative AS patients to see if  an association could be 
made. Conversely another study has shown that there is no significant association 
between B39 and B27 negative disease (Brown, 1996).
The distribution o f the other B gene was also investigated in the AS patients in 
comparison to several disease features. Of the features studied no differences were seen 
those patients with and without peripheral joint disease or those with a younger onset of 
disease. Neither were there any differences in the patients with a family history compared 
to those without apart from a slight increase in B40 in those patients with a family 
i  history'. However in those patients with a history of uveitis there was a significant
j|
| increase in the number of individuals heterozygous for B27 and B7 compared to those
!
I without uveitis. This was in comparison to the significant decrease in the number 
heterozygous for B27 and B12 (T4=0.0069). The presence of B7 in conjunction with B27 
would appear to increase the risk o f developing uveitis in these AS patients but greater 
numbers would have to be investigated to confirm this finding.
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3.5 MHC Class II: DRpl* Alleles Results
The MHC is a highly polymorphic region that has several genes associated with the 
inflammatory response. Examples include the class I genes which are involved in antigen 
presentation to CD8 positive T cells, the complement and TNF genes in the class III 
region, and the Class II genes which are also involved in antigen presentation to CD4 
positive T cells. Recent genome scans have confirmed the strong linkage disequilibrium 
with the MHC that has been shown to extend across the MHC from the marker D6S276 
to the HLA DRpi locus and beyond (Brown, 1998). Only a few studies have investigated 
the role of the MCH class II alleles in AS with some studies suggesting as association 
with the DRpl *01 alleles. In this study the distribution of the MHC Class II DR|31 alleles 
were investigated in 139 AS patients compared to the two control populations.
The distribution of the DR(31 alleles in 139 AS patients compared to 216 normal West of 
Scotland healthy controls is shown in Table 10 and Figure 27. The overall distribution 
between the two groups was statistically different when examined by the Clump test 
(T^<0.0005). On closer examination this was due in particular to the increased frequency 
of the D R p l*01 alleles in the AS patients (27% versus 8.8%, p<0.0005) and the 
increased frequency of the D R p l*04 alleles (31% versus 20.8%, p=0.038). This was 
partly compensated for by the decrease in frequency of the DRpi*03 alleles (9% versus 
19(/o) although this failed to reach statistical significance.
The distribution of the DRpi *alleles were compared between the 139 AS patients and 61 
B27 positive controls as can be seen in Table 11 and Figure 28. The overall distribution 
between the two groups was significantly different as determined by the Monte Carlo
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Simulation test (T4=0.03). As seen with the normal controls this is mainly due to a 
significant difference in the distribution o f the D R pl*01 alleles. The frequency o f the 
D R p l*01 is significantly increased in the AS patients compared to the controls (27% 
versus 16%, p=0.013). Unlike the HLA B27 negative normals the distribution o f the 
D R pi*04 alleles is not different in the two groups. The distribution o f the DRpi*03 
alleles is decreased in the AS patients compared to the B27 positive controls, but this was 
not statistically significant.
Several disease features have been suggested as indicators o f a more severe outcome in 
AS such as an early onset, the presence of uveitis and peripheral joint disease. The 
distribution o f the DRpl* alleles was examined in the AS patients in relation to the 
presence or absence o f these particular features. The results are described in Tables 12 to 
15. In the 64 patients with an early onset compared to the 71 with a later onset there were 
no statistical significant differences. A slight increase in the frequency o f DRpi*04 was 
seen in the patients with a younger onset (35% versus 27%). This was in contrast to the 
52 AS patients with a history o f uveitis where a slight decrease o f the DRpi*04 alleles 
was seen in comparison to the 82 without uveitis (25% versus 36%). In the 20 AS 
patients with a family history the frequency o f both the DRpi*04 and 06 alleles were 
increased compared to the 104 patients with no family history. This was compensated for 
by a decrease in the incidence of the DRpi*03 and 07 alleles. Previous studies have 
suggested an increased frequency o f D R pl*04 alleles in patients with peripheral joint 
disease (PJD) (Miehle, 1985). In the 44 AS patients with PJD there was no association
105
with D R pl*04 with the frequency the same in those patients without (36% and 30% 
respectively).
The DRpi*04 subtypes were determined in 68 AS patients, 24 o f which were 
homozygous. The results o f the distribution of the D R pl*04 subtypes in the AS patients 
compared to the two control groups are described in Table 16. Overall the distribution 
was significantly different in the AS patients compared to the West o f Scotland controls 
as determined by the Clump test (T4<0.0005). This was due to the increased frequency of 
the DRP 1*0401 and 0404 subtypes in the patients (p<0.0005). In contrast the 
D R p l*0405 alleles were significantly decreased in the patients compared to the normal 
controls.
The distribution was compared in the AS patients to the B27 positive controls but no 
significant differences were seen. There was an increase in the frequency o f the 
DRP 1*0404 in the AS patients compared to the B27 positive controls (24% versus 13%) 
but this failed to reach significance. However numbers o f control subjects was small.
In conclusion there appears to be a significant association of the D R p l*04 subtypes in 
the AS patients compared to the West o f Scotland healthy controls that looks to be linked 
with the presence o f B27 however numbers of control individuals would have to be 
increased to confirm this.
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DRpl* Alleles AS Patients [n=139] 
(% )
West of Scotland 
Controls [n=2011 (%)
02 [15+16] 28(10) 28(14)
03 26 (9) 41 (20)
05 [11+121 9 (3 ) 8 (4 )
06 [13+141 24 (9) 25 (12)
07 25 (9) 28 (14)
08 2 (1 ) 6 (3 )
09 3 (1 ) 0 (0 )
10 0 1(1)
Legend for Table 10
Distribution o f  MHC Class II D R pl*  alleles in AS patients compared to 
normal unrelated blood donors from the West o f Scotland are shown in Table 
10. The overall distribution o f D R pl*  alleles differ in the AS population 
when compared to the West o f Scotland controls when analysed by Clump 
(T4<0.0005). In particular the frequency o f the DRP 1*01 alleles are 
significantly increased in the AS patients compared to the controls 
(**p<0.0005). The frequency o f the D R pl *04 alleles are also increased 
(*p=0.038)
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Distribution of DR|3l * alleles in AS patients compared 
to Wfest of Scotland
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Legend for Figure 27
The distribution o f  the D R bl*  alleles in AS patients compared to the 
W est o f Scotland controls are described in Figure 27. Overall the 
distribution differed significantly between the two groups (T4<0.0005)
1 0 8
DRpl* Alleles AS Patients [n=139] 
(% )
B27 Positive Controls 
[n=6! j (% )
02 [15+161 28(10) 7 (6 )
03 26 (9) 19(16)
04 86 (31) 37 (30)
05 111+121 9 (3 ) 9 (7 )
06 [13+141 24 (9) 12(10)
07 25 (9) 11 (9)
08 2 (1 ) H O
09 3 (1 ) 3 (2 )
10 0 4 (3 )
Legend for Table 11
The distributions o f  the DR.pi* alleles in the 139 AS patients are compared 
to the 61 B27 positive controls in Table 11. Overall the distributions between 
these two groups are different when analysed by Clump (T4=0.03). The 
frequency o f  the D R pi *01 alleles are increased in the AS patients compared 
to the B27 positive controls (*p=0.013).
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D i s t r i b u t i o n  o f  D R p 1 *  a l l e l e s  in  A S  p a t i e n t s  c o m p a r e d  t o  
B 2 7  p o s i t i v e  c o n t r o l s
□ AS patients (n=139)
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(n=61)
p=0.013
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DR(31* alleles
Legend for Figure 28
The distribution o f the DR(31*alleles in the AS patients compared to the 
B27 positive controls are described in Figure 28. Overall the distribution 
differs between the two groups (T4=0.03).
1 1 0
DRpl* Alleles Age of Onset <21yrs 
n=64 (%)
Age of Onset >21yrs 
n=71 (%)
0101,02+0103 32 (25) 39 (27)
02(15+16] 10(8) 18(12)
03 12(9) 15 (10)
04 45 (35) 39 (27)
05|11+12| 7 (5 ) 2 (2 )
06(13+14] 10(8) 12(9)
07 11(8) 13(9)
08 0 (0 ) 2 (1 )
09 1(1) 2 (1 )
10 0 (0 ) 0 (0 )
Legend for Table 12
Table 12 describes the distributions o f the DR(31* alleles in the 64 AS 
patients with a disease onset o f less than 21 years compared to the 71 with an 
onset o f  greater than or equal to 21 years. A slight increase in the number o f 
patients with a younger onset carried the D R pl*04  allele than those with a 
later onset (35% c f 27%) but this was not statistically significant.
i n
D R pl* Alleles Uveitis Present n=52 
(%>
Uveitis Absent n=82 
(% )
0101,02+0103 30 (29) 39 (24)
02(15+16] 10(9) 16(10)
03 11(10) 16(10)
04 26 (25) 60 (36)
05(11+12] 6 (6 ) 3 (2 )
06(13+14] 10(10) 11(7)
07 8 (8 ) 17(10)
08 2 (2 ) 0 (0 )
09 1(1) 2 (1 )
10 0 (0 ) 0 (0 )
Legend for Table 13
The distribution o f the DR.pi* alleles were compared in the 52 AS patients 
with uveitis with the 82 AS patients without, the results are described in 
Table 13. A slight non-significant decrease in the frequency o f the D R pi*04  
alleles was seen in those patients with uveitis compared to those without.
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DR pl* Alleles Family History 
Present n=20 (%)
Family History 
Absent n=104 (%)
0101,02+0103 9 (23 ) 57 (28)
02[15+16| 5 (12 ) 21 (10)
03 1(2) 21 (10)
04 15 (38) 59 (29)
05[11+12] 0 (0 ) 8 (3 )
06[13+14| 7 (18 ) 15 (7)
07 2 (5 ) 23 (11)
08 0 (0 ) 2 (1 )
09 1(2) 2 (1 )
10 0 (0 ) 0 (0 )
Legend for Table 14
The distribution o f the DR(31* alleles in the 20 AS patients with a family 
history were compared to the 104 without and the results are shown in Table 
14. In those patients with a family history the incidence o f the DR(31*04 and 
06 alleles was increased with a decrease in the incidence o f DR(31*03 and 
07. However this was not statistically significant.
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DRpl* Alleles P.J.D Present n=44
(%)
P.J.D Absent n=91 
(%)
0101,02+0103 25 (28) 49 (27)
02(15+16] 6 (7 ) 18(10)
03 3 (3 ) 24 (13)
04 32 (36) 54 (30)
05(11+12| 4 (4 ) 4 (2 )
06(13+14] 8 (9 ) 13(7)
07 8 (9 ) 17(9)
08 1(1) 1(1)
09 1 (1) 2 (1 )
10 0 (0 ) 0 (0 )
Legend for Table 15
The distribution o f the D R pl*  alleles in the 44 AS patients with peripheral 
joint disease is compared to the 91 patients without in Table 15. There were 
no significant differences between the two groups.
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Distribution of DR|31*04 alleles in AS 
patients with and without peripheral 
joint d isea se
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□  P.J.D Absent (n=91)
Legend for Figure 29
No significant differences were seen in the distribution of DRbl*04 
alleles in AS patients with peripheral joint disease compared to those 
without.
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DRp 1*04 
Subtypes
AS patients 
n=68 (%)
West of 
Scotland 
Controls n=806 
(%)
B27 Positive 
Controls n=24
(%)
14(58)
0402 0 (0 ) 41 (5) 2 (8 )
0403 0 (0 ) 89(11) 0 (0 )
3 (1 3 )
0 (0 )
0406 0 (0 ) 32(4 ) 0 (0 )
0407 5 (7 ) 5 6 (7 ) 2 (8 )
0408 2 (3 ) 8 (1 ) 1 (4)
0409 0 (0 ) 0 (0 ) 0 (0)
0410 0 (0 ) 16(2) 0 (0)
0411 0 (0 ) 0 (0) 0 (0 )
0412 0 (0 ) 8 (1 ) 0 (0 )
others 1(1) 0 (0 ) 2 (8 )
Legend for Table 16
The results o f  the distribution o f the DRp 1*04 subtypes in the AS patients 
compared to the W est o f  Scotland controls and the B27 positive controls are 
given in Table 16. The overall distribution o f the subtypes in the AS patients 
is significantly different to the West o f Scotland controls (T4 <0.0005). This 
is due to the significant increase in the DRp 1*0401 and 0404 alleles in the 
AS patients (p<0.0005) compared to the controls. This is balanced by the 
significant decrease o f the DRp 1*0405 alleles in the AS patients (p<0.005). 
No significant differences were seen in the AS patients compared to the B27 
positive controls although the distribution o f the DRp 1*0404 was increased 
in the patients but failed to reach statistical significance.
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3.6 MHC Class II: DRpi* Alleles Discussion
Several studies have investigated the role o f other MHC genes in AS since it is well 
established that B27 is not the only gene involved. Some o f these studies have looked at 
genes involved in the antigen-processing pathway such as the TAP genes 
(Maksymowych, 1995) or genes involved in the inflammatory response such as the TNF 
genes. Other groups have suggested that the MHC Class II genes may also have a role to 
play.
The MHC Class II region contains 17 HLA Class II genes and pseudogenes but of 
greatest interest is the HLA DR(3 genes which encode the (31 chain o f the DR molecule 
since this is the most polymorphic region with approximately 180 alleles described 
(Beck, 1999). There are five distinct human HLA-DR haplotypes that differ in their 
genomic organization and number o f HLA DRp Class II genes (Anderson G. Evolution of 
Human HLA DR region). The recent genome wide scan has confirmed the strong linkage 
disequilibrium with the MHC region and AS. This linkage has been shown to extend at 
least 8cM across the region between markers D6S276 and DRpi (Brown, 1998). It has 
been proposed that this may simply be due to linkage disequilibrium with HLA B27 or 
may be due to extended haplotypes that may contain several genes relevant to 
susceptibility to AS (Martinez-Borra, 2000). However the broad linkage reported by 
Brown is due to the weakness o f linkage as a method of fine mapping because of the 
limited numbers o f recombination events in families over short distances, not due to 
linkage disequilibium which refers to population effects.
In thiis study the distribution o f the HLA DRpi alleles was investigated in 139 AS 
patients and compared to the control populations. Overall the distribution of the DRp 1 
alleles was significantly different in the AS patients compared to the West of Scotland 
controls as determined by the Clump test. This appeared to be due to the significant 
increase in the distribution o f the DRp 1*01 alleles in the AS patients as compared to the 
controls (p<0.0005), along with a significant increase in the DRp 1*04 alleles (p=0.012). 
A corresponding decrease in the DRp 1 *03 alleles was seen but this was not statistically 
significant. Similarly when the AS patients were compared to the B27 positive controls 
the overall distribution was significantly different as determined by the Clump test 
(T4=0.03). However although the DRpl*01 alleles were still significantly increased in 
the AS patients (p=0.013) the DRp 1*04 distribution was the same between the two 
groups. It could be that the DRp 1 *04 alleles are in linkage disequilibrium with the B27 
gene but family studies would be required to confirm this. Linkage disequilibrium 
between B27 and DRp 1 *04 has been demonstrated in Scandinavian countries (Westman, 
1996) and in British Caucasians (Brown, 1998). Again the distribution of the DRp 1*03 
alleles is reduced in the AS patients compared to the controls although this is not 
statistically different.
Not many studies have looked at the distribution of the HLA DRP 1 alleles in AS but one 
important study by Brown and collegues has also shown a significant increase in the 
distribution o f the DRp 1*01 alleles (Brown, 1998). They suggest that at most the effect 
of the DRp 1*01 alleles are minor on disease susceptibility. Dizy gotic twins carry ing both 
B27 and DRp 1*01 are said to be more concordant for spondylarthritis than those without
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DRp 1*01 (Brown, 1997). Haplotypes containing DR1;DQ5 have been shown to be 
transmitted preferentially within families to children with AS (Nahal, 1996). An early 
British study has also suggested an association with DRp 1 alleles and AS susceptibility 
but this study did not investigate B27 positive controls (Armstrong, 1983).
It has been demonstrated previously that TNFa production varies between individuals 
according to their HLA DR alleles (Jacob, 1990). They can be divided into two groups, 
high producers that carry DRp 1*03 and 04 alleles and low producers that carry' DRp 1*02 
[15+16] alleles. In this study the incidence of DRp 1*01 alleles is increased in the AS 
patients but there is also a decrease in the high producer phenotype o f the DRp 1*03 
alleles. This significant increase would appear to be disease associated since the increase 
is seen in comparison to both the normal and the B27 positive population.
So DRp 1 appears to have an effect on disease susceptibility in AS patients but does it 
have an effect on disease phenotype. It has been suggested in polygenic disorders that 
genes may determine clinical phenotype without conferring overall disease susceptibility'. 
Previous studies have suggested particular DRpi* alleles may have increased risk with 
particular clinical manifestations. Studies in Japanese patients have reported associations 
of DRp 1*08 with increased risk of acute anterior uveitis [AAU], (Islam, 1995). This has 
also been confirmed in another study of Norwegian AS patients but was not replicated in 
a study o f Mexican patients (Maksymowych, 1997) and in a UK population (Brown, 
1998). Associations with DRp 1*0103 have also been described for AS patients with the 
complication o f inflammatory bowel disease (Orchard, 2000). Both DRp 1*04 and more 
commonly DRp 1*07 have previously been associated with peripheral arthritis (Sanmarti,
1987). Although, other groups have not confirmed the link with DRp 1*04 and peripheral 
arthritis.
In the present study the distribution of the DRpi* alleles was investigated in the AS 
patients in relation to different clinical features. No significant differences were seen at 
all in any of the features studied. In those patients with an early onset o f disease 
compared to those with a later onset only a slight increase in the 04 alleles was seen 
although previously an association with DRp 1*08 and an early onset has been suggested 
(Ploski, 1996). Interestingly a slight decrease in the DRP 1*04 alleles was seen in the AS 
patients with uveitis compared to those without but no associations with DRp 1*08 were 
seen. However this is not surprising as the incidence of DRp 1*08 in the West o f Scotland 
overall is very low. Of the only two patients in the study that had DRp 1*08 alleles 
however both did have uveitis. Of the patients that had a family history the DRp 1 *04 
and 06 alleles were slightly increased with a corresponding decrease of the DRp 1 *03 and 
07 alleles but again these were not statistically significant. No differences were seen in 
the patients with or without a peripheral joint disease. It has been said that DR12, which 
is a split o f DRp 1*05 may have a protective role in AS. The distribution of DRP 1*05 
was very similar between the AS patients and the West of Scotland controls.
The overall conclusion therefore is that DRP 1*01 may be an additional susceptibility 
gene but that it appears to not play a role in determining disease phenotype.
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4. Polymorphisms within the Tumour Necrosis Factor region
AS is understood to be a polygenic disease and one candidate gene that has been 
proposed as having a role to play is that of the gene for the proinflammatory 
cytokine Tumour necrosis factor (TNF). TNF is an important proinflammatory 
cytokine and as has been discussed in the introduction this cytokine may have a role 
to play in the disease pathogenesis of AS. It has been suggested that particular 
polymorphisms within the TNF region may predispose individuals to higher levels 
o f TNF protein leading to joint destruction. Certain TNF polymorphic sites 
previously associated with high or low levels of the actual proteins have been 
associated with other inflammatory conditions. This raised the question was the 
distribution of any of these polymorphisms associated with increased production 
different in the AS patients when compared to controls.
Six individual polymorphic sites spanning the TNF region from the Class I region 
through towards the Class II region were investigated. The actual sites examined 
are highlighted in figure 8. The six polymorphisms were investigated in a large 
population of well characterised AS patients and two control populations as 
discussed in the materials and methods section.
4.1 Nco.l Polymorphism results
The first site to be examined was the Nco. 1 RFLP, which lies within the first intron 
of the lymphotoxin alpha gene. This single base substitution gives rise to two 
possible alleles Nco. 1.1 and Nco. 1.2 and therefore three possible genotypes. The 
Nco. 1.2 allele has previously been shown to be associated with increased levels of 
TNFa in vitro.
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148 AS patients were examined at the Nco. 1 site and the results are shown in Table 
17. Comparison of the alleles and genotypes o f the 148 AS patients with the 82 
HLA B27 negative controls are shown in Figure 32a and b. This comparison 
revealed a significant increase (p=0.0014) in the Nco.l 2*2 genotype in the HLA 
B27 negative controls compared to the AS patients (42% in the controls compared 
to 22% in the patients). This was also confirmed in the distribution o f the alleles 
with a significant increase (p=0.0007) of the Nco. 1.2 allele in the HLA B27 
negative controls compared to the AS patients (64% compared with 48%) as seen in 
Figure 32b. The Nco. 1.2 allele previously associated with increased production of 
TNFa in vitro is significantly decreased in this group o f AS patients compared to 
the normal control population.
However when the distribution of the alleles and genotypes in the 148 AS patients 
were compared to 54 HLA B27 positive controls no significant differences were 
found (see Table 18). The distribution of the Nco.l 2*2 genotype was 22% in the 
AS patients compared to 24% of the B27 positive controls and the Nco. 1.2 allele 
was found in 48% of the patients compared to 51% of the HLA B27 positive 
controls. This suggests that the differences seen in the Nco. 1 distribution between 
AS patients and HLA B27 negative controls could therefore be related to the 
presence o f HLA B27 itself and not to the disease.
During the clinical examination o f the AS patients various other clinical findings 
were recorded such as whether the patient had a history of the disease in the family, 
the age of onset of the disease, the presence of extra-spinal manifestations such as 
uveitis, peripheral joint disease etc. All the clinical findings are discussed in chapter 
3.1. Previous work in other inflammatory conditions has suggested that the 
presence o f certain TNF alleles is associated with disease severity and not just the
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presence o f disease. The distribution of the Nco.l alleles and genotypes were 
examined in the AS patients along with the presence o f extra features o f disease 
which may be regarded as indicators o f disease severity. The results are 
summarised in Table 19.
Information regarding the presence of uveitis was recorded in a total o f 145 out of  
the 148 AS patients who had been investigated at the Nco.l site. The distribution o f  
the Nco.l alleles and genotypes were examined in 56 AS patients who had a 
previous history o f uveitis and compared to 89 AS patients who had never had an 
episode o f uveitis. There were no significant differences between the two groups of  
patients.
The presence or absence o f a family history was recorded in 131 of the 148 AS 
patients who had been investigated at the Nco.l site. There were no significant 
differences between the 26 AS patients who had a history o f disease in the family 
and the 105 AS patients were no family history had been noted.
Another indicator of a more severe disease is an early onset o f disease. In this case 
an onset o f disease before the age o f 21 was regarded as early and was compared to 
those patients who had an onset equal to or above the age o f 21. Information 
regarding the onset of disease was recorded in 144 o f the AS patients. The results of 
the 69 AS patients with an onset below the age of 21 compared to the 75 AS 
patients with an onset of 21 years or above are shown in table 19. There was a 
slight increase in the distribution of the Nco. 1 2*2 genotype in the AS patients with 
an early onset compared to those with a later onset (29% compared to 16%) but this 
was not statistically significant.
At some point throughout the course of their disease approximately 30-40% of AS 
patients will suffer from peripheral joint disease. Joints other than the axial spine
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but not including hips and shoulders may become inflamed. In this study 33% of 
the AS patients have recorded a history of peripheral joint disease (P.J.D). Out of 
the 148 AS patients examined at the Nco. 1 site 143 have a record o f the presence or 
absence o f P.J.D. The results of the distribution of the Nco. 1 alleles and genotypes 
in the 48 AS patients with a history of P.J.D compared to the 95 AS patients with 
no history of P.J.D are shown in table 19. No significant differences where seen in 
the two groups o f patients.
Overall the differences seen at the Nco.l site appear to be associated with the 
presence o f HLA B27 and not with the disease itself.
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Nco.l AS Patients 
n=148 (%)
B27 -ve Controls 
n=82 (%)
1*1 39 (26) 11(13)
1*2 77 (52) 37 (45)
2* 141 (48) 105 (64)
Legend for Table 17
The frequency o f  the distribution o f  the Nco. 1 genotypes and alleles in 
the AS patients compared to the B27 negative control group are shown 
in Table 17. The frequency o f  the N co.l 2*2 genotype was significantly 
decreased (*p=0.0014) in the AS patients compared to the B27 negative 
controls (22%  versus 42%). This was reflected in a significant increase 
in the frequency o f the N co .l. 1* allele in the AS patients (*p=0.007, 
52% compared to 36%) compared to the B27 negative controls
Nco.l AS Patients 
n=148 (%)
B27 +ve Controls 
n=54 (%)
1*1 39 (26) 12 (22)
1*2 77 (52) 29 (54)
2*2 32 (22) 13 (24)
1* 155 (52) 53 (49)
2* 141 (48) 55 (51)
Legend for Table 18
The results o f  the distribution o f the N co.l genotypes and alleles in the 
AS patients compared to the HLA B27 +ve controls are depicted in 
table 18. There were no significant differences between the two groups.
1 2 8
Nco.l Genotypes and alleles
Extra Features of 
Disease
1*1 1*2 2*2 1* 2*
Age of Onset<21 n=69 17 32 20 66 72 (52)
(% ) (25) (46) (29) (48)
Age of Onset>21 n=75 20 43 12 83 67 (45)
(% ) (27) (57) (16) (55)
Uveitis Present n=56 15 30 11 60 52 (46)
(% ) (26) (54) (20) (54)
Uveitis Absent n=89 24 45 20 93 85(48)
(%> (27) (51) (22) (52)
Family History Present 
n=26 ( % )
8 (31 ) 16
(62)
2 (7 ) 32
(62)
20 (38)
Family History Absent 25 52 28 102 108
n=105 (%) (24) (49) (27) (49) (51)
Peripheral joint disease 
Present n=48 (%)
16
(33)
23
(48)
9 (19 ) 55
(57)
41 (43)
Peripheral joint disease 22 52 21 96 94 (49)
Absent n=95 (%) (23) (55) (22) (51)
Legend for Table 19
A comparison o f the distribution o f  the N co.l alleles and genotypes in 
the AS patients with and without extra disease features is shown in 
Table 19. In the 69 AS patients with an age o f onset below the age o f 
21 years a slight increase in the 2*2 genotype was seen compared to 
those with an onset greater than 21 years (29% versus 16%), although 
this was not statistically significant. The N co.l l*allele was increased 
in the 26 AS patients with a family history compared to those without 
(62% versus 49%) but this failed to reach statistical significance. No 
significant differences where seen in those patients with or without 
uveitis or those with or without peripheral joint disease.
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D i s t r i b u t i o n  O f  N c o . 1  g e n o t y p e s  i n  A S  p a t i e n t s  
c o m p a r e d  t o  B 2 7 - v e  C o n t r o l s
Genotypes
□  AS Patients n=148
□  B27 -ve Controls 
n=82
*p=0.0014
Legend for Figure 32a
The distributions of the Nco.l genotypes in 148 AS patients compared to 82 B27 
negative controls are given in Figure 32a. The 2*2 genotype was significantly 
decreased in the AS patients compared to controls (pr=0.0014).
D i s t r i b u t i o n  o f  N c o . 1  a l l e l e s  i n  A S  p a t i e n t s  
c o m p a r e d  t o  B 2 7  - v e  C o n t r o l s
<DO)
<e4-»
C0>Gi_Q
CL
I
□  AS Patients n=148
□  B27 -ve Controls n=82
* p=0.0007
Alleles
Legend for Figure 32b
The distributions of the Nco. 1 alleles in the AS patients compared to the controls 
are described in figure 32b. The frequency of the 1* allele was significantly 
increased in the AS patients compared to the controls (p=0.0007).
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D i s t r i b u t i o n  o f  N C o . 1  g e n o t y p e s  i n  A S  p a t i e n t s  
c o m p a r e d  t o  B 2 7  + v e  C o n t r o l s
□  AS Patients n=148
□  B27 +ve Controls n=54
60
50
40
20
1*2 2*2
Genotypes
Legend for Figure 33a
The distributions of the Nco. 1 genotypes in the AS patients compared to the 54 B27 
positive controls are described in figure 33a. There were no significant differences 
between the two groups.
D i s t r i b u t i o n  o f  N c o . 1  a l l e l e s  i n  A S  p a t i e n t s  
c o m p a r e d  t o  B 2 7 + v e  C o n t r o l s
□  AS Patients n=148
□  B27 +ve Controls n=54
1*  2 *  
Alleles
Legend for Figure 33b
The distributions of the Nco. 1 alleles in AS patients compared to the B27 positive 
controls are described in figure 33b. There were no significant differences.
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4.2 -308  Polym orphism  Results
The second polymorphism to be investigated was the -308 RFLP, which lies within 
the promoter region of the TNFa gene. This single base substitution gives rise to 
two alleles. The -308.2 allele has previously been suggested to be involved with 
increased risk of developing cerebral malaria and mucocutaneous Leishmaniasis. A 
decreased frequency of this allele has also been linked to patients with ulcerative 
colitis. There have also been some reports that allele 2 may be able to induce 
increased transcription of TNF. This link with other diseases and the ability to 
affect transcription of the protein suggest that this polymorphic site may be 
involved in the pathogenesis of AS.
A total of 203 AS patients who are all HLA B27 positive were examined at this site 
and compared to 91 normal controls who were known to be HLA B27 negative. 
The distribution of the two alleles and the three genotypes in these two groups are 
shown in Table 20 and Figure 34a and b. It can be seen that there is a significant 
increase in the frequency of the -308.1 allele in the AS patients compared to the 
B27 negative controls (p=0.0028), OR 2.0, 95%CI 1.3-3.1, which is reflected in the 
decreased frequency of the -308.2 allele. The distribution of the genotypes also 
differ with a significant increase (p=0.011), OR 2.0, 95%CI 1.2-3.4 in the 1*1 
genotype in the AS patients compared to the B27 negative controls (78% versus 
64%).
When the 203 AS patients where compared to the second control group of 81 HLA 
B27 positive individuals (shown in Table 21 and Figure 35a and b) the -308. 1*1 
genotype was significantly increased (p=0.0015), OR 2.4, 95%C1 1.4-4.0, [78% 
versus 59%] with an expected concomitant decreased in the -308. 1*2 genotype 
[22% versus 41%]. The rarer -308.2*2 genotype was not seen in either the AS
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patients nor the B27 positive controls but was seen in 4% of the B27 negative 
controls. The allele distribution showed a significant increase in the -308.1 allele in 
the AS patients compared to the B27 positive controls (p=0.0037), OR 2.1, 95%CI 
1.3-3.4, with the expected decrease in the frequency o f the -308.2 allele.
The results for the distribution of the -308 alleles and genotypes in the AS patients 
with and without extra features of disease are summarised in Table 22. Of the 203 
AS patients examined at the -308 site information regarding their age o f onset was 
available in 199 o f which 100 had an age of onset below the age o f 21 and 99 had 
an age o f onset equal to or greater than 21. The distribution of the -308 alleles and 
genotypes did not significantly differ between the two groups. A slight increase in 
the -308.1 allele was seen in the 35 AS patients with a history of disease in the 
family compared to the 141 AS patient where there was no family history (86% 
compared to 76%). This was not statistically significant.
The distribution o f the -308 alleles and genotypes in the 199 AS patients where 
information was available regarding the presence o f peripheral joint disease are 
shown in Table 22. Out of the 199 patients 66 had a history of peripheral joint 
disease compared to 133 with no history. There were no statistically differences 
between the two groups o f patients.
Information was recorded in 196 AS patients with respect to the presence of uveitis 
and the results are shown in Table 22. The distribution of the alleles and genotypes 
did not differ between the 74 AS patients with uveitis compared to the 122 without. 
The results clearly show an association with AS and the presence o f the -308.1 
allele. This difference appears to be disease associated and not with the presence of 
HLA B27 as it was confirmed in the HLA B27 positive population. However this 
allele has not previously been associated with increased production of TNF. In fact
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the -308. 2 allele that has been associated with increased production was 
significantly decreased with the -308. 2*2 genotype being completely absent. No 
apparent associations were seen between the presence of the -308 alleles and any of 
the extra disease features.
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-308 AS patients n=203 
<%)
B27 Negative 
Controls n=91 (%)
1*2 45 (22) 29 (32)
2*2 0 (0 ) 4 (4 )
2* 4 5(11) 37 (20)
Legend for Table 20
The results o f the distribution o f the -308 alleles and genotypes in 203 
AS patients compared to 91 B27 negative controls are shown in Table 
18. A significant increase (*p=0.011) in the frequency o f the 1*1 
genotype was seen in the AS patients (78% versus 64%) compared to 
the controls. The frequency o f the 1* allele was significant increased 
(**p=0.0028) in the AS patients compared to the B27 negative controls 
(89% versus 80%).
-308 AS patients n=203 
(%)
B27 Positive 
Controls n=81 (%)
2*2 0 (0) 0 (0)
Legend for Table 21
The distribution o f the -308 genotypes and alleles in 203 AS patients 
compared to 81 B27 positive controls is given in Table 19. The 1*1 
genotype was significantly increased (*p=0.0015) in the AS patients 
compared to the controls. Correspondingly the 1*2 genotype was 
significantly decreased in the patients. The -308 1* allele was 
significantly increased (*p=0.0037) in the patients compared to the B27 
positive controls (89% versus 79%).
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-308 Genotypes and Alle cs
Extra Features 
of Disease
1*1 1*2 2*2 1* 2*
Age of Onset 75 25 0 (0 ) 175 25
<21n=100 (%) (75) (25) (88) (12)
Age of Onset >21 80 19 0 (0 ) 179 19
n=99 (%) (81) (19) (90) (10)
Uveitis Present 58 16 0 (0 ) 132 16
n=74 (%) (78) (22) (89) (11)
Uveitis Absent 94 28 0 (0 ) 216 28
n=122 (%) (77) (23) (88) (12)
Family History 
Present n=35
30
(86)
5 (1 4 ) 0 (0 ) 65 (93) 5 (7 )
(%>
Family History 107 34 0 (0 ) 248 34
Absent n=141 (76) (24) (88) (12)
(%>
Peripheral Joint 53 13 0 (0 ) 119 13
Disease Present (80) (20) (90) (10)
n=66 (%)
Peripheral Joint 101 32 0 (0 ) 234 32
Disease Absent (76) (24) (88) (12)
n=133 (%)
Legend for Table 22
The distribution o f  the -308  alleles and genotypes in the AS patients 
with and without extra features o f disease are shown in Table 22. No 
significant differences were seen in the patients with or w ithout any o f 
the other features examined.
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Distribution of -308 g e n o ty p e s  in AS 
patients com pared  to B27-ve controls
G en otypes
*p= 0.0 11
□  A S  pat ient s  n = 2 0 3
□  B 2 7  -ve  C o n t r o l s  n=91
Legend for Figure 34a
The distributions of the -308 genotypes in the AS patients compared to the B27 
negative controls are shown in Figure 34a. A significant increase (p=0.0011) in the 
frequency of the 1*1 genotype was seen in the AS patients compared to the 
controls.
Distribution of  -308 A lle les  in AS 
patients  com p ared  to B27-ve contro ls
□  A S p atien ts  n=203
□  B27 -ve C o n tro ls  
n=91
* p = 0 .0 0 2 8
1*
A lleles
Legend for Figure 34b
The distributions of the -308 alleles in the AS patients compared to the B27 
negative controls are shown in Figure 34b. The frequency of the -308*1 allele was 
significantly increased (p=0.0028) in the AS patients compared to the controls.
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D i s t r i b u t i o n  o f  - 3 0 8  g e n o t y p e s  i n  A S  p a t i e n t s  
c o m p a r e d  t o  B 2 7 + v e  c o n t r o l s
*
80 □  AS patients n=203
□  B27 +ve Controls n=81
60 
50 
40 
o 30
Cl
20
reO)re*->creoL.
1*1 1*2
Genotypes
Legend for Figure 35a
The distributions of the -308 genotypes in the AS patients compared to the B27 
positive controls are described in figure 35a. The frequency of the 1*1 genotype 
was significantly increased in the AS patients compared to the controls (p=0.0015)
D i s t r i b u t i o n  o f  - 3 0 8  a l l e l e s  i n  A S  p a t i e n t s  
c o m p a r e d  t o  B 2 7 + v e  c o n t r o l s
□  AS patients n=203
□  B27 +ve Controls n=81
90
80
70 p=0.0037
reo>re
creo
re
CL
1*
Alleles
Legend for Figure 35b
The distributions of the -308 alleles in the AS patients compared to the B27 
positive controls are shown in figure 35b. The frequency of the 1* allele was 
significantly increased in the AS patients compared to the controls (p=0.0037).
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4.3 LST.l Polymorphism
The LST.l gene located 4 kilobases upstream of the lymphotoxin b gene contains a 
polymorphic Pvu II restriction site 260 base pairs downstream of the 
polyadenylation signal. The LST.l gene codes for an IFN gamma inducible 800 nt 
transcript which has been shown to be present on macrophages and T cells. The 
position of this polymorphic site and its pattern of expression have implied it may 
have a role in autoimmune diseases.
A total of 142 AS patients were investigated at this site and the results compared to 
48 normal controls as can be seen in Table 23. The majority of individuals studied 
carried the wild type allele. No significant differences were seen in either the 
distribution of the alleles or genotypes. Similarly in the AS patients compared to 52 
B27 positive controls (results in Table 24) no significant differences were seen.
The distribution pattern was examined in the AS patients with regard to the 
presence or absence of extra features of disease, there were no significant 
differences (data not shown).
In conclusion there appears to be no significant associations with this polymorphic 
site and AS.
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LST.l AS Patients n=142 
(% )
B27 -ve Controls 
n=48 (%)
1*1 1(1) 0 (0 )
1*2 13(9) 3 (6 )
2*2 128 (90) 45 (94)
1* 15(5) 3 (3 )
2* 269 (95) 93 (97)
Legend for Table 23
The distribution o f the LST .l alleles and genotypes in the 142 AS 
patients compared to 48 B27-ve controls are shown in Table 23. There 
were no significant differences between the two groups.
LST.l AS Patients n=142 
1%)
B27+ve Controls 
n=52 (%)
1*1 1 (1) 0 (0 )
1*2 13(9) 2 (4 )
2*2 128 (90) 50 (96)
1* 14(5) 2( 2)
2* 269 (95) 102(98)
Legend for Table 24
The distribution o f  the LST. 1 genotypes and alleles in the AS patients 
compared to the B27 positive controls are shown in Table 24. There 
were no significant differences between the two groups.
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D i s t r i b u t i o n  o f  L S T . 1  a l l e l e s  i n  A S  p a t i e n t s  
c o m p a r e d  t o  B 2 7 - v e  C o n t r o l s
□  AS Patients n=142
□  B27-ve Controls n=48100
90
80
70
60 ill
Alleles
Legend for Figure 36a
The distributions of the LST.l alleles in the AS patients compared to the B27-ve 
controls are shown in figure 36a. There were no significant differences between the 
two groups.
D i s t r i b u t i o n  o f  L S T . 1  a l l e l e s  i n  A S  p a t i e n t s  
c o m p a r e d  t o  B 2 7 + v e  C o n t r o l s
□  AS Patients n=142
□  B27+ve Controls n=52
100
90
80
70
60
40
30
20
Alleles
Legend for Figure 36b
The distributions of the LST.l alleles in the AS patients compared to the B27+ve 
controls are shown in figure 36b. There were no significant differences between the 
two groups.
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4.4 Tumour Necrosis Factor Polymorphisms Discussion
The position of the TNF genes in the MHC class III region and their role in the 
inflammatory process has suggested they may have a role to play in MHC 
associated diseases such as AS. As mentioned previously there are numerous 
polymorphic sites in the TNF locus some of which have been associated with 
alterations in the actual levels of protein produced. High levels of mRNA for TNFa 
have been detected in biopsies from the sacroiliac joints of AS patients (Braun, 
1995 ). In transgenic mice the dysregulation of TNFa expression has been shown to 
induce arthritis (Kontoyiannis, 1999). Serum levels for TNFa in AS patients have 
been shown to be increased (Gratacos, 1994). This study was therefore carried out 
to investigate a number of these polymorphic sites in the AS patients in comparison 
to the controls in order to determine if there was an increased frequency of any of 
the alleles associated with increased production.
A total of six polymorphic sites were investigated, three biallelic RFLP’s and three 
microsatellites. These polymorphic sites were chosen as they span the TNF locus 
from close to the B27 locus towards the DR locus. Each site was investigated in the 
AS patients compared to the two control populations.
4.5 Nco.l Discussion
The first site to be investigated was the Nco. 1 biallelic RFLP, which lies within the 
first intron of the LTa gene and gives rise to two alleles. Previous work has 
associated the Nco. 1*2 allele with increased levels of TNFa in some populations 
(Abraham, 1993). In this study the distribution of the Nco.l alleles were 
significantly different in the AS patients compared to the normal control group who
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were all healthy unrelated B27 negative individuals. The Nco. 1*1 allele was 
significantly increased in the AS patients (p=0.0007). This appeared to be due to a 
significant decrease in individuals homozygous for the Nco. 1*2 allele (p=0.0014). 
In a similar study the distribution o f the Nco. 1 alleles have also been shown to be 
significantly different in a group o f AS patients when compared to the normal 
population (Fraile, 1998). A significant decrease in the frequency of the 2*2 
genotype was also seen in the AS patients with a similar distribution as was seen in 
this study. However this is in contrast to another study of AS patients where no 
differences where seen (Veijans, 1991).
The Nco. 1*1 allele has previously been shown to be associated with increased 
production of LTa and it would appear that this allele is significantly increased in 
the AS patients compared to the normal population. However it could be that this 
difference in distribution is due to linkage disequilibrium with the B27 gene since 
this significant difference disappeared when the AS patients where compared to the 
B27 positive control population. The frequency of each o f the genotypes and alleles 
were very similar between these two groups. This is comparable to the Spanish 
study where they also saw no difference between the AS patients and B27 positive 
controls. They go on to suggest that the Nco. 1*1 allele is in strong linkage 
disequilibrium with B27. It has been demonstrated that B27 positive cells have 
increased production of TNFa compared to B27 negative cells (Repo, 1988). This 
could be due to the increased frequency of the Nco. 1*1 allele, associated with 
increased production, in B27 positive individuals.
The role of TNFa in other autoimmune diseases such as Rheumatoid arthritis is 
much more established and several studies have suggested that particular TNF 
alleles may not only be disease associated but may also be a marker for disease
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severity. In order to investigate this in relation to disease severity in the AS patients 
several features were examined. There were no significant differences found in any 
of the extra disease features investigated. Although in other studies the N co.l*! 
allele has been shown to be associated with an early onset of disease in patients 
with myasthenia gravis (Hjelmstrom, 1998).
In conclusion at this site a significant increase of the Nco. 1*1 allele was seen in the 
AS patients compared to the normal population but that this difference disappeared 
when the patients where compared to the appropriate control population. This 
would predict that the Nco. 1 polymorphic site does not play a primary role in the 
disease pathogenesis of AS. But that it points to possible haplotypes that may exist 
across the MHC.
4.6 -3 0 8  Discussion
The -308 polymorphic site within the TNF promoter region has been the subject of 
much interest in a variety o f autoimmune diseases including SLE, IDDM, Crohns 
disease as well as parasitic diseases such as cerebral malaria and Leishmaniasis. 
Increased frequency of the -308*2 allele has been demonstrated in other 
autoimmune conditions such as SLE (Wilson, 1994).
Previous studies have led to conflicting results as to the functional consequences of 
this polymorphism. Some in vitro studies have shown increased levels of TNFa 
associated with the -308*2 allele (Louis, 1998). It has been suggested that this 
difference in TNFa levels is due to ability of the allele*2 to bind nuclear factors 
imolved in transcription differently to allele* 1 (Abraham, 1997). This gives rise to 
a two-fold increase in the levels of transcription in PMA-stimulated Jurkat and 
U937 cells. This has been attributed to a lObp sequence around the -308 site that is
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homologous to the binding site of an activator protein-2 (AP-2) element (Kroeger, 
1996). However other studies have failed to confirm these findings in a transient 
transfection system where both alleles were said to contribute equally to the total 
amount of mRNA (Brinkman, 1996). Associations with TNFa production and 
particular -308 genotypes have been described in peridontal disease where the 1*2 
genotype was correlated with increased production in patients with advanced 
disease (Galbraith, 1998). This raised the question was the distribution of the -308  
alleles in AS patients different from the control populations and was the incidence 
of the -308*2 allele, which is associated with higher levels o f TNFa, increased in 
this patient group.
The results clearly show a significant increase in the distribution of the -308*1 
allele in the AS patients not only when compared to the normal control group but 
also when compared to the B27 positive controls. This implies a link between this 
allele in the TNF promoter region in these patients that is not present in the HLA- 
B27 positive controls. It would be of interest to know if the increased expression o f  
this allele is also found in B27 negative AS patients, but as they number less than 
10% of the AS population, multicenter studies would be required to achieve 
sufficient numbers for statistical analysis.
A number o f other groups have investigated this site in AS and found conflicting 
results. In the study by Veijans no significant differences where seen, however only 
a small number o f patients and controls where examined (66 patients and 19 
controls). It may also be that there are regional differences as seen in the 
distribution o f the -308*2 allele which in the Veijans study had a very low 
frequency in the control group compared to other Western European control groups 
(Verjans, 1994). A similar study carried out on British Caucasians has also failed to
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demonstrate this association with allele* 1 and AS and in fact found a weak 
association with the rare -308*2 allele being increased in AS patients. (Brown, 
2000). Brown and colleagues have since carried out a further study on a second 
cohort of patients and have established an association with the -308*1 allele in a 
cohort of German AS patients (Milicic, 2000).
One alternative interpretation of the data seen in this study could be that there is a 
reduction in the frequency o f the -308*2 allele as was implied in a recent study 
where it was suggested that the -308*2 allele had a protective role against the 
development o f AS in B27 positive individuals (Hohler, 1998). The association of 
the -308*2 allele with the HLA DR(31*03 alleles as seen in SLE patients also 
suggest a protective role against the development of nephritis (Jacob, 1990). The 
-308*2 allele in conjunction with the IL-lRa*2 allele may also be protective 
against infection with cytomegalovirus (Hurme, 1998). Cytomegalovirus has been 
implicated in patients with uveitis (De Boer, 1996) So could it be in diseases such 
as AS where infections have been implicated in the pathogenesis, B27 positive 
individuals carrying the -308*2 allele are better equipped to combat these 
infections.
Previous work has shown the -308*2 allele to be in linkage with the HLA 
DRpi*03 allele in SLE patients, although it has also been suggested that the -  
308*2 allele may have an independent effect as well (Sullivan, 1997). This is part 
of the HLA A1-B8-DR3-DQ2 extended haplotype, which is known to confer 
susceptibility to celiac disease (McManus. 1996). TNFa levels are also known to 
vary according to particular HLA DR alleles (Jacob, 1990, Bendtzen, 1988). 
Individuals carrying the HLA-DR2 allele are low producers compared to those with 
HLA-DR3 and HLA-DR4 alleles that are high producers. It is of interest to note
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that in this study the incidence of HLA-DRpl*03 alleles was reduced which is what 
would be expected if  the -308*2 allele is part o f an extended haplotype.
As with the other polymorphic sites investigated the distribution of the -308 alleles 
were compared in the AS patients with and without several different disease 
features. In a study of primary biliary cirrhosis patients the -308 1*1 genotype was 
associated with more advanced disease suggesting that this allele may be linked to 
disease progression rather than disease susceptibility (Jones, 1999). No significant 
differences were seen in the distribution of the -308 alleles in any o f the features 
examined in our AS patients. In conclusion this study has shown a significant 
increase of the -308*1 allele in the AS patients when compared to both control 
groups implying that this region o f the genome is associated with AS, independent 
of HLA B27. However as it is the -308*2 allele that is associated with higher 
mRNA production then the increase in -308*1 allele would imply that if  TNF is 
important in the pathogenesis of sacroilitis in AS, any genetic influence over the 
differential production is unlikely to be important.
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4.7 T NFa Microsatellite Results
The TNFa microsateilite is highly polymorphic and contains at least 13 alleles that 
differ according to the number of AC/GT repeats. The TNFa microsateilite is located 
upstream of the LTa gene and in vitro stimulation studies have indicated that TNFa 
levels vary dependant on different TNFa alleles (Pociot, 1993). Previous studies have 
shown associations with TNFa6 allele in RA patients and TNFa2 with IDDM. The 
TNFa6 allele has been linked with decreased secretion of TNFa in IDDM patients 
whereas TNFa2 has been associated with higher production. The TNFa microsateilite 
was investigated in 138 AS patients, 91 B27 negative controls and 72 B27 positive 
controls, the results are depicted in Table 25 and 26.
The distribution of the TNFa alleles in the AS patients compared to the B27 negative 
controls are shown in Figure 37. Overall the distribution of the TNFa alleles are 
significantly different between the two groups when analysed by Clump (T4<0.0005). 
A significant increase in TNFa6 allele was seen in the AS patients compared to the 
B27 negative controls (40% versus 18 %, p<0.005). This was balanced by a significant 
decrease in the TNFal 1 allele in the patients compared to the controls (6% versus 
20.9%, p<0.005). None of the other alleles differed significantly.
As was seen in the Nco.l site, however this significant difference did not hold true 
when examining the AS patients to the B27 positive controls. As can be seen in Figure 
38 the distribution of all the alleles were very similar between these two groups 
suggesting that the differences seen may be part of an extended haplotype with B27 
and not predisposing to disease.
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Previous studies have suggested that particular alleles may predispose not only too 
higher levels of TNFa but may be associated with more severe forms of disease. The 
increased frequency o f TNFa6 allele in a study of RA patients was even more 
pronounced in those patients with a more severe disease (Hajeer, 1996).
The distribution o f the 13 alleles in the 67 AS patients with an onset o f disease below 
the age o f 21 years compared to the 68 AS with an onset greater than 21 years is 
described in Table 27. No significant differences between the two groups were seen. . 
In the 48 AS patients with uveitis the TNFa4 allele was represented only once 
compared to the 86 AS patients without a history o f uveitis where the TNFa4 allele 
was seen in 19 patients (p=0.04). The results can be seen in Table 28. The distributions 
of the 13 TNFa alleles in the 23 AS patients with a family history compared to the 98 
patients with no family history are recorded in Table 29. Some differences were noted 
although none reached statistical significance. For instance the frequency of the TNFa2 
allele was reduced in the patients with a family history compared to those without (7% 
versus 21%). Also an increase in the frequency o f the TNFa6, 7 and 10 alleles was seen 
in the patients with a family history. A reduction of the frequency of the TNFa2 allele 
was also seen in the 41 AS patients with peripheral joint disease compared to the 94 
without as can be seen in Table 30 (12% versus 20%).
Although some differences were seen in the distribution of the TNFa alleles in the AS 
patients with and without extra features of disease they failed to reach statistical 
significance.
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TNFa Alleles AS Patients 
n=138 (%)
B27 Negative 
Controls n=91 
( % )
1 3 (1 ) 2 (1 )
2 49 (18 ) 37 (20)
3 2 (1) 3 (2)
4 18 (7) 17(9)
5 5 (2) 12(7)
7 14(5) 12 (7)
8 2 (1) 1 (0.5)
9 2 (1 ) 3 (2 )
10 47 (17) 16 (9)
12 3 (1 ) 1 (0.5)
13 4 (1) 7 (4 )
Legend for Table 25
The distribution o f  the 13 different alleles at the TN Fa locus in 138 AS 
patients compared to 91 B27 negative controls is described in Table 25. 
The TNFa6 allele was significantly increased in the AS patients compared 
to the controls (p<0.005). The TN Fal 1 allele was significantly reduced in 
the AS patients compared to the controls (p<0.005).
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Distribution of TNFa alleles in AS patients 
conpared to B27-ve Controls
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Legend for Figure 37
The distribution o f the 13 different TNFa alleles in the 138 AS patients 
compared to the 91 B27-ve controls are shown in Figure 37. The 
frequency o f the TNFa6 allele was significantly increased in the AS 
patients (p<0.005) compared to the controls. Correspondingly the T N F a ll 
allele was significantly decreased (p<0.005).
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TNFa Alleles ] AS Patients
n=138 (%)
...............  L
B27 positive
controls n=72
'
( % )
l 3 (1 ) 1 (1)
2 49 (18 ) 38 (26)
3 2 (1) 0 (0)
4 18 (7) 7 (5)
5 5 (2) 2 (1)
6 111 (40) 51 (35)
7 14(5) 9 (6)
8 2 (1) 2 (1 )
9 2 (1 ) 9 (6)
10 47 (17) 20 (14 )
11 16(6) 4 (3)
12 3 (1 ) 0 (0)
13 4 (1) 1 (1)
Legend for Table 26
Table 26 depicts the distribution o f  the 13 TNFa alleles in the 138 AS 
patients compared to the 72 B27 positive. There were no significant 
differences between the two groups.
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Distribution of TNFa alleles in AS patients 
compared to B27+ve Controls
□ AS Patients n=138
□ B27+ve Controls n=72
flleles
Legend for Figure 38
The distribution o f the 13 TNFa alleles in the AS patients compared to the 
B27 positive controls are shown in Figure 38. There were no significant 
differences between the two groups.
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TNFa Alleles AS Patients with 
Age of Onset 
<21yrs n=67 (%)
AS Patients with 
Age of Onset 
>21yrs n=68 (%)
1 1 (1) 2 (1 )
2 25 (19) 23 (17)
3 0 (0 ) 2 (1 )
4 7 (5) 10(7)
5 2 (1 ) 3 (2 )
6 52 (39) 55 (40)
7 9 (7 ) 5 (4 )
8 1 (1) 1 (1)
9 2 (1 ) 0 (0)
10 23 (17) 24(18)
11 9 (7 ) 7 (5)
12 1(1) 2 (1)
13 2 (1) 2 (1 )
Legend for Table 27
Distributions o f the 13 TNFa alleles in 67 AS patients with an onset o f 
disease <21 years o f age compared to 68 AS patients with an onset > than 
21 years are shown in Table 27. No significant differences in the 
frequency o f the alleles were seen between the two groups.
154
TNFa Alleles Uveitis Present 
n=48 (%)
Uveitis Absent 
n=86 (%)
1 0 (0 ) 3 (2)
2 23 (24) 25 (15)
3 1 (1) 1(1)
5 4 (4 ) 2 (1 )
6 40 (42) 64 (37)
7 2 (2) 11(6)
8 0 (0) 2 (1 )
9 1 (1) 1 (1)
10 16(17) 31 (18)
11 5 (5 ) 9 (5 )
12 2 (2 ) 1(1)
13 1 (1) 3 (2 )
Legend for Table 28
The distribution o f the TNFa alleles in 48 AS patients with uveitis 
compared to 86 AS patients without are shown in Table 28. The TNFa4 
allele was represented only once in the 48 AS patients with uveitis 
compared to 19 out o f  86 patients (p=0.04).
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TNFa
alleles
Family History 
Present n=23 (%)
Family History 
Absent n=98 (%)
1 0 (0 ) 2 (1 )
2 3 (7 ) 42 (21)
3 0 (0 ) 2 (1 )
4 2 (4 ) 12 (6)
5 0 (0 ) 5 (2.5)
6 22 (48) 73 (37)
7 6 (1 3 ) 7 (4 )
8 0 (0 ) 1 (0.5)
9 0 (0 ) 1 (0.5)
10 10 (22) 34(17)
11 2 (4) 12 (6)
12 1(2) 1 (0.5)
13 0 (0 ) 4 (2)
Legend for Table 29
Distributions o f the 13 different TNFa alleles in AS patients with and 
without a family history are depicted in Table 29. The frequency o f the 
TNFa2 allele was reduced in the 23 AS patients with a family history 
compared to the 98 AS patients without (7% versus 21%). In the patients 
with a family history the frequency o f  the TNF a6, a7 and alO alleles were 
increased compared to the patients without a family history.
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TNFa Alleles PJD Present 
n=41 (%)
PJD Absent n=94 
( % )
i 0 (0 ) 3 (2 )
2 10 (12) 38 (20)
3 0 (0) 2 (1 )
4 3 (4) 15(8)
5 2 (2) 3 (2 )
6 40 (49) 68 (36)
7 7 (9 ) 7 (4 )
8 0 (0 ) 2 (1 )
9 1 (1) 1 (1)
10 12(15) 35 (19)
11 5 (6 ) 9 (5 )
12 1 (1) 2 (1)
13 1 (1) 3 (2)
Legend for Table 30
The distribution o f the 13 TNFa alleles in 41 AS patients with PJD 
compared to 94 AS patients without PJD are shown in Table 30. The 
frequency o f the TNFa2 allele was reduced in the AS patients with PJD 
compared to those without (12% versus 20%).
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4.8 TNFc Microsateilite results
The TNFc microsateilite is a biallelic polymorphism that lies within intron 1 of the 
LTa gene. O f the two possible alleles allele *2 has been previously associated with 
increased secretion of TNFa . In the same publication the TNFc *1 allele was shown to 
be associated with low TNFa production in IDDM patients (Pociot, 1993). The TNPc 
*1 allele has also shown an association with RA in a multiplex family study (Mulcahy, 
1996). Several reports have suggested that some of the TNF polymorphisms play a role 
in extended haplotpyes that extend across the MHC Class I, II and III regions. The 
TNFc *2 allele has been shown to be linked to the presence of DR4 (Jongeneel, 1991). 
However in a study of Reactive arthritis patients in which B27 plays a role the TNFc 
*1 allele was proposed to have an independent role on disease susceptibility (Tuokko, 
1998).
A total of 159 AS patients were investigated at the TNFc site and the results were 
compared to 98 B27 negative controls. The results of the distribution of alleles and 
genotypes are described in Table 31 and depicted in figures 39a and b. The 
distributions were very similar between the two groups.
However when the 159 AS patients were compared to the 50 B27 positive controls the 
TNFc 1*2 genotype was significantly decreased in the patients (30% versus 50%, 
p=0.01). The results are described in Table 32 and shown in Figure 40a and b. No 
statistical differences in the distribution of alleles were seen in the AS patients 
compared to the B27 positive controls.
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The distribution o f the TNFc alleles and genotypes were investigated in the AS patients 
with and without the extra disease features as described in Table 33. There were no 
significant differences in any o f the features investigated.
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TNFc AS Patients n=159 
(% )
B27-ve Controls 
n=98 (%)
1*1 105 (66) 62 (63)
1*2 48 (30) 30(31)
2*2 6 (4 ) 6 (6 )
1* 258 (81) 154 (79)
2* 60(19) 42 (21)
Legend for Table 31
The distribution o f the TNFc genotypes and alleles in the AS patients 
compared to the B27 negative controls are displayed in Table 31. There 
were no significant differences between these two groups
TNFc AS Patients n=159 
(% )
B27 +ve Controls 
n=50 (%)
1*1 105 (66) 25 (50)
2*2 6 (4 ) 0 (0 )
1* 258 (81) 75 (75)
2* 60(19) 25 (25)
Legend for Table 32
The results o f the distribution o f the TNFc genotypes and alleles in the AS 
patients compared to the B27 positive controls are shown in Table 32. The 
TNFc 1*2 genotype was significantly increased (p=0.01) in the B27 
positive controls compared to the AS patients (50% versus 30%). There 
were no significant differences in the distribution o f the alleles.
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D i s t r i b u t i o n  o f  T N F c  G e n o t y p e s  i n  A S  p a t i e n t s  
c o m p a r e d  t o  B 2 7 - v e  C o n t r o l s
70 -| □  AS Patients n=159
□  B27-ve Controls n=9860
O)
40
30
20
2*2
Genotypes
Legend for Figure 39a
The distributions o f  the TNFc genotypes in the AS patients compared to 
the B27-ve controls are shown in Figure 39a. There were no significant 
differences between the two groups.
D i s t r i b u t i o n  o f  T N F c  a l l e l e s  i n  A S  p a t i e n t s  
c o m p a r e d  t o  B 2 7 - v e  C o n t r o l s
□  AS Patients n = 159
□  B27-ve Controls n=9890
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Legend for Figure 39b
The distributions o f the TNFc alleles in the AS patients compared to the 
B27-ve controls are shown in Figure 39b. There were no significant 
differences between the two groups.
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Distr ibution of  TNFc genotypes  in AS patients  
com pared  to B27+ve Controls
□  AS Patients n = 1 59 
HB27+ve Controls n=98
60
*p=0.01
o>
20
2*2
Genotypes
Legend for Figure 40a
The distributions o f the TNFc genotypes in the AS patients compared to 
the B27+ve controls are shown in Figure 40a. The frequency o f the TNFc 
1 *2 genotype was significantly decreased in the AS patients compared to 
the controls (p=0.033).
Distr ibution of TNFc alleles in AS patients  
com pared  to B27 + ve Controls
□  AS  Pat ien ts  n = 1 59
□  B27 + ve Cont ro l s  n = 98
1 *  2 *  
A l l e l e s
Legend for Figure 40b
The distributions o f  the TNFc alleles in the AS patients compared to the 
B27+ve controls are shown in Figure 40b. There are no significant 
differences between the two groups.
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TNFc Genotypes and Alleles
Extra Features 
of Disease
1*1 1*2 2*2 1* 2*
Age of Onset <21 
n=78 (%)
50
(60)
24 (31) 4(5) 124
(79)
32 (21)
Age of Onset >21 
n=78 (%)
52
(67)
24 (31) 2(2) 128
(82)
28(18)
Uveitis Present 
n=59 (%)
35
(59)
20(34) 4(7) 90
(76)
28(24)
Uveitis Absent 
n=95 (%)
66
(70)
27 (28) 2(2) 159
(84)
31(16)
Family History 
Present n=25 
(%)
19
(76)
5(20) 1(4) 43
(86)
7(14)
Family History 
Absent n=116
(%)
72
(62)
39 (34) 5(4) 183
(79)
49(21)
Peripheral Joint 
Disease Present 
n=47 (%)
35
(74)
10 (21) 2(5) 80
(85)
14
(15)
Peripheral Joint 
Disease Absent 
n=109 (%)
68
(62)
37 (34) 4(4) 173
(79)
45 (21)
Legend for Table 33
The distribution o f the TNFc alleles and genotypes in the AS patients with 
and without extra features o f disease are shown in Table 33. The TNFc 1 
allele was reduced in the AS patients with uveitis (76% versus 84%) with 
a corresponding increase in the TNFc 2 allele but this was not statistically 
significant. Similarly the TNFc 1*1 genotype was increased in those 
patients with a family history (76% versus 62%). Overall there were no 
statistical differences.
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4.9 TNFe Microsatellite Results
At the centromeric end of the TNF locus, which still remains largely undefined, lies the 
TNFe microsatellite. This site contains at least three alleles with some studies detecting 
four. No known associations with any of the TNFe alleles and alterations in protein 
levels have been established. Flowever the TNFe *3 allele has been demonstrated to be 
over-represented in a group of RA patients compared to controls (Field, 1997). The 
TNFe locus may also be linked with possible extended haplotypes spanning the MFIC 
as in the same study the increase of the TNFe *3 allele was accounted for by the 
presence of DR4 in these RA patients.
Since this site was not associated with any functional difference only a small number 
of the AS patients and controls were investigated. The results of the distribution of the 
TNFe alleles in the AS patients are described in Table 34. There were no significant 
differences between the two groups. Similarly the distribution of the TNFe alleles in 
the AS patients compared to the B27 positive controls are shown in Table 35. A slight 
decrease in the distribution of the TNFe *3 allele was seen in the AS patients (80% 
versus 90%) but this was not statistically significant. No significant differences in the 
distribution of the genotypes were seen (data not shown) in the AS patients compared 
to both control groups.
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TNFe AS Patients n=61 B27-ve Controls
(%) n=122 (%)
1* 19(16) 26 (21)
2* 5(4) 4 (3 )
3* 98 (80) 92 (76)
Legend for Table 34
The distribution o f the TNFe alleles in the AS patients compared to the 
B27 negative controls are described in Table 34. There were no significant 
differences between the two groups either in the distribution o f the alleles 
or the genotypes (data not shown).
TNFe AS Patients n=61 
(%)
B27 +ve Controls 
n=48 (%)
1* 19(16) 5(10)
2* 5(4) 0 (0 )
3* 98 (80) 43 (90)
Legend for Table 35
No significant differences were seen in the distribution o f  the TNFe alleles 
in the AS patients compared to the B27 positive controls either in the 
frequency o f alleles or the genotype frequencies (data not shown).
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D i s t r i b u t i o n  o f  T N F e  a l l e l e s  i n  A S  p a t i e n t s  
c o m p a r e d  t o  B 2 7 - v e  C o n t r o l s
70
60a>
C D
CO■*->c0)o 40
© 30 '
CL
20
Cl AS patients n=61 
□  B27 -ve Controls n=122
Alleles
Legend for Figure 41
The distribution o f the TNFe alleles in the AS patients compared to the 
B27-ve controls are described in Figure 41. There were no significant 
differences between the two groups.
D i s t r i b u t i o n  o f  T N F e  a l l e l e s  i n  A S  p a t i e n t s  
c o m p a r e d  t o  B 2 7 + v e  C o n t r o l s
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□  AS patients n=61
□  B27+ve Controls n=48
Legend for Figure 42
The distribution o f the TNFe alleles in the AS patients compared to the 
B27 +ve controls are shown in Figure 42. There were no significant 
differences between the two groups.
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4.10 TNF Microsatellite Discussion
Three microsatellite loci were investigated in this study, with the TNFa being one of 
the more informative regions. This is a highly polymorphic site with at least 13 
possible alleles being described. Previous work has attributed differences in production 
of TNFa to particular alleles at this site. The TNFa2 allele linked with DR.pi*03 in an 
extended haplotype correlates with increased production whereas TNFa6 is associated 
with decreased production (Pociot, 1993).
In the present study a significant increase in the frequency of the TNFa6 allele was 
seen in the AS patients compared to the normal control population. This was in 
comparison to the significant decrease of the TNFal 1 allele in the patients. However 
this association appears to be secondary to the presence of B27 since the distributions 
did not differ between the patients and the B27 positive controls. This would suggest 
that any association with the TNFa microsatellite alleles is part of an extended 
haplotype and not predisposing to disease. Large multi-case family studies would be 
required to confirm this finding.
Similar results have been described for Reactive arthritis patients where an increase in 
the TNFa6 allele and decrease in TNFal 1 was also seen. Reactive arthritis also has an 
association with B27 and it would appear in this study that the differences seen are also 
secondary to B27 (Tuokko, 1998). In RA patients an independent association with 
TNFa6 has also been described (Mulcahy, 1996) along with studies showing the allele 
to be in linkage with DRp 1*0401 (Hajeer, 1996). The TNFa6 has been associated with 
decreased secretion of TNFa in IDDM patients but to date information on levels in AS 
patients in relation to these alleles have not been studied.
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It would appear that these TNFa alleles are part o f an extended haplotype in our 
population involving both MHC Class I (B27) and MHC Class II (DRpi) genes and 
therefore do not have an effect on disease susceptibility in AS patients. It has been 
suggested that these alleles may have a role in disease severity with TNFal 1 linked to 
severity in RA patients (Mu, 1999). Therefore the distributions of these alleles were 
examined in relation to different features o f disease. Only in the AS patients with and 
without uveitis was a difference seen in that AS patients with uveitis had a decreased 
incidence o f TNFa4 allele. However numbers where small and no functional relevance 
of the TNFa4 allele has been described. It would be interesting to investigate this 
further in AS patients with uveitis who where B27 negative to determine if  this was 
independent o f B27.
Of the other microsatellite regions investigated no significant differences were seen at 
the TNFe locus. At the TNFc locus the AS patients differed significantly in the 
distribution o f the TNFc 1*2 genotype which was decreased in the AS patients. 
Associations with TNFc*l allele with decreased production and TNFc2 allele with 
increased production o f TNFa have been demonstrated in IDDM patients. The 
TNFc*l allele has also shown an association with RA in a family study (Mulcahy, 
1996). The TNFc alleles have also been demonstrated to be part o f an extended 
haplotype with particular TNFc alleles being linked with particular Nco.l alleles 
(Pociot, 1993). The significance of the decreased frequency o f the TNFc 1*2 genotype 
in the patients is unclear as it is not seen in the normal population and does not hold for 
the distribution o f the alleles themselves. With the small numbers studied it may just 
reflect linkage patterns across the MHC.
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5.1 Interleukin 1 Polymorphism
A recent genome screen carried out on a large number of AS patients highlighted areas 
other than the MHC as candidate sites, which could play a role in the pathogenesis of 
AS. One area lies within six centimorgans of the genes for the three interleukin 1 
proteins (IL -la , IL -lp , and IL-IRa). II-la  and IL-ip are important proinflammatory 
cytokines whose prolonged production has been implicated in autoimmune diseases. 
IL-1 is a powerful stimulant of osteoclastic bone resorption, has potent catabolic 
effects on cartilage, induces the acute phase response and increases the release of other 
inflammatory mediators. In particular IL-1 has been shown to be important in animal 
models such as the rabbit model of immune mediated colitis and in cartilage 
destruction in the collagen induced model (Cominelli,1992). Although there is no 
direct evidence of the involvement of IL-1 proteins in AS the presence of TNF in 
sacroiliac biopsies suggest IL-1 may be important since it is well recognised that TNF 
can induce IL-1. IL-IRa blocks the effects of IL -la  and p and it is thought to be the 
balance between the three proteins that is important in limiting the activity of IL-1.
The genes for the three proteins along with the genes for the IL-1 receptors are all 
found on chromosome two. The IL-1 a ,p  and Ra genes all map to a common 
restriction site where known linkage between the genes has been recognised (Cox, 
1998). Stable variations in protein levels between individuals have been reported 
previously (Danis, 1995), implying genetic factors may be important. Several 
polymorphic sites have been identified in all three genes some of which are known to 
affect cytokine production. Particular alleles at some of these sites have also been 
associated with other autoimmune conditions.
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It is therefore feasible that in a condition such as AS where fibrous joints are destroyed 
that IL-1 may be implicated. It could be that AS patients have an increased frequency 
of particular IL-1 alleles linked to high IL-1 production that may contribute to disease 
pathogenesis. In order to investigate this the frequency of alleles at three polymorphic 
sites, the -889 RFLP in IL-la, the -511 RFLP in IL-1 (3 and the 86 base pair repeat in 
the IL-IRa gene were examined in the AS patients and compared to controls.
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5.2 Interleukin 1 Receptor Antagonist Results
The role of the IL-IRa is as a naturally occurring inhibitor, which is capable of binding 
to the IL-1 receptor without inducing any intracellular response. Although there are 
two structural variants o f IL-IRa, a secreted form and a form that remains in the 
cytoplasm, both are transcribed from the same gene through the use o f alternative first 
exons (Arend, 1998). The human IL-IRa gene has been mapped to the band q 14-q21 
on the long arm of chromosome 2 and contains within intron 2 an 86 base pair variable 
number tandem repeat (VNTR). This VNTR has been reported to have five alleles 
depending on the number of repeats of the 86bp fragment. There are three potential 
protein binding sites in this region suggesting a possible functional role although none 
is known at present. Allele 2 which has two repeats has previously been associated 
with a variety of diseases including, ulcerative colitis, Graves disease, SLE, severe 
peridontitis and reduced bone loss in women with an early menopause (Keen, 1998).
A total of 182 AS patients where examined by PCR for the IL-IRa 86bp VNTR as 
described in the materials and methods section. The distribution of the alleles and 
genotypes where compared to two control populations, the first group consisted of 115 
unrelated healthy blood donors who were all known to HLA B27 negative and the 
second group consisted of 76 HLA B27 positive healthy individuals. The results of the 
AS patients compared to the normal HLA B27 negative controls are described in Table 
36. Only three of the possible five alleles and only four genotypes were seen in this 
study. Alleles 4 and 5 are uncommon and where not seen in either the patients or both 
control groups in this study.
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In the AS patients the frequency o f the IL-IRa 1*1 genotype was decreased compared 
to the control population (80% Vs 90%). The frequency of the 1*2 genotype was 8% in 
the patients and was only seen in one of the controls (1%) and the 2*2 genotype was 
seen in 9% of the patients compared to 7% of the controls (Fig 43a). The overall 
frequency of the genotypes in the AS patients as seen in Figure 43a differed 
significantly from the B27 negative controls when examined using the Monte-Carlo 
simulation index (T4=0.02). Carriage o f at least one copy o f allele 2 in the AS patients 
was 16% compared to 8% in the B27 negative controls giving an odds ratio of 2.3 with
' 95% confidence limits of 1.1 to 4.9, p=0.03. An increased carriage of allele 2 has been
!
| shown previously for other autoimmune diseases such as ulcerative colitis
i
(Mansfield, 1994).
The frequency and distribution of the IL-IRa alleles in the AS patients were compared 
to a second group o f healthy individuals who were known to HLA B27 positive. The 
results are described in Table 37 and shown on Figure 44a and b. The 1*1 genotype 
1 was decreased in the patients compared to controls (80% Vs 91%). None of the B27 
positive controls carried the 1 *2 genotype. The overall distribution of the genotypes in 
the AS patients was significantly different to the B27 positive controls when analysed 
by the Monte-Carlo simulation index (T4=0.04). This accounted for the slight increase 
in the frequency of allele 2 seen in the patient group (13% Vs 8%). The carriage rate 
therefore of allele 2 was higher in the patients compared to the B27 positive controls 
(16% Vs 8%) giving an odds ratio of 2.3 with 95% confidence levels of 0.91 to 5.8,
p=0.06.
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Although the IL-1 genes lie on chromosome two and therefore the possibility of any 
association with genes on chromosome six is unlikely the distributions were still 
examined in the AS patients compared to the two individual control populations. If the 
distributions were examined in the AS patients in comparison to the combined control 
groups a significant difference was seen. The carriage rate o f the allele 2 was higher in 
the patients when compared to the combined control population (16% cf 8%, OR 2.3, 
95% Cl 1.2-4.4, p=0.01).
A comparison between the distribution o f the IL-IRa alleles and genotypes in the 
normal control population in this study and two other control populations from other 
studies was carried out and the results are shown in Table 38. It can be seen that the 
frequency of the 1*1 genotype is increased in the West of Scotland controls compared 
to the control group from Sheffield and the second control group from Germany (89% 
cf 54% and 46%). Similarly the 1*2 genotype is decreased (0% cf 35% and 41%). A 
corresponding increase of allele 1 and decrease of allele 2 was seen in the three groups 
(90% cf 73% and 69% for allele 1) and 6% cf 24% and 27% for allele 2. The carriage 
rate o f allele 2 in the West o f Scotland controls is 9% compared with 42% for the 
controls from Sheffield and 49% for the controls from Germany. Although all three 
control groups are European Caucasian healthy blood donors different ethnic 
differences have previously been shown to affect the distribution of alleles at this site 
(Tountas, 1996). The number of control individuals in the West of Scotland group is 
small. Other studies carried out by different investigators in the same laboratory on 
different patient groups (e.g. Rheumatoid Arthritis patients and patients with Septic 
arthritis) have shown very similar distributions o f alleles.
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In summary an increased carriage o f allele 2 was seen in the AS patients compared to 
both the B27 negative healthy controls and the B27 positive healthy controls. The 
controls were pooled in order to increase the power o f the study as for these sites they 
did not require to be separated. The results were no different in the AS patients when 
compared to the pooled control populations (McGarry, 2001).
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IL-IRa AS patients n=182 
(%)
B27 Negative 
Controls n=115 (%)
1*2 14(8) 1(1)
2*2 16(9) 8(7)
1*3 5(3) 2(2)
1* 313(86) 211(92)
2* 46(13) 17(7)
3* 5(1) 2(1)
Legend for Table 36
Only three alleles at the IL -IR a polymorphic site were seen in these 
populations the distribution o f which are shown in Table 36. The 
distribution o f  the 1*1 genotype was significantly decreased in the AS 
patients compared to the B27 negative controls. Overall the distribution o f 
the genotypes were significantly different (T4=0.02)
IL-IRa AS patients n=182 
(% )
B27 positive 
controls n=76 (%)
1*2 14(8) 0(0)
2*2 16(9) 6(8)
1*3 5(3) 1(1)
1* 313(86) 139(91)
2* 46(13) 12(8)
3* 5(1) HO
Legend for Table 37
The results o f the distribution o f the IL -IR a alleles and genotypes in 182 
AS patients compared to 76 B27 positive controls are recorded in Table 
37. Overall the distribution o f the genotypes differed significantly between 
the two groups (T4=0.04).
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IL-IRA West of 
Scotland 
Controls
n—11S
[%i
Healthy 
Controls 
(Sheffield)* 
n=261 [%]
Healthy 
Controls 
(Germany)* 
* n=234
.............. J M
1*1 104 [90] 141 [54] 107 [46]
1*2 1 [1] 90 [35] 97 [41]
2*2 8 [7] 17 [6] 13 [5]
1*3 2 [2] 9 [3] 10 [4]
2*3 0 [0] 2 [1] 4 [2]
1*5 0 [0] 0 [0] 2 [1]
1*4 0 [0] 2 [1] 1 [1]
1* 211 [92] 383 [73] 324 [69]
2* 17 [7] 126 [24] 127 [27]
3*,4*,5* 2 [1] 13 [3] 17 [4]
Legend for Table 38
A comparison between the distribution o f the alleles and genotypes o f  the 
IL-1 Ra VNTR between three different healthy populations are depicted in 
Table 38. The frequency o f allele 2* and 1*2 genotype are decreased in 
the W est o f Scotland healthy controls compared to the Sheffield group 
(Mansfield, 1994) and the German healthy control group (Hacker, 1997).
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D istributionof IL -IR a genotypes in AS patients 
com pared to B27-ve C ontrols
^AS Patients n=182
^ B27-ve Controls 
n=l 15
70
60
8  40
£  30:
^  20
1*1 1*2 2*2 1*3
G enotypes
Legend for Figure 43a
The distributions o f the IL -IR a genotypes in the AS patients compared to 
the B27-ve controls are shown in Figure 43a. Overall the distributions are 
significantly different when analysed by the M onte-Carlo simulation index
(T4=0.02).
Distribution o f IL -IR a alleles in AS patients 
com pared to B27-ve C ontrols
^ A S  Patients n=182
100
80
c
S-O>
Cl
40
1* 2 *
^  B27-ve C ontrols 
n=115
Alleles
Legend for Figure 43b
The distribution o f the IL -IR a alleles in the AS patients compared to the 
B27-ve controls as is shown in Figure 43b.
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Distribution o f  IL -IR a genotypes in AS patients 
com pared to B27+ve C ontrols
^  AS Patients n=182
ax
C*
Uta
2-
100
90
80
70
60
50
40
30
20
10
0 id
1*1 1*2 2*2 1*3
B27+ve C ontrols 
n=76
G enotypes
Legend for Figure 44a
The distributions o f the IL -IR a genotypes in the AS patients compared to 
the B27+ve Controls are shown in Figure 44a. Overall the distributions 
differed significantly when analysed by the M onte-Carlo simulation index
(T4=0.04).
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Distribution o f IL-IR a alleles in AS patients 
com pared to B27+ve C ontrols
100
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0
^  AS Patients n=182
^  B27+ve C ontrols 
n=76
1*
A lleles
Legend for Figure 44b
The distributions o f the IL -IR a alleles in the AS patients compared to the 
B27+ve controls are given in Figure 44b.
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5.3 Interleukin 1 Alpha Results
Interleukin 1 alpha (IL -la) is an important proinflammatory cytokine that is known to 
contribute to inflammatory joint disease. It is thought to be the balance between the 
agonists ( IL -la  and p) and the antagonist IL-IRa that is important in controlling the 
effects o f IL-1. In patients with inflammatory bowel disease an imbalance at the 
mRNA level between IL-1 and IL-IRa has been seen in biopsy specimens 
(Isaacs, 1992). A number of polymorphic sites in the IL -la  gene have been investigated 
in autoimmune diseases but it was decided to examine the single base pair change at 
position -889 in this study. This particular site has previously been linked with early 
onset pauciarticular juvenile rheumatoid arthritis with increased carriage of allele 2 
(McDowell, 1995).
A total of 182 AS patients where examined for the frequency of the IL -la  alleles and 
genotypes in comparison to 113 healthy controls. The results are described in Table 39 
and shown in Figure 45a and b. The frequency of the IL -la  alleles 1 and 2 in the AS 
group was 66% and 34% respectively compared to 72% and 28% in the controls. This 
slight increase in allele 2 was reflected in a carriage rate of 58% in the As patients 
compared to 47% in the controls. There were no significant statistical differences 
between the two groups.
The frequency of the IL -la  alleles and genotypes were compared between the AS 
patients and the HLA B27 positive controls, the results are given in Table 40 and 
Figure 46a and b. There were no statistical significant differences in the distribution of 
the genotypes in the AS patients compared to the controls although the 1*2 genotype 
was increased slightly in the AS patients (43% cf 38%).
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The distribution of the IL -la alleles and genotypes in the control populations were 
very similar to distributions seen in other control groups such as the Norwegian 
randomly selected controls from the study by McDowell etal and the healthy blood 
donors from Sheffield in the Study by Mansfield etal. The frequencies of these alleles 
would appear to be stable throughout European populations which differs from the 
distributions o f the IL-IRa alleles.
At this polymorphic site no significant differences were seen in the distribution o f  
alleles or genotypes in the AS patients compared to either control group. Although a 
small increase in the carriage o f at least one copy o f allele 2 giving an odds ratio of 1.7 
was seen in the patients compared to the B27 negative controls. It would appear that 
the IL -la -889 polymorphic site is not a marker for disease susceptibility to AS.
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IL-1 alpha AS patients n=188
(%>
B27 Negative 
Controls n=l 13 (%)
1*1 82(45) 62(55)
1*2 80(43) 39(35)
2*2 22(12) 12(10)
1* 244(66) 163(72)
2* 124(34) 63(28)
Legend for Table 39
The distribution o f the IL-1 a  genotypes and alleles are depicted in Table 
39. A slight decrease in the 1*1 genotype was seen in the 188 AS patients 
compared to the 113 B27 negative controls (45% Vs 55%).
Correspondingly a slight decrease in the 1* allele (66% Vs 72%) was seen 
in the patients but this did not reach statistical significance.
IL-1 alpha AS patients n=188 
(%)
B27 Positive 
Controls n=81 (%)
1*1 82(45) 41(51)
1*2 80(43) 31(38)
2*2 22(12) 9(11)
1* 244(66) 113(70)
2* 124(34) 49(30)
Legend for Table 40
Table 40 represents the results o f  the distribution o f the IL-1 a  alleles and 
genotypes in 188 AS patients compared to 81 HLA B27 positive controls. 
There were no significant differences between these two groups.
182
Distribution of IL-la genotypes in AS patients 
compared to B27-ve Controls
& oiC3■*—
C
wu
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60 
50 
40 
30 
20 
101 
0 -
1*1 1*2 2*2 
Genotypes
□  AS Patients 
n=182
□  B27-ve Controls 
n=l 13
Legend for Figure 45a
The distributions o f the I L - la  genotypes in the AS patients compared to 
the B27-ve controls are shown in Figure 45a. No significant differences 
were seen between the two groups.
Distribution of IL-la alleles in AS patients 
compared to B27-ve Controls
ju cn i_i B27-ve Controls
« n—113
s4*
Lm 0>
O.
1*  2 *  
Alleles
□  AS Patients 
n=182
Legend for Figure 45b
The distribution o f  the IL -la  alleles in the AS patients compared to the 
B27 -v e  controls is described in Figure 45b. There were no significant 
differences between the two groups.
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Distribution of IL-la genotypes in AS patients 
compared to B27+ve controls
□  AS Patients 
n=123
□ B27+ve Controls 
n=81
Genotypes
Legend for Figure 46a
The distributions o f the IL - la  genotypes in the AS patients compared to 
the B27+ve controls are shown in Figure 46a. No significant differences 
between the two groups were seen.
Distribution of IL-la alleles in AS patients 
compared to B27+ve controls
ex 50
□ AS Patients 
n=123
□ B27+ve Controls 
n=81
Alleles
Legend for Figure 46b
The distributions o f the IL - la  alleles in the AS patients compared to the 
B27+ve controls are shown in Figure 46b. There were no significant 
differences between the two groups.
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5.4 Interleukin 1 Beta Results
The normal production of IL-1 is critical for the host response to injury and infection 
with prolonged or inappropriate production implicated in a variety of pathological 
conditions. The major extracellular from of IL-1 found in humans is IL-lp since IL-1 a  
appears to remain membrane bound. IL-1 (3 has been shown to be present at the 
cartilage-pannus interface in RA patients (Chu, 1992).
Within the IL-1 (3 gene lie several polymorphic sites but the site investigated in this 
study was the bi-allelic site at -511 within the promoter region. To date no functional 
relevance has been assigned to this site. No significant associations with the site and 
any autoimmune diseases have been established but it has been proposed that the IL-1 (3 
and IL-IRa genes are in linkage disequilibrium. Although IL-1 (3-511 has been 
implicated in inflammatory bowel disease (Nemetz, 1999).
A total of 188 AS patients and 111 B27 negative controls were investigated. The 
results of the distribution of the alleles and genotypes are described in Table 41 and 
Figure 47a and b. No significant differences were seen between the two groups. The 
patients were compared to 81 B27 positive controls with the results described in Table 
42 and Figure 48a and b. Again the distribution of both the alleles and genotypes were 
very similar between the two groups. No significant differences were seen.
Several studies have investigated the distribution of alleles not in relation to disease 
susceptibility but to disease severity markers. For example an association with IL-1 a  
and rheumatoid arthritis suggest the presence of IL-1 a  allele 2 could constitute a risk 
factor for a more destructive form of the disease (Jouvenne, 1999). A statistically 
significant increase of allele 2 of the IL-1 (3 gene has been correlated with a high
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secretor phenotype in patients with diabetic nephropathy (Loughrey, 1998). Allele 2 of  
the IL-IRa gene has been suggested as being a marker o f more severe forms of  
Sjogren’s syndrome (Perriere, 1998).
The distribution o f alleles and genotypes of each o f the IL-1 polymorphic sites were 
investigated in relation to different disease features. The results are described in Tables 
43,44 and 45. There were no significant differences in the patients with or without any 
of the features examined. In the 52 patients with an early onset the IL-IRa l*allele was 
increased compared to the 55 patients with a later onset (70% versus 59%) but this was 
not statistically significant.
In conclusion o f the three IL-1 sites investigated a significant association was seen in 
the carriage o f the IL-IRa 2*allele in the AS patients as compared to controls. This 
appeared to be associated with disease susceptibility and not with disease phenotype. 
The correlation with the increased levels of IL-IRa and allele 2 warrant further 
investigation.
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IL-1 beta AS patients n=188 
(%)
B27 Negative 
Controls n = ll l  (%)
1*1 71(38) 46(42)
1*2 91(48) 47(42)
2*2 26(14) 18(16)
1* 233(62) 139(63)
2* 143(38) 83(37)
Legend for Table 41
The distributions o f the IL-1 (3 alleles and genotypes in 188 AS patients 
compared to 111 B27 negative controls are shown in Table 41. No 
significant differences were seen between the two groups.
IL-1 beta AS patients n=188
(%)
B27 Positive 
Controls n=81 (%)
1*1 71(38) 32(40)
1*2 91(48) 39(48)
2*2 26(14) 10(12)
1* 233(62) 103(64)
2* 143(38) 59(36)
Legend for Table 42
No significant differences were seen in the distribution o f the IL-1 (3 
alleles and genotypes between the 188 AS patients and the 81 B27 positive 
controls.
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D istribution o f  the IL -lp  genotypes in AS patients  
com pared to B27-ve C ontrols
^ A S  Patients n=188
® B27-ve C ontrols  
n= l 11
2*21*1
G enotypes
Legend for Figure 47a
The distributions o f  the IL -lb  genotypes in AS patients com pared to B27- 
ve Controls are shown in Figure 47a. No significant differences were seen 
between the two groups.
Distribution o f IL -lp  alleles in A S patients 
com pared to B27-ve C ontrols
^  AS Patients n=188
60
B27-ve C ontrols  
n = ll  140
20
10
A lleles
Legend for Figure 47b
The distributions o f the IL -lb  alleles in the AS patients com pared to the 
B27-ve controls are shown in Figure47b. There were no significant 
differences.
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Distribution o f IL -lp  genotypes in AS patients 
com pared to B27«ve C ontrols
^ A S  patients n=188
B27+ve Controls 
n=81
1*1 1*2 2*2
G enotypes
Legend for Figure 48a
The distributions o f the IL -lb  genotypes in the AS patients compared to 
the B27+ve controls are shown in Figure 48a. No significant differences 
were seen between the two groups.
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Distribution o f IL -lp  alleles in AS patients 
com pared to B27-ve C ontrols
n AS patients n=188
® B27+ve Controls 
n=81
A lleles
Legend for Figure 48b
The distributions o f the IL -ip  alleles in the AS patients compared to the 
B27+ve controls are shown in Figure 48b. There were no significant 
differences.
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Polymorphic
site
Alleles Age of 
O nset <21
yrs (% )
Age of 
Onset >21 
yrs (% )
IL-1 a 1* 73 (70) 65(59)
2* 31 (30) 45 (41)
IL-1 p 1* 68 (65) 63(58)
2 * 36 (35) 45 (42)
IL -IR a 1* 79 (84) 88(82)
2 * 14(15) 20(18)
3 * 1 (1) 0 (0 )
Legend for I able 43
The distribution o f the IL 1 alleles in those patients with an onset o f disease 
below the age o f 21 years compared to those with an onset equal to or 
greater than 21 years is shown in Table 43. In the 52 AS patients with an 
onset below the age o f 21 the IL-1 a  1 * allele was increased compared to 
the 55 patients with a later onset (70% Vs 59%) but this was not 
statistically significant.
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Polymorphic
site
:
Alleles
- ' ■
. , - ■ - ■ . .
Uveitis
Present
(% )
Uveitis
Absent
IL-1 a 1* 48 (63) 90 (65)
2* 28 (37) 48 (35)
IL-1 (3 1* 46(59) 83 (63)
2* 32(41) 49(37)
IL-IRa 1* 66(89) 100(78)
2* 8(11) 26(20)
3* 0 (0 ) 2 (2 )
Legend for Table 44
Table 44 describes the distribution o f alleles at each o f the IL1 sites 
investigated in AS patients with uveitis compared to those without. 
No significant differences were seen between the two groups.
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Polymorphic
site
Alleles Peripheral 
joint disease 
present (%)
Peripheral 
joint disease 
absent (%)
IL -la 1* 54 (68) 85 (62)
2* 26 (32) 51 (38)
IL-lp 1* 48(60) 82 (62)
2 * 32(40) 50 (38)
IL-1 Ra 1* 60(83) 108 (82)
2* 11(15) 23 (17)
3* 1(2) K D
Legend for Table 45
The results o f the distribution o f each o f the alleles at the three 
polymorphic sites investigated in AS patients with and without peripheral 
joint disease are given in Table 45. There were no significant differences 
between the AS patients who had a history o f  peripheral jo in t disease with 
those that did not at any o f the sites investigated.
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5.5 Interleukin 1 Receptor Antagonist Discussion
Several studies have been carried out to investigate associations with the IL-IRa 
VNTR and inflammatory conditions in particular inflammatory bowel disease. Like AS 
inflammatory bowel disease has a genetic predisposition and has been associated with 
genes in the MHC Class II region such as HLA-DR2 with ulcerative colitis and HLA 
DR1 in Crohn’s disease. Again like AS these are not thought to be the only genes 
involved (Toyoda., 1993).
The role of IL-IRa in inflammatory bowel disease has suggested that the IL-1 genes 
may be suitable candidate genes for this disease, evidence for this comes from both 
animal models and studies on biopsy material from diseased tissue. Neutralisation of 
endogenous IL-IRa with specific antibodies in an animal model of rabbit immune 
colitis failed to resolve the colitis or the chronic inflammation (Ferretti, 1994). 
Similarly the administration of recombinant IL-IRa in these animals prevented the 
development of colitis (Cominelli, 1992). Several studies have been carried out to 
investigate the role of polymorphisms within the IL-1 genes in relation to susceptibility 
and severity of inflammatory bowel disease. In a study carried out by Mansfield etal an 
association between allele 2 of the IL-IRa and patients with ulcerative colitis was seen 
although other studies have failed to confirm this (Hacker, 1997). Increased carriage of 
allele 2 has also been associated with other conditions such as reduced bone loss at the 
spine in early postmenopausal women (Keen, 1998). Inflammatory bowel disease is 
frequently seen in patients with AS and consequently it is feasible that IL-IRa could 
have a role to play in disease susceptibility to AS.
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The distribution o f the IL-IRa alleles o f the 86bp VNTR in intron 2 o f the IL-IRa gene 
was investigated in 182 AS patients and compared to the control populations. A 
significant increase in the carriage o f allele 2 was found in the AS patients compared to 
the controls.
Association studies and twin analyses have not previously examined the IL-1 locus in 
AS patients. However, the recent study o f AS sibling pairs showed that one area on 
chromosome 2 marked by microsatellite D2S160 is strongly associated with AS 
(Brown, 1998). This marker is within 6 centimorgans of the genes in the IL-1 family 
(Genebank:http://www.ncbi.nlm.nih.gov/genemap/map.cgi?CHR=2),so the presence of  
a polymorphism in the IL-IRa gene could represent a candidate gene in AS associated 
with the D2S160 marker. However, other important genes close to D2S160 could be 
relevant in which case the IL-IRa association would be due to linkage disequilibrium. 
An association with allele 2 of this polymorphic site and increased production of IL- 
IRa protein has been established in mononuclear cells from healthy individuals when 
stimulated with GM-CSF (Danis, 1995). In a second study o f 200 healthy blood donors 
allele 2 has been associated with higher levels o f IL-IRa in plasma (Hurme, 1998). 
Although in one study this allele was associated with reduced expression of mRNA for 
IL-IRa in tissues from ulcerative colitis (Carter, 1999). These studies suggest that the 
presence of the IL-IRa allele 2 could be linked with high steady state production o f IL- 
IRa, and increased levels of IL-Ra production in response to gram negative antigenic 
stimulation. By implication it would imply that in these AS patients a poorer response 
to the standard levels o f IL-1 would ensue.
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The apparent discrepancies between the distributions o f the IL-IRa alleles in the 
groups seen in this study in comparison to other groups could reflect differences in 
gene inheritance dependent on the local genetic pool. The results were similar between 
the local unselected normal group and the HLA B27 normals indicating this frequency 
is likely to be a true representation o f gene frequencies in the West of Scotland. This is 
confirmed by the observation that in 100 rheumatoid arthritis patients, also local to the 
West o f Scotland, the IL-IRa 2 allele frequency was similar to those examined in this 
study (Crilly A Submitted to Ann Rheum Dis). In a study of Czech RA patients and 
controls the frequency of the IL-IRa alleles were similar to those seen in this study 
(Vencovsky, 2000). This comparison between populations highlights the importance of 
using locally recruited controls in comparative studies.
In conclusion the increased carriage of the IL-IRa allele 2, which has been suggested 
to be associated with increased production of IL-IRa, may have a role to play in the 
disease pathogenesis in AS patients.
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5.6 Interleukin 1 Alpha Discussion
IL-1 a  is known to contribute to inflammatory joint disease through its catabolic effects 
on cartilage and its ability to stimulate other inflammatory mediators. It also stimulates 
fever and directly or indirectly through 1L-6 induces the acute phase response. High 
levels o f IL - la  and p have been detected in synovial fluid from RA patients and serum 
levels of circulating IL-1 have been related to disease severity. Direct roles for IL-1 
have come from animal studies where anti-IL-1 antibodies are able to reduce cartilage 
destruction in murine arthritis models (Van de Loo, 1990). In contrast the injection of 
IL-1 directly into the joints of animals causes leukocyte accumulation and cartilage 
degradation (Pettipher, 1986).
There are several polymorphic sites within the IL -la  gene which have been 
investigated in a variety of autoimmune diseases including inflammatory bowel 
disease, early onset pauciarticular juvenile rheumatoid arthritis (EOPA-JRA), Graves 
disease and rheumatoid arthritis. Within intron 6 of the gene is a 46bp VNTR with a 
total of seven alleles being demonstrated in Caucasian populations (Bailly, 1993). This 
VNTR may have some functional relevance to the actual protein levels produced. 
However in a study of RA patients no significant differences were seen compared to 
controls (Bailly, 1995). No associations for the AC dinucleotide repeat within intron 5 
have been established as yet. However the Cytosine to Thymine substitution at position 
-889 relative to the transcription start site has been associated with EOPA-JRA. An 
increase in the carriage of allele 2 was seen in the patients compared to the controls 
(McDowell, 1995). However this was not confirmed in a second study where no 
association was seen in a group of British oligoarticular juvenile chronic arthritis
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individuals (Donn, 1999). Several studies have established that single base pair 
changes can alter the transcription of proteins either by affecting the binding of trans- 
activating factors or by alterations of the secondary structure of the DNA leading to 
interference of the protein-protein interactions within the transcriptional assembly 
(Smith, 1992).
In this study the distribution of the IL -la  alleles were investigated in a large group of 
AS patients compared to controls. No significant differences were seen either in the 
distribution of alleles, genotypes or in comparison to extra disease features. Therefore 
it is unlikely that the IL -la  site has a role to play in the disease pathogenesis of AS.
5.7 Interleukin 1 Beta Discussion
IL-lp is structurally related to IL -la  with both exerting their effects through binding to 
two specific receptors IL-1R type I and type II. IL -la  binds preferentially to the IL-1R 
type I with IL-lp binding better to the type II receptor. It has been suggested that it is 
only binding to the type I receptor that is capable of transducing a signal (Sims, 1993). 
The binding to the type II receptor is thought to act as a decoy and therefore aids the 
regulation of IL-1 under appropriate conditions.
Within the IL-ip gene are several polymorphic sites the +3953, which is bi-allelic and 
the site investigated in this study the cytosine to thymine single base change at position 
-511 within the promoter region. To date no functional association has been assigned 
to this site but since it lies within the promoter region it cannot be ruled out. No 
significant associations with the site and any autoimmune diseases have been 
established but it has been proposed that the IL-ip and the IL-IRa genes are in linkage
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disequilibrium. From physical mapping studies the IL-ip gene has been shown to lie 
closer to IL-IRa (Nicklin, 1994). Allelic associations between IL-lp and IL-IRa have 
been investigated since it has been suggested that it is the ratio between the two 
proteins that is crucial in the regulation o f inflammation. It could be that there is co­
ordinate regulation between the two genes.
Several studies have shown associations between alleles at the -511 site and the VNTR 
in the IL-IRa site. Allele 2 o f the IL-IRa site has been associated with allele 2 of the 
IL-lp gene and also with the absence of allele 2 at the +3953 site (Santtila, 1998). 
Mononuclear cells from carriers of allele 2 at -511 and non-carriers o f allele 2 at 
+3953 had a slight increase in their ability to produce IL-ip in vitro. It has also been 
shown that the increase in the IL-IRa protein plasma levels seen in association with the 
carriage of IL-IRa allele 2 also requires the presence of the -511 allele 2. The 
regulation o f the IL-IRa production appears to be under the influence o f both the IL-Ra 
and IL-lp genes (Hurme, 1998). Although there were no significant differences in the 
distribution of the IL-ip alleles or genotypes in this AS patient group compared to 
controls the association with allele 2 with the IL-IRa allele 2 was demonstrated.
A statistically significant increase of allele 2 of the IL-1 P gene has been correlated with 
a high secretor phenotype in patients with diabetic nephropathy (Loughrey, 1998). 
However no significant differences were seen in the distribution of the IL-lp alleles 
and genotypes in the AS patients with and without extra features o f disease.
In conclusion a significant increase in the carriage of IL-IRa allele 2 was seen in the 
AS patients compared to the controls with no differences seen at the other two sites 
investigated. If this IL-IRa allele 2 is linked with increased IL-IRa protein production,
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then it could be suggested that since IL-IRa prevents IL-1 signalling through the IL-1 
receptor, the presence of this allele will exert some limitation o f IL-1 mediated signals.
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For over forty years the strong family association with Ankylosing Spondylitis has been 
known and for over twenty-five years the link with the MHC class I allele HLA B27 has 
been demonstrated. However the fact that only a small proportion of B27 positive 
individuals go on to develop the disease and the pattern of disease in monozygotic and 
dizygotic twins has suggested other factors must be involved. While environmental 
factors such as Klebsiella have been implicated, various studies confirm that other genes 
must be important. In fact it has been proposed that there are a further five to ten other 
genes that may interact together to cause the disease (Brown, 1998). This study was 
carried out to investigate several candidate genes that could possibly play a role in 
susceptibility to AS.
From the clinical information gathered this particular group o f AS patients would appear 
to be very similar in their clinical features to those o f other studies. The fact that all the 
patients and both sets of control patients all come from the West of Scotland is important 
to remember as it is well established that not only are there ethnical differences but as has 
been shown before there are regional differences in the distribution of particular alleles. 
Although the association with HLA B27 is one of the strongest known associations 
between an autoimmune disease and a MHC molecule the pathogenesis of the disease is 
still poorly understood. The lack o f association with any one particular subtype o f the 
HLA B27 molecules has been disappointing. Of the twelve possible B27 subtypes only 
two have been suggested as being non-disease associated (B*2706 and B*2709), 
although these results need to be confirmed in other studies (Fiorilo, 1995). It has been 
suggested that it is the lack o f a C-terminal Tyr motif in these two subtypes that do not 
allow arthritogenic peptides to be presented by HLA B27 molecules (Garcia, 1997). In
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this study all the patients that had been subtyped were B*2705 which is the most 
common subtype found in nearly all populations and has been reported to be the ancestral 
haplotype from which all other subtypes have arisen. The HLA B27 subtype present on 
the contra-lateral chromosome may be o f importance in the susceptibility to AS in that 
individuals homozygous for B27 may have increased risk of disease. The presence of 
HLA B60 has also been shown to increase the risk o f developing AS (Brown, 1996). In 
this study the number of patients homozygous for HLA B27 was significantly increased 
in comparison to the control population. This confirms previous studies were the apparent 
frequency o f homozygotes is greater than the expected frequency (Khan, 1978). However 
no increase in the incidence of HLA B60 was seen in our study.
Whilst the importance o f B27 is not in question, the fact that 75% of HLA B27 positive 
identical twins are concordant for the disease compared to only 27% of HLA B27 
positive non-identical twins confirm the significance of B27 to the development of the 
disease but highlight the requirement for other genes to be involved (Salvetti, 2000). 
Animal studies also confirm these findings along with the importance of an 
environmental trigger as can be seen when the animals are maintained in a germ free 
environment in that they do not develop disease. Rats transgenic for HLA-B*2705 and 
human (32-microglobulin are susceptible to developing an inflammatory arthritis similar 
to the B27-associated human disease (Hammer, 1990). However backcross studies in 
these animal models (Taurog, 1999) also confirm the importance of the particular genetic 
background o f the animals in disease susceptibility confirming again that AS is an oligo- 
genetic disease.
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To investigate other possible candidate genes, three regions were investigated, two 
within the MHC on chromosome six and one on chromosome 2. Within the MHC class II 
region lie the DRpi* alleles where a previous association with DRpi *01 alleles has been 
demonstrated in AS patients (Brown, 1998). This has been confirmed in our study where 
a significant increase in the distribution o f the DRpi* alleles was seen in the AS patients 
when compared to the control groups. This association with DRpi* 01 alleles would 
appear to be independent o f B27 confirming the work o f Brown and colleagues. No 
associations where seen between any o f the DRpi* alleles and the presence of any extra 
disease features that may be indicators of disease severity.
Previous studies have shown inter-individual differences in the production of TNFa in 
relation to particular alleles of the class II locus. The presence of HLA-DR2 has been 
linked with decreased TNFa production following stimulation of PBMC’s by LPS 
(Jacob, 1990), implying the MHC can exert some genetic control over TNFa production. 
The close proximity between the MHC class II locus and the TNF locus has raised the 
possibility that any variations within the TNF locus could have arisen simply because of 
linkage disequilibrium with the MHC. Studies on cell lines have shown haplotypes that 
cross both the Class I and Class II loci are inherited as a group (Deglie-Esposit, 1992). 
The HLA A1-B8-DR3-DQ2 haplotype is frequently seen in autoimmune diseases in 
particular SLE and has been linked with increased TNFa production (Jacob, 1988). 
Further studies have confirmed the presence o f certain TNF alleles in this haplotype, 
including the TNFb3 and TNFa2 microsatellite alleles and the rare TNF -308*2 allele 
(Gallagher, 1997). In this particular study the frequency of the D R pi*03 alleles which 
are associated with increased production o f the pro-inflammatory cytokine TNFa was
203
reduced in AS patients. This was in conjunction with the decreased frequency of the -  
308*2 allele. This implies that there is a haplotype in our AS patients covering 
D R pi*03, and -308*2 as is seen in other normal and patient populations. However the 
lack o f family studies in our population makes it difficult to confirm at this time. 
Therefore although the DRpi * alleles appear to have a role to play in susceptibility to the 
disease it does not appear to be linked to increased production of TNF.
The second region investigated lies within the MHC class III region and involved the 
TNF locus itself. Six different polymorphic sites were examined; three single base pair 
substitutions that were examined by restriction enzymes and three microsatellites that 
where examined by PCR and electrophoresis. The results clearly showed a significant 
increase in the distribution o f the -308*1 allele in the AS patients which implied a link 
between this allele in the TNF promoter that is present in the patients but not in the HLA 
B27 positive controls. It should be noted however that the HLA B27 positive normal 
individuals were not examined by a clinician, nor where they X-rayed they only 
completed a general health questionnaire. As has been reported the incidence of 
asymptomatic AS in the general population may be higher than expected and therefore 
some of the controls included in this study may have underlying disease or may go on to 
develop the disease (Braun, 1998). It would be o f interest to the know the frequency of 
the -308*1 allele in HLA B27 negative AS patients but as this consists of less than 10% 
of patients multi-center studies would be required to achieve sufficient numbers. 
However at the -308 site the significant increase of the -308.1* allele in the patients was 
different in both control populations suggesting that this is disease associated. This 
finding has been confirmed by some groups and not by others however in the studies
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were this increase has not been seen the number o f subjects and controls were small 
(Verjans, 1994). It has been proposed that the -308*2 allele actually has a protective 
effect (Hohler, 1998). The functional consequences o f this polymorphism have been the 
subject of much debate. Some studies have associated the -308*2 allele with increased 
production o f TNFa, the increased frequency o f the -308*1 allele in the AS patients 
suggest a less pro-inflammatory response in these patients. In fact T cell stimulation 
with PHA produces a response more characteristic o f a TI12 profile. T cells from AS 
patients produce less TNFa and IFN ythan controls when analysed by ELISA of 
supernatants and Facs analysis of stained PBMCs (Rudwaleit, 2001). This is also seen in 
other spondyloarthropathies such as Reactive arthritis where it has been proposed that the 
decreased TNFa production might lead to a less active pro-inflammatory response which 
contributes to the bacterial persistence seen in ReA (Braun, 1999).
The third region to be investigated was on chromosome two where the genes for the pro- 
inflammatory cytokine IL-1 lie. The genes for EL-la, IL-lp and IL-IRa all lie close 
together on this region that have been highlighted in a large genome screen as a possible 
candidate region. Single base pair substitutions where examined in the IL-la and IL-lp 
genes along with an 86bp repeat in the IL-IRa gene. No associations were seen in the IL- 
la  or IL-lp sites. However a significant increase in the carriage of the IL-IRa 2*allele 
was seen in the AS patients compared to the controls. This allele which has been shown 
to predispose to increased levels o f the anti-inflammatory cytokine IL-IRa (Hurme, 
1998) would appear to be disease associated. A recent study investigating the IL-1 gene 
cluster in multiplex families with spondylarthropathies did not find any associations in 
particular with the IL-IRa 86bp VNTR. However numbers in this study where small and
205
not all the subjects studied where HLA B27 positive (Djouadi, 2001). Although no 
obvious link exists between the IL-1 cluster and the MHC, this does suggest that these 
patients are far from genetically homogeneous. Therefore it could be suggested that the 
carriage o f an allele associated with increased production of IL-IRa could lead to 
decreased effectiveness o f the pro-inflammatory cytokines IL-la and p. This in itself 
could lead to decreased TNFa production because IL-1 can initiate production of other 
pro-inflammatory cytokines.
The results in this study suggest associations with the IL-IRa 2*allele on chromosome 
two, the -308 1* allele in the MHC class III region and the HLA D R pi*01 alleles with 
predisposition to AS. However, we have also been able to show that in patients and 
controls that carry HLA-B27 other haplotypes could exist across the TNF locus into the 
MHC Class II region. However to confirm the presence of these haplotypes large family 
studies would be required.
Of the associations established in this study none were associated with any o f the alleles 
that have previously been linked to increased production of TNFa. Although increased 
transcription and serum levels have been shown previously there is little evidence to 
suggest that there are increased levels of TNFa protein in the joint. In the AS patients 
mRNA for TNFa has been demonstrated in a small number of sacroiliac biospies, but 
there is no direct evidence that the actual TNF protein is increased in these patients. 
Increased serum levels of TNFa have been previously demonstrated levels are not as 
high as other autoimmune diseases such as rheumatoid arthritis and they have been 
shown not to correlate with clinical markers o f disease activity (Gratacos, 1994). In fact 
in AS patients without additional peripherial joint disease, ESR and CRP levels would
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appear to be normal (R.D.Sturrock, personal communication) suggesting that in patients 
with sacro-ileitis alone, these individuals are not undergoing a systemic pro-inflammatory 
response. In contrast the use o f anti-TNF therapy has shown some promising results in 
the treatment o f AS patients (Braun, 2000), but only those with peripheral joint disease. 
There is no evidence o f change to the clinical or pathological features o f sacro-ileitis. 
Efficacy, placebo-controlled trials and long term safety need additional evaluation.
It could be hypothesised that the genetic associations seen in this study could lead to a 
reduced pro-inflammatory response from monocytes; firstly reduced TNF production and 
secondly a less effective IL-1 response. Studies in systemic lupus erythematosus have 
shown an association between multiple polymorphic sites predicting an increased 
predisposition to apoptosis. It could be hypothesised that in AS a similar prediction could 
be built up for multiple polymorphisms linked with a less effective pro-inflammatory 
cytokine response. Since AS has the appearance of a fibrotic disease it could be that 
genes involved in the fibrosis process such as transforming growth factors (TGFP) may 
be important. TGFp has been implicated in the process of scarring and matrix synthesis 
and in AS skeletal lesions it is the process of fibrosis and ossification that predominate 
(Edwards, 2000). TGFP is known to stimulate IgA production and in patients with AS 
increased levels of IgA have been detected in serum. In sacroiliac biopsies mRNA for 
TGFP has been detected in particular in areas o f fibroblast infiltration (Braun, 1998). 
Future work is required to confirm this hypothesis and preliminary work investigating 
polymoprhisms within the TGFpl gene has shown promising results in that a particular 
allele associated with increased TGFp production is increased in the AS patients 
(McGarry, 2001). Other studies have demonstrated associations with this allele and other
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fibrotic diseases. Other genes involved in the fibrotic process may be o f interest. For 
example the collagen genes may be likely candidates since levels o f IgM and IgG 
antibodies to four of the collagens have been shown to be increased in AS patients 
(Tiwana, 2001).
This study would be strengthened if the results shown here could be demonstrated in a 
second population of AS patients. A second group o f Hungarian patients and controls are 
currently under investigation.
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